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SUMMARY 
Inflammatory bowel disease (IBD) is a chronic idiopathic disorder resulting in the 
inflammation of the gastrointestinal tract, which encapsulates both Crohn’s disease (CD) 
and ulcerative colitis (UC). There is strong evidence of familial aggregation of IBD, and 
more than 200 genetic variants have been identified as associated with IBD (1, 2). 
Currently, more than 1.5 million individuals in the United States suffer from IBD, with 
prevalence of the disease on the rise, particularly in minority populations (3). Although 
African American and Caucasian populations in the US share a similar burden of disease, 
studies suggest that African American CD patients are at a greater risk for disease 
complications and often experience worse outcomes when compared with Caucasian 
patients (4-6). Despite this, African Americans are greatly underrepresented in clinical 
trials and research studies on IBD, where the majority of genetic contributors to disease 
have been identified in cohorts of exclusively Caucasian individuals of European descent. 
Resolving this disparity is critical to determining whether there are biological mechanisms 
underlying CD in African Americans which differ from those in Caucasians. 
The primary question driving this thesis is whether genomic and transcriptomic 
profiling have the potential to direct personalized therapeutic interventions for IBD 
patients. Prediction of disease course is especially relevant in IBD, because early, 
appropriate introduction of anti-TNFα therapy can slow the progression of the disease in 
patients who would otherwise experience severe flares, bowel penetration, or require 
invasive surgeries. Conversely, early prediction can also identify patients who are not 
expected to progress and thus help to avoid unnecessary, harmful, and costly therapy with 
 xv 
biologics. Our prior studies have demonstrated that transcriptomic data can be used to 
identify patients who are likely to progress from B1 stable CD to B3 penetrating CD, and 
that gene expression can also be linked to GWAS via Transcriptional Risk Scores (TRS) 
(7, 8). 
In this thesis, I first describe a comparative analysis of gene expression and eQTL 
in IBD and juvenile idiopathic arthritis, another clinically heterogeneous immune-related 
disorder. Next, I examine the influence of African ancestry proportion on gene expression 
in the ileum of Crohn’s disease patients. I then discuss the utility of gene expression at time 
of disease diagnosis to predict risk of progression to colectomy in an inception cohort of 
pediatric ulcerative colitis patients. Finally, I present an exploration of cell type 
composition of ileal epithelial cells at single-cell resolution in healthy, treatment-naïve, 
and treated Crohn’s disease. I conclude with a summary of the progress achieved and 
challenges to be overcome for the successful application of genomics for precision 








CHAPTER 1. INTRODUCTION 
Inflammatory bowel diseases, comprised mainly of Crohn’s disease and ulcerative 
colitis, are chronic relapsing and remitting diseases of unknown etiology which result in 
the inflammation of the gastrointestinal tract. Historically, IBD was considered to be a 
disease of westernized nations, but recent epidemiological studies have demonstrated the 
growing impact of IBD mirroring trends in global socioeconomic development (9). In the 
United States, it is now estimated that more than 1.5 million individuals suffer from IBD, 
with prevalence of the disease continuing to rise (3). Our healthcare system has been tasked 
with the challenge of providing quality, cost-effective, long-term care, which begins with 
Figure 1 – The growing global impact of IBD. Incidence and prevalence of IBD 
increasing in newly industrialized countries echoes historical trends of 




understanding the underlying biological mechanisms of this complex disease. To that end, 
validation of the utility of transcriptomic profiling at diagnosis for prediction of disease 
course, evaluating the influence of African ancestry on disease via transcriptomic profiling, 
and identifying the individual contributions of immune cell types to transcriptomic 
signatures of disease progression will offer critical insights. 
 
1.1 Influencing the Natural History of Inflammatory Bowel Disease  
The two most common forms of IBD are Crohn’s disease and ulcerative colitis. 
Inflammation in UC is typically restricted to the mucosal and submucosal layer of the 
colon, while CD may affect the entirety of the gastrointestinal tract (10, 11). Physicians 
attempt to classify subtypes of disease with clinical indices and administer standardized 
therapeutic regimens accordingly. 
1.1.1 Clinical classifications of IBD 
Current indices of IBD severity such as PUCAI (Pediatric Ulcerative Colitis 
Activity Index) and CDAI (Crohn’s Disease Activity Index), are typically based on clinical 
phenotypes and markers like rectal bleeding, albumin, and C-reactive protein levels (12, 
13). A scoring system known as the Lémann Index was also recently developed to provide 
multiple assessments of bowel damage over the course of CD (14). One of the measures of 
activity included within the Lémann Index is disease behavior, where non-stricturing and 




disease is termed “B3”, in order of least to greatest severity (15). At diagnosis, CD patients 
typically present with inflammatory-only B1 disease, with an estimated 50% of patients 
proceeding to complicated disease within five years (16). As disease progresses to B2 and 
B3, blockages of the bowel occur which must be addressed with surgical resection in up to 
80% of patients with complicated disease (17). 
 
 
Figure 2 – Subtypes of IBD. Top row: Crohn’s disease presents patchy 
inflammation throughout the GI tract, while UC is typically restricted to the colon. 
Illustration by The Hospital for Sick Children (11). Bottom row: Lémann index 




1.1.2 Standard therapeutics for IBD  
The goal of therapy for CD is to maintain disease at the stable B1 state and delay 
or eliminate the need for invasive surgical procedures. Some of the commonly used 
medications for treatment of IBD include aminosalicylates, corticosteroids, 
immunomodulators like methotrexate and azathioprine, and biologics such as infliximab 
and vedolizumab. Of particular interest in current pharmacological research are anti-TNFα 
therapies. Tumor necrosis factor-α plays a key role in mucosal inflammation, and is thought 
to mediate the inflammatory cascade in IBD by inducing the activation of various immune 
cells, including neutrophils, monocytes, macrophages, and lymphocytes (18). Infliximab, 
a common anti-TNFα drug used in IBD, binds to TNF-α, preventing its binding with 
receptors and thereby inducing the apoptosis of the immune cells causing inflammation. 
Prior studies have shown that early treatment with anti-TNFα therapy is associated with a 
reduction in disease complications later on (7, 19-21). However, aggressive drug therapy 
of all patients is not a feasible solution due to toxicity and economic burden. The need for 
tools capable of early discrimination of patients with poor prognosis to direct prompt 
therapeutic decision making is clear. 
 
1.2 Tools for Studying the Genetics of Disease  
Three major approaches capture complementary information key to characterizing 
the genetics of IBD—bulk transcriptomic profiling, single cell transcriptomic profiling, 




1.2.1 Bulk RNA-sequencing 
Bulk transcriptomic profiling uses RNA-seq to quantify the levels of gene 
expression present in a biological sample. Classically, the central dogma of biology states 
that information stored in genes flows from DNA to RNA, and is then transcribed into 
proteins (22). Messenger RNA (mRNA) are the molecules complementary to DNA which 
serve as the intermediate between DNA and protein and collectively constitute the 
transcriptome. Historically, methods like hybridization-based microarrays were utilized to 
perform gene expression profiling, but had drawbacks such as high technical variability 
and limitations in probe design (23). Next-generation sequencing is the successor to those 
technologies and offers considerable advantages over prior techniques. RNA-seq starts 
with the isolation of RNA from a tissue sample. An RNA-seq library is generated by 
purifying down to the desired RNA molecules, typically mRNA, then reverse-transcribing 
the RNA into cDNA. Tens of millions of RNA-seq reads per sample are aligned to a 
reference genome, then transcript length and GC content biases can be adjusted for 
computationally in subsequent normalization procedures (24, 25). Commonly, differential 
gene expression analysis then follows to identify genes which are statistically distinguished 
between groups of interest.  
1.2.2 Single-cell RNA-sequencing 
One caveat of bulk transcriptomic profiling is that gene expression varies greatly 
between different tissue and cell types, which can lead to loss of detection of genuine 




cell RNA-seq offers much higher resolution (26). The basic principles of single cell RNA-
seq are similar, albeit with two additional challenges—isolating single cells and amplifying  
the much smaller amounts of mRNA (27). Appropriately adjusted single-cell data has the 
potential to reveal rare cell populations and track the developmental trajectories of certain 
cell lineages (28).  However, normalization and analysis methods are not as well 
established as in bulk RNA-seq studies. Due to the sparsity of single cell RNA-seq data, 
normalization methods previously developed for use in bulk RNA-seq studies can be 
inaccurate when applied to single-cell data (29). Numerous single cell specific 
bioinformatics methods are currently being developed; two examples of such tools include 
Seurat and Monocle (30, 31).  
1.2.3 Mapping of eQTL 
Combining genotype data with gene expression data also enables the discovery of 
genetic loci associated with differences in gene expression, or expression quantitative trait 
loci (eQTL). Traditionally, eQTL studies have been performed with bulk RNA-seq data, 
Figure 3 – The potentially signal-obscuring effects of grouped gene expression 




which has uncovered numerous associations. For example, the Blood eQTL Browser is 
based on a genome-wide analysis which identified cis-eQTL for 44% of tested genes (32). 
Another large consortium, the Genotype-Tissue Expression (GTEx) Project, aims to 
characterize genetic effects on gene expression in a tissue-specific manner, and has 
catalogued effects across 44 human tissues (33). It is also possible to perform cell type 
specific eQTL studies. Previously, single-cell eQTL analyses were performed by 
deconvoluting bulk gene expression data, or by using purified cells from sorting techniques 
like FACS, as was done for the Database of Immune Cell Expression (DICE) project. In 
their first report, the DICE group examined 13 immune cell types and 2 activated cell types, 
and identified cis-eQTL for 12,154 genes, 41% of which were specific to a unique cell type 
(34). However, these methods can be limited by dependence on surface marker genes and 
exclusion of rare cell populations (35). Utilizing single cell RNA-seq theoretically enables 
the discovery of eQTL associations without these biases but is more complicated in 
practice. A proof of concept study in 2018 used single cell RNA-seq data of 25,000 PBMCs 
from 45 individuals to validate associations identified previously in whole blood eQTL 
studies, but faced difficulties when investigating cell type dependent associations because 
of the high levels of dropout characteristic of single cell RNA-seq data (36). More recently, 
the single-cell eQTLGen Consortium was established to systematically analyze single cell 
expression of peripheral blood mononuclear cells, building upon knowledge previously 
collected in the bulk whole blood eQTLgen Consortium (37). The OneK1K study also 
represents another large-scale study of over 1.2 million PBMCs from nearly one thousand 




expression (38).  As the cost of single-cell sequencing technologies drops and new 
techniques are developed to address current challenges in analysis and replicability, similar 
groups will continue to emerge to synthesize single-cell RNA-seq datasets across 
additional tissues and fully characterize gene regulation at the single cell level. 
 
1.3 Successive Efforts to Leverage Genetics in the Study of IBD 
As the cost of nucleic acid sequencing has fallen, the potential for genomic and 
transcriptomic profiling to direct and improve clinical care has risen. In the field of 
inflammatory bowel disease, ever-evolving approaches to characterizing the genetic 
architecture underlying disease risk and pathogenesis continue to be successfully applied 
to larger and larger cohorts of patients. 
1.3.1 GWAS identify IBD risk loci 
Following the sequencing of the first human genome in the early 2000s, rapid 
advancements in sequencing technologies enabled novel mapping of genotype to 
phenotype associations via genome-wide association studies (GWAS). GWAS have been 
particularly successful within the field of inflammatory bowel disease. The power of 
GWAS to identify risk loci has increased with both technological improvements in 
genotyping arrays and increasing numbers of IBD patients. Numerous GWAS on Crohn’s 
disease, ulcerative colitis, and combined inflammatory bowel diseases can be summarized 




culminating in a total of approximately 240 variants associated with risk for inflammatory 
bowel disease identified to date (1, 2, 39). Cumulatively, well over 100,000 individuals 
have been profiled in these studies. The authors report overlap of susceptibility loci with 
other inflammatory and immune-mediated diseases, including ankylosing spondylitis and 
psoriasis. De Lange et al. in particular identified associations located near integrin genes, 
notable because of the recent emergence of drugs such as vedolizumab that prevent 
immune cell migration to the gut by blocking integrin receptors (39). 
Despite the impressive size and achievements of these recent integrated studies, 
some of the fundamental weaknesses of GWAS remain to be addressed. First is the issue 
of missing heritability, the proportion of heritability left unexplained by GWAS which may 
be attributed to poor detection of rare variants, common variants with low individual 
effects, and unaccounted environmental or gene interactions (40). In inflammatory bowel 
disease specifically, estimations of heritability of risk for CD and UC based on GWAS are 
37% and 27% respectively, just under half of the heritability calculated from twin studies, 
75% and 67% (41, 42). Second, the great majority of GWAS, including GWAS of IBD, 
have been conducted in cohorts of primarily European and secondarily East Asian 
populations, limiting applications in populations of other ancestries (43). This bias will be 
further addressed in the following section on inflammatory bowel disease in African 
Americans. Finally, one of the major weaknesses of genome-wide association studies is 
the missing link between identified risk variants and underlying causal mechanisms of 




demonstrated limited predictive power to distinguish disease risk, further highlighting the 
necessity for complementary information to translate research into reality (44).  
1.3.2  Transcriptomics offers insights into causal mechanisms 
Bridging the gap between GWAS and biological interpretation, gene expression 
and more recently single-cell gene expression studies offer insights into potential 
mechanisms of disease. Bulk tissue RNA-Seq studies have previously revealed differential 
expression of key inflammatory and immunomodulatory genes distinguishing subtypes of 
disease (7, 45-47). Newer single-cell profiling has enabled the dissection of more refined 
Figure 4 – Population bias in GWAS. GWAS population proportions contrasted 




cell-type specific contributions to disease (48). For example, Parikh et al. sampled colonic 
tissue from three healthy individuals and inflamed and uninflamed colonic tissue from 
three individuals with ulcerative colitis (49). They identified two clusters representing 
inflammation-associated goblet cells and intraepithelial immune cells, and discovered 
1,147 differentially expressed genes in inflamed UC samples. Individual cell subtypes such 
as colonocytes, goblet cells, and Paneth cells each induced different pathways contributing 
to overall signatures of disease. Additionally, the authors tested UC risk loci identified in 
GWAS for cell-type expression specificity and found that while intra-epithelial T cells 
were most associated with IBD in healthy tissue, diverse subsets of immune and absorptive 
epithelial cell types each contributed small defects in function to the overall failure of the 
epithelial barrier seen in disease. 
Similarly, Smillie et al. sequenced 366,650 cells obtained from a collection of 68 
paired colonic biopsies from 18 ulcerative colitis patients and 10 healthy controls (50). 
They characterized 51 subsets of cells based on gene expression, and identified changes in 
cell type composition between non-inflamed, inflamed, and healthy samples. Additionally, 
they studied the cell type specific expression of GWAS-implicated genes and discovered 
enrichment both in a cell type and disease specific manner. Their findings both confirmed 
previously reported associations and revealed novel associations that could have only been 





1.4 Inflammatory Bowel Disease in African Americans  
Approximately 40 million individuals who self-identify as African American live in 
the United States. The influence of ethnicity on IBD phenotypes remains poorly 
characterized, as the great majority of studies are based on cohorts of exclusively white 
individuals, and what research does exist is limited by small sample sizes. Although this 
discrepancy is not by any means unique to the field of IBD, it presents challenges to 
understanding the etiology of disease in African Americans, as evidence exists that there 
may be population-specific differences in risk and outcomes. It has been estimated, fairly 
Figure 5 – Tissue-specific enrichment of UC GWAS loci in single-cell clusters in 





consistently, that the prevalence of IBD is approximately two to three times greater in 
Caucasians compared with African Americans (53-55). However, the literature offers 
conflicting reports on prognosis in African Americans. Several studies claim to observe no 
significant differences in outcomes between Caucasian and African American patients 
(56). Yet others report that African Americans experience more severe disease, worse 
outcomes, and require more intensive medical interventions. For example, one study of 
racial disparities in pediatric CD found that black children had a shorter time to first 
hospital readmission and greater risk of readmission, with longer lengths of hospitalization, 
findings seemingly corroborated by other hospital-based studies in adult cohorts (4, 57, 
58). In addition, differences in clinical phenotypes such as perianal disease, occurrence of 
fistulas, and ileal involvement have also been noted (5, 59, 60). African American race was 
also found to be associated with increased risk of progressing to stricturing or penetrating 
disease in CD, and increased rate of postoperative complications (7, 60). These findings 
suggest that the biological mechanisms of disease in IBD may differ between populations, 
but purely epidemiological and clinical data is insufficient to draw conclusions. It is 
necessary to examine the underlying genetics of IBD to separate the contribution of factors 
like socioeconomic status and healthcare utilization from intrinsic ancestry-specific 
differences in disease. 
Immune response is a highly complex phenotype that has been shaped by natural 
selection over the course of many generations. Conducting genetic research in African 
Americans requires consideration of the unique features and evolution of the population. 




African and 20% European ancestry (61). Owing to their high proportion of West African 
ancestry, African American genomes are much more diverse than Caucasian genomes, and 
possess shorter linkage disequilibrium (LD) blocks (62). Studies of immune response 
variation between populations have consistently shown that individuals of African descent 
have stronger responses to bacterial and viral challenges (63, 64). Underlying this ancestry-
specific variation are antiviral and inflammatory-related genes enriched for eQTL 
associations, and changes in allele frequencies (64). Increased diversity within the major 
histocompatibility complex (MHC), a critical region of the genome that has been associated 
with numerous autoimmune diseases, in African American populations is well documented 
and may also account for variations in immune response (65-68). 
Some of the known risk factors which contribute to the risk of disease progression in 
IBD include age at diagnosis, inflammation location, response to microbial antigens, and 
variants associated with certain genes such as NOD2 and MMP3 (69-72). Current research 
has identified variants associated with IBD risk that appear to be common amongst African 
American and Caucasian populations, as well as ancestry specific variants. NOD2, 
nucleotide oligomerization domain, is the gene most consistently associated with risk for 
complications in white and especially Jewish populations (73). Multiple studies have 
concluded that NOD2 mutations are solely due to European admixture, the variants confer 
a similar increase in risk compared with whites, but account for a lower attributable amount 
of risk due to reduced allele frequencies in African American populations (74-76). 
Numerous large genome-wide association studies have been performed in IBD in mostly 




60,000 individuals (39, 77). An initial GWAS of IBD in African Americans with a total 
sample size of approximately 3,000 individuals replicated several European loci but was 
underpowered to detect novel associations; however, a newer study expanded to more than 
7,000 individuals identified two novel African-specific UC loci associated with ZNF649 
and LSAMP, and multiple associations in the HLA region for IBD which were African-
specific (78, 79). A very recent whole-genome sequencing study of over 3,000 individuals 
established genome-wide significant association of PTGER4 with Crohn’s disease in 
African Americans for the first time (80). Importantly, the authors demonstrated that 
utilizing ancestry-matched weights for the generation of polygenic risk scores significantly 
improved performance in the highest risk percentiles. Further investigation into the 
function of risk variants is necessary to understand their contributions to disease. 
 
1.5 Personalized Medicine for IBD with Genomic & Transcriptomic Profiling  
 As mentioned previously, early therapy with anti-TNFα can influence the course of 
CD and reduce the risk of developing complications. A recent study found that the per-
member per-year cost of the average IBD patient taking biologics in 2015 was $36,051, a 
nearly 8-fold increase in costs compared with patients taking 5-ASA only and 36-fold 
increase compared with patients taking immunomodulators only (81). In addition, the 
potential off-target effects of anti-TNFα include immunogenicity, increased rate of 
infections, and organ failure, making blanket drug prescription unconscionable (82). The 




early identification of patients at risk for progressing to complicated disease and thus who 
would benefit the most from treatment with biologics.  
Although GWAS has successfully identified thousands of variants associated with 
disease, the predictive capability of genetic risk scores is hampered by the low percentage 
of heritability explained (40). Gene expression signatures are often associated with 
outcomes of interest, as is the case in progression of disease in Crohn’s, but it is difficult 
to ascertain causality of specific genes. By integrating genomic and transcriptomic data 
through eQTL studies and beyond, we may be able to capture the full potential of both to 
further precision medicine for IBD (83). For example, Transcriptional Risk Score (TRS) is 
Figure 6 – Per-member per-year costs of common IBD medications. The cost of 





an approach which successfully combines GWAS results, eQTL information, and gene 
expression to identify patients who will progress to complicated CD, effectively linking 
statistical associations to underlying biological mechanisms (8). Holistically, this thesis 
seeks to achieve this type of integration of genetics and the transcriptome for 
characterization of disease, with additional foci on elucidating the influences of ancestry 







CHAPTER 2. DISEASE-SPECIFIC REGULATION OF GENE 
EXPRESSION IN A COMPARATIVE ANALYSIS OF JUVENILE 
IDIOPATHIC ARTHRITIS AND INFLAMMATORY BOWEL 
DISEASE 
 The genetic and immunological factors that contribute to differences in 
susceptibility and progression between sub-types of inflammatory and autoimmune 
diseases continue to be elucidated. Inflammatory bowel disease and juvenile idiopathic 
arthritis are both clinically heterogeneous and known to be due in part to abnormal 
regulation of gene activity in diverse immune cell types. Comparative genomic analysis of 
these conditions is expected to reveal differences in underlying genetic mechanisms of 
disease. 
 We performed RNA-Seq on whole blood samples from 202 patients with 
oligoarticular, polyarticular, or systemic juvenile idiopathic arthritis, or with Crohn’s 
disease or ulcerative colitis, as well as healthy controls, to characterize differences in gene 
expression. Gene ontology analysis combined with Blood Transcript Module and Blood 
Informative Transcript analysis was used to infer immunological differences. Comparative 
expression quantitative trait locus (eQTL) analysis was used to quantify disease-specific 
regulation of transcript abundance. 
 A pattern of differentially expressed genes and pathways reveals a gradient of 
disease spanning from healthy controls to oligoarticular, polyarticular, and systemic 
juvenile idiopathic arthritis (JIA); Crohn’s disease; and ulcerative colitis. Transcriptional 




found to have similar effects across disease sub-types, but we also identify disease-specific 
eQTL at loci associated with disease by GWAS. JIA and IBD are characterized by 
divergent peripheral blood transcriptomes, the genetic regulation of which displays limited 
disease specificity, implying that disease-specific genetic influences are largely 
independent of, or downstream of, cis-eQTL effects. 
 This study was performed in collaboration with the Prahalad lab and Kugathasan 
lab at Emory University. Our findings were published in Genome Medicine (84). 
 
2.1 Introduction 
 While genomic analyses have clearly established a high degree of shared genetic 
susceptibility across autoimmune and inflammatory disorders, the reasons for disease-
specific effects of particular loci are yet to be understood (85). Likely explanations range 
from the technical, such as variable statistical power across studies, to the biological, 
including restriction of effects to relevant cell types for each condition, and interactions 
between genotypes and either the environment or genetic background. Since the majority 
of genome-wide association study (GWAS) associations are likely regulatory, attention has 
focused on mapping genetic effects on gene expression and/or epigenetic marks, namely 
discovery of expression quantitative trait locus (eQTL) and their methylation counterparts, 
mQTL (86). With a few exceptions, most studies attempting to relate GWAS to functional 
genomics have utilized large public eQTL and epigenetic datasets of peripheral blood-
derived profiles of healthy volunteers. These implicitly assume equivalence of eQTL 




treatments which mimic perturbations corresponding to disease states (63, 87). In order to 
evaluate the ratio of common to disease-specific effects in inflammatory autoimmune 
disease, here we describe side-by-side comparative eQTL analysis of juvenile idiopathic 
arthritis (JIA) and inflammatory bowel disease (IBD), also comparing the transcriptomes 
among major sub-types within both JIA and IBD. 
IBD has been extensively studied using a variety of genomic approaches, but 
despite several early publications, JIA has been less well characterized (88-91). JIA is the 
most common rheumatic disease of childhood, with an estimated prevalence of 
approximately 1.2 individuals per 1000 in the USA (92). It comprises multiple clinically 
and genetically distinct forms of arthritis with onset prior to age 16. Although all forms of 
JIA are characterized by persistent swelling of the joints, the disease is further classified 
into sub-types based on clinical presentation (93). Oligoarticular JIA affects four or fewer 
joints and is the most common and typically the mildest form of JIA (93, 94). Polyarticular 
JIA involves five or more joints and is intermediate in severity. Both oligoarticular and 
polyarticular JIA disproportionately affect females. Systemic JIA (sJIA) is distinct from 
other JIA sub-types, displaying unique symptoms and no bias towards females (93, 95). 
Diagnosis is based on presentation of arthritis accompanied by spiking fever, rash, and 
lymphadenopathy. Approximately 10% of sJIA patients are also diagnosed with life-
threatening macrophage activation syndrome, and about 50% experience a persistent 
course of disease and are unable to achieve remission (95, 96). 
The categorization of sub-types based primarily on clinical criteria reflects 




The immune system is thought to play a critical role in the pathogenesis of JIA. Levels of 
immune-related cells like lymphocytes, monocytes, and neutrophils are differentially 
elevated between sub-types (97), as is also seen in other autoimmune and autoinflammatory 
diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (98). Evidence 
of T cell activation has been described in oligoarticular and polyarticular patients, 
suggesting the importance of adaptive immunity in these sub-types (94, 99), but there is 
considerable heterogeneity in immune profiles that masks differences between levels of 
severity (100, 101), with age-of-onset also an important factor influencing gene expression 
(102). In contrast, sJIA is thought to be more characterized by activation of innate 
immunity and upregulated monocytes, macrophages, and neutrophils (95, 103). 
Extensive genome-wide association studies have been performed across 
autoimmune classes and are conveniently summarized on the ImmunoBase website 
(https://genetics.opentargets.org/immunobase), which as of February 2018 lists 23 
validated loci for JIA, 81 for RA, 102 for ulcerative colitis (UC), and 122 for Crohn’s 
disease (CD) (104). Previous studies have demonstrated familial aggregation of JIA, 
supporting the idea that genetics plays a role in susceptibility (105) as well as sub-type 
development. Studies of genetic variants within the major histocompatibility complex 
region have uncovered associations between various human leukocyte antigen (HLA) 
polymorphisms and sub-types of JIA (106, 107). HLA-independent loci such as PTPN22 
and STAT4 have also been repeatedly found in genome-wide association studies to be 
associated with oligoarticular and RF-negative polyarticular JIA at genome-wide 




identified as occurring at higher frequencies in sJIA patients (112, 113). The most recent 
international GWAS of 982 children with sJIA concluded that the systemic form of JIA 
engages more inflammatory than autoimmune-related genes (114), consistent with clinical 
observations of the course of disease. 
Diverse autoimmune conditions certainly are attributable in part to intrinsic aspects 
of the focal tissue and in part to gene activity in the immune system, some of which should 
be detectable in peripheral blood samples. It is thus surprising that side-by-side 
comparisons of immune gene expression across disease sub-types have not been reported. 
Transcriptomic studies of disease are for practical reasons orders of magnitude smaller than 
GWAS, typically involving fewer than 200 patients, but these are nevertheless sufficient 
to identify eQTL given the relatively large effect of regulatory polymorphisms on local 
gene expression. Numerous blood- and tissue-specific susceptibility loci and eQTL have 
previously been discovered (115-117). It is likely that sJIA in particular shares associated 
risk polymorphisms with IBD given the auto-inflammatory component of both diseases. 
For instance, a mutation in LACC1 that was initially associated with Crohn’s disease was 
later found also to be associated with sJIA (118, 119). Thus, IBD is an attractive candidate 
for comparison with JIA to elucidate the mechanisms behind each of the sub-types. Here 
we contrast healthy controls; patients with oligoarticular, polyarticular, or systemic JIA; 
and patients with two forms of IBD, CD, or UC. As well as evaluating overall transcriptome 
differences among sub-types, we evaluate the disease specificity of whole blood eQTL 
effects in order to infer what fraction of risk can be attributed to differences in genetic 






In total, there were 190 patients and 12 controls. Protocols including signed consent 
of all participants and/or assent of parents in the case of minors were approved by the IRBs 
of Emory University and Georgia Institute of Technology. All patient cohorts were 
comprised of individuals of European (n = 141) or African (n = 49) ancestry from the USA. 
The cohorts are further divided into IBD and JIA subgroups. Within the IBD subgroup, 60 
individuals were CD patients while 15 were UC patients. The average age of disease onset 
for CD and UC patients was approximately 14 years, with ages of onset ranging from less 
than 1 to 26 years. The JIA subgroup was comprised of 43 oligoarticular, 46 polyarticular, 
and 26 systemic JIA patients. The average age of disease onset for JIA patients was 8 years, 
with onset ages ranging from 0.7 to 17 years. 
2.2.2 RNA-Seq processing and differential gene expression analysis 
RNA was isolated from whole blood, and RNA-Seq was used to determine profiles 
of gene expression. The paired-end 100 bp reads were mapped to human genome hg19 
using TopHat2 (120) with default parameters, with 90.4% success rate. The aligned reads 
were converted into number of reads per gene using SAMtools and HTSeq with the default 
union mode (121, 122). The raw counts were then processed by trimmed mean of M-values 
normalization via the edgeR R package into normalized counts (123). To further normalize 
and remove batch effects from gene expression data, surrogate variable analysis (SVA) 




all genes with greater than 10 individuals with greater than six read counts and FPKM > 0.1 
were extracted. Expression of the sex-specific genes RPS4Y1, EIF1AY, DDX3Y, 
KDM5D, and XIST was used to verify the gender of each individual. The SVA R package 
(124) was used to identify 15 latent confounding factors, and these were statistically 
removed without compromising known disease variables using the supervised 
normalization procedure in the SNM R package (125). Pairwise comparisons between 
control, CD, UC, oligoarticular JIA, polyarticular JIA, and systemic JIA were performed 
to quantify the extent of differential expression. Using edgeR’s generalized linear model 
likelihood ratio test function, the log fold change and Benjamini-Hochberg adjusted p value 
were obtained for all genes within each contrast (123). 
Gene ontology analysis was performed using the GOseq R package, which 
incorporates RNA-Seq read length biases into its testing (126). Genes with an edgeR-
calculated FDR of < 0.01 were considered to be differentially expressed and input into the 
GOseq software. Genes were distinguished by positive and negative log fold change to 
classify upregulation in specific sub-types. Only pathways within the biological processes 
and molecular function gene ontology branches were called. 
Analysis of established immune-related gene sets was performed using BIT (Blood 
Informative Transcript) and BTM (Blood Transcript Module) gene expression (127, 128). 
The BITs are highly co-regulated genes which define seven axes of blood immune activity 
that are highly conserved across whole blood gene expression datasets. Standard PCA 
analysis including multiple PC captures most of the variance also described by the BIT, 




meaning. By contrast, the BIT axes, as originally characterized by Preininger et al. (127), 
capture components of variation that are consistently observed across all peripheral blood 
gene expression studies, for the most part independent of platform. We simply take PC1 
for the representative genes for each axis and note that this typically explains upwards of 
70% of variance of those transcripts, so it is highly representative of overall gene 
expression in the axis. Whereas in previous work (127) we labelled nine axes BIT axis 1 
through 9, subsequent analyses and comparison with BTMs has led to affirmation of the 
immunological functions captured by six of the axes, which we here rename reflecting 
these functions as axis T (T cell-related, formerly 1), axis B (B cell-related, formerly 3), 
axis N (neutrophil-related, formerly 5), axis R (reticulocyte-related, formerly 2), axis I 
(interferon-responsive, formerly 7), and axis G (general cellular biosynthesis, formerly 4). 
axis 6 remains of uncertain function, while axes 8 and 9 are dropped since they are 
derivative and less consistent. Finally, a newly identified axis C captures numerous cell 
cycle-related aspects of gene activity. Each of these axes clusters with a subset of the 247 
BTMs identified by Li et al. in their machine-learning meta-analysis of 30,000 peripheral 
blood gene expression samples from over 500 studies (128), and these relationships were 
visualized by hierarchical cluster analysis performed using Ward’s method in SAS/JMP 
Genomics (129). 
2.2.3 SNP data processing and eQTL analysis 
The Affymetrix Axiom BioBank and Illumina Immunochip arrays were used to 
perform genotyping, at Akesogen Inc. (Norcross, GA). Quality control was performed 




Weinberg equilibrium at P < 10−3, minor allele frequency < 1%, and rate of missing data 
across individuals > 5% (130). 
The Affymetrix Axiom BioBank array, which has a coverage of 800 k SNPs, was 
utilized to genotype the 115 JIA samples and 27 IBD samples. The Immunochip, which 
includes a high density of genotypes at loci containing markers known to be associated 
with various autoimmune and inflammatory diseases, including CD and UC, was used to 
genotype the remaining IBD samples. Following QC, imputation was performed using the 
SHAPEIT and IMPUTE2 software in order to merge the datasets (131, 132). However, due 
to the nature of the Immunochip, imputation failed to generate reliable results for sites 
outside of the densely genotyped regions. Consequently, the eQTL analysis was initially 
performed independently on the JIA and IBD datasets, and then, overlapping loci 
significant in either study were pooled for the interaction testing. For JIA, following QC, 
we analyzed 109 individuals with 5,522,769 variants. For IBD, the available Affymetrix 
samples were merged with the remaining 27 IBD samples from the Immunochip dataset 
by selecting overlapping SNPs, which following QC resulted in 54 individuals with 58,788 
variants in the vicinity of the 186 immune-related loci, plus the HLA complex, included on 
the Immunochip. In summary, 27 IBD samples were genotyped on the Affymetrix array, 
while 27 were typed on the Immunochip, and the remaining 21 IBD samples had expression 
but not genotype data. 
Using the genes from the SVA and SNM adjusted expression data and the separate 
compiled variants from JIA and IBD, a list of genes and SNPs within 250 kb upstream and 




was performed using the linear mixed modelling method in GEMMA (133), which 
generated a final file of 16,913,152 SNP-gene pairs for JIA samples and 338,005 SNP-
gene pairs for IBD samples. Since there are on average close to five candidate genes per 
SNP, between the two diseases, 263,575 SNP-gene pairs were shared that were analyzed 
jointly. A common p value threshold of p < 0.0001 corresponding to an empirical FDR 
< 5% was chosen, yielding 814 SNP-gene univariate associations. Conditional analysis was 
underpowered to detect secondary signals consistently, so we simply retained the peak 
eSNP associations defining 142 eGenes. Since low minor allele frequencies can drive 
spurious eQTL signatures if the minor homozygotes have outlier gene expression, we 
checked for an overall relationship between MAF and eQTL significance. None was 
observed, implying that rare variants are not driving the results in general, but we also 
examined each of the loci with significant interaction effects manually, identifying a small 
number of false positives. A notable example is IL10, which had an anomalously high 
disease-by-interaction (p~10−7) driven by a large effect size in IBD (beta = 2.7) that turns 
out to be due to a single outlier, removal of which abrogates any eQTL effect at the locus 
(also consistent with the blood eQTL browser report (32)). 
The eQTL×disease interaction effect which evaluates whether the genotype 
contribution is the same in JIA and IBD was modeled by combining the imputed rsID 
genotypes for the lead SNP in either disease into a joint linear model with gene expression 
as a function of genotype, disease, and genotype-by-disease interaction, assuming the 
residuals are normally distributed with a mean of zero. A caveat to this analysis is that the 




secondary SNPs in one or other condition may skew the single-site evaluations. Post hoc 
analyses revealed that secondary eQTLs are evident at three loci reported (PAM, SLC22A5, 
and GBAP1). 
2.2.4 Adjustments for medication and disease duration 
Because the JIA patients in our study were not recruited from a single cohort, 
therapeutic interventions and duration of disease vary between individuals. Environmental 
factors include exposure to medications and impact gene expression profiles (134). In 
addition, it has previously been shown that gene expression networks are altered over the 
first 6 months of therapy for JIA patients (135). To characterize the effects of these 
covariates, our JIA patients were classified by three non-exclusive categories of 
medication: known treatment with disease-modifying anti-rheumatic drugs (DMARDs), 
biologics, and steroids at the time of sample collection, as well as three categories of 
disease duration prior to sampling: less than 180 days, 180–360 days, and greater than 360 
days. Nearly all IBD patients were sampled at diagnosis, so this stratification was only 
necessary for JIA patients. Medication and time variables were then modeled and removed 
using SNM, resulting in an adjusted gene expression dataset (125). The previously 
described BIT axis analysis was performed again using this adjusted dataset and compared 
with results from the unadjusted dataset (Appendix B: Supplementary Figure 1A). 
Appendix B: Supplementary Figure 1B shows the correlation between unadjusted gene 
expression and category of disease duration. In addition, the JIA eQTL study was rerun 
using the adjusted expression dataset. The correlation of betas from the unadjusted and 




Furthermore, we were able to replicate the major trends in gene expression 
observed in our dataset in a published Affymetrix microarray study of samples from the 
various subsets of JIA (135). They studied PBMC gene expression for 29 controls, 30 
oligoarticular, 49 polyarticular, and 18 systemic JIA patients all obtained prior to initiation 
of therapy (135). As shown in Appendix B: Supplementary Figure 3, axes R, B, N, I, and 
C give very similar results whereas the T cell signature which is mildly reduced in more 
severe JIA in our data does not differentiate their sample types. Additionally, axis G 
reverses the sign of effect, as it does upon adjustment for medication usage, reinforcing the 
conclusion that general cellular metabolic processes are affected by medication. By 
contrast, Hu et al. (136) report effects of anti-TNF biologic therapy specifically on certain 
neutrophil-related pathways, a result not recapitulated in our data, likely due to differences 
in experimental design. 
2.2.5 Colocalization and transcriptional risk score (TRS) analysis 
Colocalization analysis was performed using JIA and IBD eQTL data and prior 
IBD, rheumatoid arthritis, and JIA GWAS study data. The coloc R package uses a Bayesian 
model to determine posterior probabilities for five hypotheses on whether a shared causal 
variant is present for two traits (137). The analysis considered all SNPs associated with 
IBD (n = 232), RA (n = 101), or JIA (n = 28) as discovered by GWAS, where n = 198, 57, 
21 and n = 198, 83, 20 were present in SNP-gene eQTL datasets for IBD and JIA, 
respectively. Cross-comparisons between both of the eQTL datasets and each of the GWAS 
studies’ reported loci was performed, following which select SNP-gene pairs with high 




(same causal variant driving the signal at the eQTL and GWAS peaks) were plotted using 
LocusZoom (138) to visualize the region surrounding the variants. 
Two independent transcriptional risk scores (TRS) were generated using GWAS 
results for IBD (2) and RA (139) as a proxy for JIA (since the JIA pool of variants is 
currently too small). As previously described, TRS sums the z-scores of gene expression 
polarized by the direction of effect of the eQTL relative to the GWAS risk allele (8). Thus, 
if the risk genotype is associated with decreased expression, we invert the z-score in the 
summation such that positive TRS represents elevated risk. We only used genotypes that 
are validated as both eQTL and GWAS by H4 in the coloc analysis, taking the eQTL list 
from the blood eQTL browser since it has much higher power than the small disease 
samples. Thirty-nine and 23 genes were included in the IBD and RA TRS, respectively, as 
listed in Appendix A: Supplementary Table 1. ANOVA was performed between groups to 
establish whether the TRS can be used to predict disease from blood gene expression. 
 
2.3 Results 
2.3.1 Heterogeneity of gene expression within and among disease sub-types 
In order to contrast the nature of differential gene expression between three sub-types of 
JIA and two sub-types of IBD as well as relative to healthy controls, we conducted whole 
blood gene expression profiling on a combined sample of 202 children with disease onset 




polyarticular JIA, 26 of systemic JIA, 60 of Crohn’s disease, and 15 of ulcerative colitis. 
RNA-Seq analysis was performed with a median of 19.6 million paired-end 100 bp reads 
per sample. After normalization and quality control as described in the “Methods” section, 
a total of 11,614 genes remained for analysis. 
Previous microarray-based gene expression profiling of JIA has established 
significant mean differences among disease sub-types, as well as heterogeneity within sub-
types (89-92). A heat map of two-way hierarchical clustering of all genes in all individuals 
reveals six major clusters of individuals (rows in Fig. 7a) who share co-regulation of at 
least nine sets of genes (columns). For example, the top cluster labeled in dark blue consists 
of individuals with generally high innate immunity gene expression and low lymphocyte 
gene expression, whereas the bottom two clusters labeled in pale blue and green have the 
opposite profile, though with differences in T cell-related expression. Individuals in each 
of the six health and disease categories are dispersed throughout the matrix but with highly 
significant tendencies for enrichment of specific expression clusters in each sub-type, as 
shown in Fig. 7b. Eighty percent of the healthy controls are in the pale green cluster, which 
accounts for just one quarter of the oligo-JIA sub-type and less than 15% of each of the 
others. The two IBD sub-types are more likely to be in the dark blue cluster, as are sJIA 
cases, consistent with these being more inflammatory conditions, but in each case, the 
majority of individuals from each disease sub-type are dispersed throughout the other 
clusters. JIA in general has high membership in the red cluster, while there is an apparent 
gradient with oligo-JIA more control-like and sJIA more IBD-like. As with other 




gene expression pattern is dominated by heterogeneity without ambiguous separation by 
disease type. Figure 7c shows that 9.5% of the gene expression captured by the first five 
principal components is among disease categories and another 7.3% among the sub-types 
within JIA and IBD, with a small component also attributable to age-of-onset less than 6. 
Figure 7 – Heterogeneity of gene expression within and among disease sub-types. 
(a) Two-way hierarchical clustering using Ward’s method of standardized normal 
(z-scores) of transcript abundance of 11,614 genes (columns) in 202 individuals 
(rows). Six clusters identified to the right group individuals with similar profiles 
with respect to at least nine clusters of co-expressed genes. Letter beneath the heat 
map highlight BIT corresponding to genes enriched in reticulocytes (R), neutrophils 
(N), B cells (B), T cells (T), or for the interferon response (I). (b) Proportion of 
individuals of each disease sub-type represented in each of the six clusters of 
individual. For example, 45% of the UC samples are in the dark blue cluster, 30% 
in the red, 20% in the green, and 5% in the pale green, with none in the brown or 
light blue. (c) Principal variance component analysis shows the weighted average 
contribution of disease, sub-type within disease, or age-of-onset before 6 to the first 
five PC (67%) of the total gene expression variance, with the remainder residual 




2.3.2 Functional characterization of the gradient of differential expression 
Contrasts of significant differential expression performed between healthy controls 
and sub-types of JIA as well as combined IBD and sub-types of JIA confirm the gradient 
of differential expression between disease groups of different severities. Appendix A: 
Supplementary Table 2 lists the significantly differentially expressed genes at the 5% 
Benjamini-Hochberg false discovery rate, for each comparison of two disease groups from 
the six under consideration. In the comparison between healthy controls and oligoarticular 
JIA, 82 genes were significantly upregulated in healthy controls, and 7 were upregulated 
in oligoarticular JIA. These numbers are lower than the 136 and 36 differentially expressed 
genes found in the contrasts between healthy controls and polyarticular JIA, and the 216 
and 547 upregulated genes found between healthy controls and sJIA. A similar graded 
pattern of differentiation was found in comparisons of IBD and JIA. The fewest 
differentially expressed genes were found in the contrast between IBD and sJIA, with 73 
upregulated genes in IBD and 170 upregulated genes in systemic JIA. Between IBD and 
polyarticular JIA, 934 upregulated IBD genes and 767 upregulated polyarticular genes 
were discovered, while the biggest differentiation was observed between IBD and 
oligoarticular JIA, where 2038 upregulated IBD genes and 1751 upregulated oligoarticular 
genes were discovered. These patterns of differential expression also confirm that of the 
three JIA sub-types, systemic JIA is the most similar to IBD. 
The biological meaning of these differentially expressed genes was investigated 
through gene ontology and modular analysis. Contrasts between healthy controls and JIA 




subtypes of JIA showed downregulation of transmembrane signaling and G-protein-
coupled receptor activity. However, oligoarticular JIA showed primarily upregulation of 
protein and phospholipid metabolic processes while polyarticular JIA showed upregulation 
in secretion, exocytosis, and granulocyte activation, as well as neutrophil activation. 
Systemic JIA showed an even more strongly significant upregulation of immune pathways, 
notably general immune response and myeloid activation. In contrast, for the comparisons 
between IBD and JIA subtypes, all JIA subtypes showed upregulation of nucleic acid 
processes compared with IBD. Both oligoarticular and polyarticular JIA showed strongly 
significant downregulation of myeloid, neutrophil, and leukocyte activity compared with 
IBD, whereas sJIA showed downregulation of general metabolic processes albeit at a much 
lower significance level. 
2.3.3 Clustering by BTMs and BITs further reveals enriched immune pathways 
Decades of blood gene expression analysis have highlighted the existence of 
modules of co-expressed genes that reflect a combination of joint regulation within cell 
types and variable abundance of the major leukocyte classes (140). Seven highly conserved 
axes of blood variation (127) are composed of genes broadly capturing immune activity 
related to T and B cells, reticulocytes and neutrophils, interferon response, general 
biosynthesis, and the cell cycle. Figure 8 shows clear trends of expression along these axes 
correlating with disease sub-type, each panel indicating the level of activation in each 
immune component in, from left to right, healthy control, oligoarticular JIA, polyarticular 
JIA, systemic JIA, Crohn’s disease, and ulcerative colitis. Axis T, representing T cell 




values correlating with severity of disease, suggesting downregulation of adaptive 
immunity in systemic JIA, CD, and UC. In contrast, axis R, representing reticulocytes, and 
axis N, representing neutrophils, show trends of increasing PC1 values with disease 
severity that indicates upregulation of the innate immune system in systemic JIA, CD, and 
UC. Axis I represents interferon-responsive gene expression and has a more parabolic 
trend, being elevated in polyarticular and systemic JIA and Crohn’s disease, but not 
ulcerative colitis, reflecting the interferon response’s dual roles in both adaptive and innate 
immunity. Axes G and C represent general and cell cycle expression, and show trends of 
higher PC1 values in inflammatory bowel disease and systemic JIA. Despite sample sizes 
of around 30 patients in each group, ANOVA indicates that the differences are significant 





Figure 8 – Axes of variation across disease sub-types. Axes of variation defined by 
the first PC of the Blood Informative Transcripts (BIT) highlight variation in types 
of immune activity across disease sub-types. Each individual data point represents 
PC1 score for 10 BIT for the indicated axis, with box and whisker plots showing the 
median and interquartile range as well as 95% confidence intervals for the sub-





These disease-specific trends are confirmed by hierarchical clustering of 247 Blood 
Transcript Modules (BTMs) (128) in Fig. 9, tabulated in Appendix A: Supplementary 
Table 3, further supporting the gradient of disrupted gene expression based on disease 
severity. Healthy controls and oligoarticular JIA show largely similar expression, except 
for apparent elevation of NK cell gene expression in controls. IBD most resembles sJIA, 
although with some key differences. Myeloid gene expression tends to be elevated in IBD 
and lymphoid gene expression suppressed, with JIA intermediate. In addition, ulcerative 
colitis appears to have a specific deficit in NK cell-biased gene expression, sJIA has a 
unique signature including inositol metabolism, and JIA in general shows reduced 
mitochondrial gene activity. 
 
Figure 9 – Blood Transcript Modules. Hierarchical clustering of blood transcription 
modules across disease sub-types. The heat map shows the mean PC1 scores for 247 
BTM identified in (127), as well seven BIT axes. Note how the BTM form ~ 10 
clusters, seven of which co-cluster with one orthogonally determined axis. See 





2.3.4 Transcriptional risk scores differentiate healthy controls, JIA, and IBD 
We recently proposed the notion of a transcriptional risk score (TRS), which is 
analogous to a cumulative burden of genotypic risk, but evaluates cumulative burden of 
risk due to elevated or suppressed gene expression relevant to disease (8, 83). By just 
focusing on genes with shared eQTL and GWAS associations, the analysis is restricted to 
genes most likely to have a causal role in pathology, whether because the risk allele directly 
promotes disease or fails to provide sufficient protection. A TRS based on eQTL detected 
in blood but with gene expression measured in ileum was highly predictive of Crohn’s 
disease progression, whereas a corresponding genetic risk score was not. Figure 10 shows 
similarly that the 39-gene IBD TRS measured in peripheral blood provides significant 
discrimination of cases and controls (difference in standard deviation units of TRS; 
∆s.d. = 1.10, p = 0.0003); notably, sJIA is elevated to the same degree as both CD and UC. 
By contrast, oligoarticular JIA and polyarticular JIA have intermediate TRS that are 
nevertheless significantly greater than healthy controls (∆s.d. = 1.04, p = 0.0031). For 
comparison, a TRS based on genes that are likely to be causal in driving the signal at 23 
genome-wide significant associations for RA does not discriminate between healthy 
controls and IBD as a group (∆s.d. = 0.11, p = 0.63) but does trend toward discrimination 
of JIA as a category (∆s.d. = 0.42, p = 0.09). This RA TRS is mostly enhanced in sJIA 
(∆s.d. = 0.86, p = 0.008 relative to healthy controls), suggesting that it is capturing the 





Figure 10 – Transcriptional risk scores associate with disease status. (a) IBD-TRS 
scores within disease sub-types for 39 genes associated with IBD in (2). Gene 
expression values for each selected gene were transformed into z-scores, polarized 
relative to risk according to whether the eQTL activity of the risk allele discovered 
by GWAS increases or decreases transcript abundance, and summed to generate the 
TRS as in (8). (b) New RA-TRS based on 23 genes associated with RA by GWAS 
(139). 
 
2.3.5 Evaluation of disease specificity of eQTL 
We next addressed the degree of sharing of the local genetic control of gene 
expression in the two classes of disease (namely JIA and IBD) by performing comparative 
eQTL analysis. Whole genome genotypes were ascertained on the Immunochip (CD and 
UC samples) or the Affymetrix Axiom Biobank array (see the “Methods” section). As far 
as possible, SNPs were imputed onto the 1000 Genomes reference, allowing cross-




on the Immunochip. Since genotypes were generated on different platforms, the eQTL 
assessment was first performed independently for the two broad disease classes, after 
which significant effects were evaluated jointly. Here we only consider genes located 
within the vicinity of the Immunochip loci. 
For JIA, 107 independent eSNPs were identified within 500 kb of a transcript at an 
FDR of 5% (approximate p < 10−4), and for IBD, which had a smaller sample size, 52 
independent eSNPs were identified. These are listed in Appendix A: Supplementary Table 
4. Twelve of the loci overlap between the two diseases, but failure to detect an eQTL in 
one condition does not necessarily imply absence of the effect, since the small sample size 
results in relatively low power. Overall, the correlation in effect sizes is high, ~ 0.7 
(p = 5 × 10−20 in JIA; p = 2 × 10−8 in IBD), which is remarkable given the small sample 
sizes, and strongly implies that most eQTL effects in whole blood are consistent across the 
diseases. Nevertheless, the plots in Fig. 11 depicting the estimated eQTL effect sizes in 
IBD relative to JIA provide some support for disease-biased effects in so far as the eQTL 
discovered in JIA (red points, panel a) tend to have larger effects on JIA (beta values) than 
those observed in IBD and hence lie between the diagonal and the x-axis. Conversely, the 
eQTL discovered in IBD (blue points, panel b) tend to have larger effects on IBD than 
those observed in JIA and hence lie between the diagonal and the y-axis. This result is 
biased by winner’s curse, the tendency to over-estimate effect sizes upon discovery, so we 
also evaluated all associations jointly in order to also identify interaction effects. At an 
FDR of 10%, 34 of the 147 independent eQTL, highlighted in panel c, show nominally 




classes of disease. Example box plots of genotypic effects on transcript abundance across 
the two disease classes are provided in Appendix B: Supplementary Figure 4. These 
genotype-by-disease interaction effects remain significant after accounting for ancestry 
(see Appendix B: Supplementary Figure 5). 
 
 
Figure 11 – Comparison of peripheral blood eQTL effects between JIA and IBD. 
Effect sizes of peak eSNPs by disease. (a) Correlation of beta effect sizes between 
IBD and JIA for the 107 peak independent eSNPs discovered in the JIA sample. (b) 
Correlation of beta effect sizes between IBD and JIA for the 52 top eSNPs identified 
in JIA. (c) Thirty-four eSNPs with a significant interaction effect between disease 





As expected, many of the detected eQTLs affect expression of genes in the vicinity 
of established GWAS hits for autoimmune disease. Table 1 lists 25 lead eSNPs that 
regulate expression in cis of 22 target genes that are listed on ImmunoBase as potential 
causal genes for IBD or arthritis (JIA or RA). Half of these associations are with IBD only, 
but this bias may simply reflect increased power of the IBD GWAS to date. Several of the 
SNPs show evidence of disease-specific or disease-biased effects. Naively, we might 
expect the eQTL to be seen only in the disease(s) for which the association with disease is 
seen, as this would be consistent with allele-specific expression driving pathology. Three 
cases (ARPC2, CPTP for IBD, and the secondary eQTL in PAM for JIA) fit the expected 
pattern, but three others have the counter-intuitive relationship where the eQTL is observed 
in one disease but the established GWAS association is with the opposite disease (PRDX6 
and ADAM1A for RA, the secondary eQTL in GBAP1 for CD). Three more cases 
(SLC22A5, CD226, and RNASET2) have possibly disease-biased eQTL effects where the 
eQTL is absent from or much less in one disease, although the interaction effect is only 
significant in one of these cases. Despite the small sample, there is not an intuitive pattern 








Table 1 – 25 lead eSNPs that regulate expression in cis of 22 target potential causal 
genes for IBD or arthritis (JIA or RA) 





ARPC2 rs13429408 0.82 6.60E−05 0.18 0.22 CD, UC – 0.01 
CPTP rs11809901 − 1.08 9.80E−05 − 0.12 0.69 CD, UC – 0.04 
PAM rs2431321 1.04 3.80E−09 1.15 2.10E−23 – RA 0.48 
PAM rs32677 0.21 0.3 0.94 5.30E−15 – RA 9.60E−05 
C5 rs1468673 0.39 0.02 0.74 3.10E−07 – RA 0.34 
PRDX6 rs4279882 1.84 3.80E−05 0.36 0.05 – RA 0.001 
ADAM1A rs11066027 1.22 2.40E−05 0.61 5.30E−03 – JIA, RA 0.09 
RNASET2 rs385863 − 0.68 1.30E−04 − 1.05 1.40E−14 CD, UC RA 0.3 
GSDMB rs11078926 − 0.51 5.90E−03 − 0.56 9.90E−07 CD, UC RA 0.87 
SLC22A5 rs11739135 0.09 0.6 − 0.8 9.80E−10 CD, UC JIA 4.00E−05 
SLC22A5 rs11950562 − 0.53 8.00E−04 − 0.86 6.10E−14 CD, UC JIA 0.07 
ORMDL3 rs1565923 1.11 8.80E−07 0.47 6.20E−04 CD, UC RA 0.01 
ICAM4 rs3093029 1.22 4.80E−04 1.3 2.90E−08 CD, UC JIA 0.69 
RMI2 rs11644184 − 0.58 7.60E−04 − 0.7 3.00E−07 CD, UC JIA 0.54 
PLTP rs7275164 − 0.56 2.10E−04 − 0.71 7.00E−07 CD, UC RA 0.58 
CD226 rs12969613 0.63 2.20E−07 0.18 0.15 CD, UC RA 0.11 
NOD2 rs1981760 1.28 2.70E−08 1.05 2.30E−16 CD – 0.23 
GBAP1 rs914615 0.6 3.20E−04 0.8 7.80E−10 CD – 0.62 
GBAP1 rs3814319 0.16 0.33 0.7 1.20E−06 CD – 0.05 
KSR1 rs2945378 − 0.48 6.20E−03 − 0.6 4.40E−07 CD – 0.52 
SULT1A1 rs7191548 − 0.49 6.50E−03 − 0.61 5.30E−07 CD, UC – 0.93 
PNKD rs13430006 0.34 0.14 0.57 6.80E−07 CD, UC – 0.41 
NLRP2 rs12975582 0.56 0.01 0.8 1.20E−06 CD, UC – 0.43 
SLC11A1 rs78846874 − 0.35 0.36 − 0.83 3.90E−06 CD, UC – 0.22 





One reason for divergent effect sizes may be that different causal variants in 
variable degrees of linkage disequilibrium could be responsible for the differential 
expression in the two disease sub-types. To investigate this, we performed colocalization 
analysis using coloc (137) to visualize the locus-wide SNP effects across all loci reported 
in IBD, RA, and JIA GWAS and present in our SNP-gene datasets for IBD or JIA and 
compared these with the distribution of GWAS summary statistics. Coloc assigns a 
posterior probability that the same SNP is responsible for both an eQTL effect and the 
disease association (H4) or that different SNPs are responsible for the two effects (H3). 
Since the power of this mode of analysis is limited when sample sizes are small, we 
identified cases from either disease with relatively strong H3 or H4 posterior probabilities 
and plotted representative examples in Fig. 12. The full results are summarized in 
Appendix A: Supplementary Table 5. 
Figure 12a shows results for association of rs12946510 with IBD from GWAS 
(bottom panel) and the eQTL profiles for the JIA (top panel) and IBD (middle panel) gene 
expression. Although coloc calls both cases as H4, the correspondence of SNP profiles in 
high LD with the lead SNP is more notable in JIA. The light blue SNPs suggest a second, 
independent, eQTL which does not produce a GWAS signal. Hence, the gene expression 
difference may be mediated by two different SNPs, possibly with different effect sizes in 
the two diseases, only one of which appears to contribute strongly to disease risk. Figure 
12b shows a clear H3 case in JIA where the eQTL effect on expression of PAM appears to 
be mediated by a cluster of variants to the left of the lead GWAS cluster. Figure 12c shows 




expression and disease, although the precise identity of the causal variant is impossible to 





Figure 12 – Colocalization of eQTL and GWAS signatures. LocusZoom plots show 
the univariate SNP-wise association statistics for each genotyped SNP either with 
the abundance of the indicated transcript (eQTL effects) or from the GWAS for 
IBD or RA. Color coding indicates the r2 measure of linkage disequilibrium of each 
SNP with the relevant peak GWAS SNP. (a) rs12946510 is most likely a shared 
causal variant for ORMDL3 gene expression in both IBD and JIA, as well as in the 
IBD GWAS. However, a likely secondary signal in the light blue region is not 
associated with IBD. (b) rs2561477 is the peak causal variant in RA but clearly does 
not colocalize with the peak eQTL for JIA. (c) rs3740415 is most likely a shared 
causal variant for expression of TMEM180 and in the IBD GWAS despite an 
extensive LD block at the locus (though it does not meet the strict GWAS threshold). 
 
2.4 Discussion 
2.4.1 Disease-specific associations with autoimmune disease 
There are multiple technical reasons why GWAS may fail to detect associations 
that are shared across multiple autoimmune diseases. These include differences in sample 
size and clinical heterogeneity, and with respect to eQTL analysis, differences in 
expression profiling platform, statistical methodology, and effects of pharmacological 
interventions could all obscure associations. However, it is also clear that the genetic 
correlation across diseases is significantly less than one, establishing the expectation that 
some effects must be disease-specific (141). The most appropriate framework for detecting 
such effects is evaluation of the significance of genotype-by-disease interaction terms, 
which motivated the current study. 
The core result of the comparative eQTL component of this study is that the 
majority of genetic influences on transcript abundance measured in whole blood are 




type specific effects will often go undetected in both whole blood and PBMC studies (97, 
101). It is though important to note that while neutrophils, lymphocytes, macrophages, and 
monocytes certainly do have unique and disease-relevant eQTL, comparative studies also 
confirm that over three quarters of eQTL are shared by the majority of immune cells (142, 
143). 
Just as importantly, equivalence of genetic influences on gene expression does not 
necessarily mean equivalence of genetic influences on disease susceptibility. Among the 
shared eQTL, some genes are still likely to be specific to CD, UC, JIA, or other conditions 
by virtue of other influences. These may include disease-specific contributions of the 
critical cell type, environmental differences (for example, microbial infection of the gut 
may elevate or suppress expression of the gene to a degree that renders the eQTL 
meaningful or irrelevant), or interactions with the genetic background (for example, 
elevated expression of a gene may only matter in the context of other genetic risk factors). 
Although there is little evidence that two-locus genotype-by-genotype interactions 
contribute meaningfully to heritability (144), renewed interest in influences of overall 
genetic risk on the impact of specific genotypes makes sense given the context of gene 
expression heterogeneity (145). 
Our analyses do provide evidence that as many as 20% of eQTL effects in 
peripheral blood may at least show disease-specific biases. Such differences in effect sizes 
are likely to trace to differences in the expression of transcription factors and epigenetic 
modifications between diseases and/or to differences in the relative abundance of 




(146), but they are low resolution and in our opinion unreliable when applied to sample 
sizes of the order of 100; next-generation studies incorporating single-cell RNA-Seq will 
be much more informative. 
The relationship between disease-specific eQTL and GWAS association at the 
same locus is less straightforward than might be expected under the assumption that the 
effect of a polymorphism on disease is mediated through its effect on transcription of the 
associated gene. It is not immediately clear why an eQTL may only be detected in one 
disease while the GWAS association is in another disease, yet multiple instances are found 
in our data. This observation adds to a growing body of data questioning whether detected 
eQTL effects explain causal associations. Two fine mapping studies of IBD published in 
2017 (147, 148) both found less than 30% identity between mapped eQTL and GWAS 
causal intervals, one suggesting that there is more significant overlap with methylation 
QTL and both arguing that the relevant effects may be specific to particular cell types or 
activation conditions, including immune activity at the sight of the pathology. Additionally, 
we described a meaningful number of “incoherent” associations, where mean differential 
expression between cases and controls is in the opposite direction to that predicted by the 
effect of the risk allele on gene expression (8). Such results highlight the need for a 
combination of fine structure mapping of causal variants and detailed mechanistic studies 
of immune cell-type contributions if we are to fully understand how segregating 





2.4.2 Disease- and sub-type-specific gene expression 
Numerous other studies have described gene expression profiles in a variety of 
inflammatory autoimmune diseases, but we are aware of just a single side-by-side 
comparison of two or more diseases on the same platform (143). Straightforward cluster 
analysis shows that both IBD and JIA subjects tend to differ from healthy controls, but they 
have overall transcriptome profiles that may belong to a half dozen types. Blood Transcript 
Module and BIT axis analyses, both based on comprehensive analysis of existing whole 
blood gene expression datasets, confirm that these types broadly reflect differences in gene 
activity in the major immune sub-types, partly reflecting cell abundance, but also innate 
states of activity of biosynthetic, cell cycle, and cytokine signaling. Immunoprofiling by 
flow cytometry has established that individuals have baseline profiles, or omic 
personalities (149), to which they return after immunological perturbation but which are 
also influenced by such environmental factors as child-rearing (150). Sub-type-specific 
blood gene expression should be seen in light of this immunological elasticity, as the 
heterogeneity among subjects may be more meaningful for disease risk than individual 
eQTL effects. 
Juvenile idiopathic arthritis is the most prevalent childhood rheumatic disease, 
encompassing multiple physically, immunologically, and genetically different sub-types of 
disease. Although diagnosis and classification is based upon largely clinical criteria, the 
genetic complexity of JIA has been well documented (110, 111). While the oligoarticular 
and polyarticular sub-types demonstrate activation of adaptive immunity, systemic JIA 




activity between sub-types differ (91, 151, 152). These findings at the gene expression level 
are consistent with emerging GWAS results suggesting that systemic JIA is etiologically a 
quite different disease. It is particularly noteworthy that both of the transcriptional risk 
scores we document show that systemic JIA is divergent from the articular forms, being 
close to the IBD profiles for the IBD-TRS, and uniquely elevated for the RA-TRS. 
In this study, we performed cross-sub-type and disease comparisons of gene 
expression and eQTLs to characterize the similarities and differences between the forms of 
JIA. Differential gene expression analysis revealed a gradient of order among the JIA sub-
types and IBD, from healthy controls, to oligoarticular, polyarticular, and systemic JIA, to 
Crohn’s disease and ulcerative colitis. Numbers of differentially expressed genes, gene 
ontology pathway types, and significance levels agree with this pattern of ordering. 
Consistent with previous research, oligoarticular and polyarticular JIA exhibits a trend of 
activated T cell gene expression relative to systemic JIA (100-103, 106). As a group, JIA 
also demonstrates increased expression of B cell-related genes. There is also an ordered 
increase in neutrophil gene expression from oligoarticular to systemic JIA, which concurs 
with systemic JIA being closely tied with innate immunity. In addition, the elevation of 
oligoarticular and polyarticular JIA over controls points to involvement of neutrophils in 
these sub-types as well, which has been previously suggested (88). Taken as a whole, these 
findings suggest that JIA sub-types are mediated through a complex relationship between 
adaptive and innate immunity, and neither disease can be fully characterized by simply one 






This study has three major limitations. Firstly, since the subjects were not a part of 
any single-cohort study, they were treated with different medications or had samples taken 
at later time points after diagnosis. The sample size, though larger than many published 
studies, is still too small to partition the effects of plausible technical covariates or of 
environmental mediators of gene expression such as those described by Favé et al. and 
Idaghdour et al. (134, 153). The results of the covariate-adjustment analyses presented in 
Appendix B: Supplementary Figures 1 and 2 suggest that the effects on our dataset are 
minimal compared with the consistent effect of disease subtype, but therapeutic effects 
should still be considered in interpretations of our findings. Secondly, whole blood samples 
were utilized to measure gene expression. Because whole blood is composed of multiple 
cell types, there will inherently be some mixture and dilution of gene signatures. Although 
it is well established that whole blood expression profiles are capable of illuminating 
aspects of autoimmune pathology, immune cell sub-type analyses will have higher 
resolution (101). Single-cell RNA-Seq has great potential both to trace general features of 
peripheral blood gene expression to specific cell types and to foster accurate eQTL analysis 
at the sub-type level. Thirdly, we describe just a cross-sectional snap shot of the 
transcriptome of each subject, whereas longitudinal profiling has the promise of correlating 







Gene expression and genotyping data can help to categorize sub-types of JIA and IBD 
beyond just clinical features. The gradient of gene expression from healthy controls to 
oligoarticular, polyarticular, and systemic JIA to IBD reflects a complex interplay between 
adaptive and innate immunity responsible for differentiation between JIA sub-types. 
Individuals have sub-type-specific probabilities of having one of a small number of global 
gene expression profiles. Since the majority of eQTL appear to have similar effect sizes 
across disease sub-types, disease-specific cis-eQTL effects only explain a small fraction of 
disease-specific genetic influences on disease. Considerably more fine mapping and 
functional analysis will be required before personalized therapeutic interventions for 





CHAPTER 3. AFRICAN ANCESTRY PROPORTION 
INFLUENCES ILEAL GENE EXPRESSION IN 
INFLAMMATORY BOWEL DISEASE 
3.1 Introduction 
 The influence of ancestry on inflammatory bowel disease (IBD) susceptibility has 
recently been examined via several large-scale genome-wide association studies (GWAS) 
(78, 79), but the effects of ancestry-specific variation in risk and modifier gene expression 
on prognosis in IBD remain poorly characterized. It has been estimated fairly consistently 
that the prevalence of IBD is approximately two-to-three times greater in individuals of 
European versus African American (AA) descent (53), but the literature offers conflicting 
reports on complications and outcomes in AA versus European ancestry patients (4, 7). AA 
individuals tend to be admixed, with approximately 80% African (YRI) and 20% European 
ancestry (CEU) (61). Although GWAS have identified hundreds of variants associated with 
IBD risk, most research has been conducted on cohorts of exclusively European ancestry 
(39). Earlier studies on IBD risk variants such as NOD2 concluded that mutations in AA 
individuals result from European admixture, and thus confer similar increases in risk (74). 
However, the largest GWAS study to date of IBD in AA identified two novel African-
specific loci associated with IBD, hinting at the existence of African-specific contributions 




 In this chapter, I evaluated ileal transcriptomic profiles of 154 individuals of mostly 
AA and European ancestry with IBD, and characterized differential gene expression 
between populations. I then examined the effect of proportions of African and European 
ancestry in AA patients on gene expression, demonstrating that observed variation in gene 
expression between populations is heritable and not solely due to environmental 
differences. This study was performed in collaboration with the Kugathasan lab at Emory 
University, and our findings have been published in Cellular and Molecular 




 In total, 129 patients and 25 controls were profiled for this study. Protocols included 
signed consent of all participants and/or assent of parents in the case of minors, and were 
approved by the IRBs of Emory University and Georgia Institute of Technology. Of the 
154 total participants, 121 self-identified as African American and 33 identified as white. 
The cohort was evenly divided by gender, with 78 female participants and 76 male 
participants. Suspected IBD, chronic abdominal pain without known etiology, and 
unexplained weight loss were amongst the most common indications for colonoscopy to 
be performed in control individuals. Controls retained for this study had normal 
colonoscopy without inflammation, as well as normal histology verified through multiple 




colitis, of whom 28 were African American and 8 were European ancestry, and 93 
individuals with Crohn’s disease, of whom 76 were African American and 17 were 
European ancestry. The average age of onset amongst patients with UC and CD was 
approximately 14 years. Amongst the characterized CD patients, 18 had L1 (ileal), 11 had 
L2 (colonic), 53 had L3 (ileocolonic), and 1 had L1-L4 (upper gastrointestinal disease) 
disease location; 54 had B1 (non-stricturing), 19 had B2 (stricturing), and 8 had B3 
(penetrating) status. Amongst the characterized UC patients, 4 had E1 location (ulcerative 
proctitis), 6 had E2 location (distal), and 25 had E3 disease location (proximal). 
3.2.2 RNA-Seq processing and gene expression analysis 
 RNA was isolated from biopsies of the ileum for Lexogen 3’ sequencing. Single 
end 75bp reads were trimmed for adapters with FastQC and Trim Galore, then mapped to 
human genome GrCh37 with the hisat2 aligner (156, 157). The aligned reads were 
converted into read counts per gene using HTSeq (122). The raw read counts were 
normalized with the edgeR R package implementation of trimmed mean of M-values 
normalization (123). A combination of surrogate variable analysis (SVA) and supervised 
normalization (SNM) was then applied to remove batch effects and other confounding 
factors (124, 125). First, expression of the sex-specific genes RPS4Y1, EIF1AY, DDX3Y, 
KDM5D, and XIST was checked to verify reported gender, resulting in the exclusion of 13 
non-matching individuals. The SVA R package was then used to identify 6 surrogate 
variables which were then removed via supervised normalization in the SNM R package. 
Pairwise differential gene expression testing between African American and white IBD 




and Benjamini-Hochberg adjusted p-values for all genes (158). Hierarchical clustering of 
the 2,705 genes differentially expressed at FDR < 0.05 was performed with the NMF R 
package. Gene set enrichment analysis was performed with GSEA, using pre-ranked mode 
on all 14,392 genes ranked by multiplying the sign of the fold change by the inverse of the 
Benjamini-Hochberg adjusted p-value (159).   Principal components of sets of 
differentially expressed genes were used to evaluate whether case-control status or 
therapeutic regimen explain the ancestry effects, as plotted in Appendix B: Supplementary 
Figure 6.  With the exception of steroids, which were only given to a subset of AA patients, 
neither of these factors associate with ancestry. 
3.2.3 Variant calling and calculation of ancestry proportion 
 The GATK Best Practices workflow for calling variants in RNAseq was followed 
to generate a VCF file of SNPs for individuals in this study (160). VCF files for 1000 
Genomes individuals belonging to either the CEU population (n=85) or YRI population 
(n=88) were extracted (161). Both VCF files were merged, and quality control for 
genotyping rate was performed with PLINK, restricting the dataset to 12,819 variants 
(162). Ancestry proportions for African American individuals were assigned using 
ADMIXTURE software in supervised mode, where 1000 Genomes CEU and white 
individuals from this study were provided as a known European population, and 1000 
Genomes YRI individuals were provided as a known African population (163). Plots of 





3.2.4 Calculation of heritable portion of gene expression variation 
 The calculation of the heritable portion of observed gene expression variation 
between populations in this study was based on methods first described by Price et al (164). 
Individuals in this study were separated into CEU+YRI and African American population 
groups. 33 white individuals and 33 individuals with African ancestry proportions ~ 0.9999 
were grouped into the CEU and YRI categories, while all other individuals were classified 
as African American. Gene expression across each gene was z-score normalized in the 
CEU+YRI group and African American group. Expression in the CEU+YRI group can be 
modeled as egs = agθs+νgs, where egs represents expression of gene g in individual s, ag 
represents observed gene expression differences between CEU and YRI, θs denotes 
genome-wide African ancestry of either 0 or 1, and νgs represents residual effects. Then, 
egs = cagθs+νgs for the African American group, where θs now ranges from 0 to 1 and c is a 
coefficient representing the extent to which ag is heritable. An estimate of ag,CEU+YRI can be 
obtained by regressing egs  against θs within the CEU+YRI group, and similarly an estimate 
of ag,AA can be obtained by regressing egs  against θs within the African American group. 
An estimate of c can then be obtained by regressing the two estimates of ag. The statistical 
significance of the estimated c was validated by testing the values of c obtained from 1000 
sets of random permutations of African ancestry among African American individuals, 
then ranking the correlations. The permutation test yielded a p-value of 0.05 for the c 







We performed RNA-seq of ileal biopsies sampled from control individuals (n=25, 
no intestinal inflammation and normal histology) and 129 patients with ulcerative colitis 
(UC, n=36) and Crohn’s disease (CD, n=93). Differential gene expression analysis 
revealed 1,360 upregulated and 1,345 downregulated genes at an FDR cutoff of 0.05 in AA 
patients compared with European ancestry patients (Figure 13). Hierarchical clustering 
based on these 2,705 genes shows separation of transcriptomic profiles by ancestry into 
two clusters (Figure 13b). To explore functional pathways implicated by differentially 
expressed genes, we performed Gene Set Enrichment Analysis (GSEA). Oxidative 
phosphorylation, adipogenesis, and xenobiotic metabolism were amongst the gene sets 
enriched for genes upregulated in AA, while TNFα signaling, inflammatory response, and 
interferon-γ response were enriched in downregulated genes (Figure 13c, Appendix A: 
Supplementary Table 6).  Each of these pathways is highly relevant to the development 
and progression of pathology in IBD, which highlights the importance of better 
understanding of the genetic contributions to the disease and possible personalized 









Figure 13 – Differential gene expression by ancestry. (a) Volcano plot depicting log 
difference (x-axis) and –log10 p-value (y-axis) for 14,392 genes between African 
(n=104) and European (n=25) ancestry IBD patients. (b) Hierarchical clustering of 
2,705 genes differentially expressed at FDR < 0.05 from (a). Top bar: individuals 
grouped into Cluster 1 (red; n=70 AA, 4 European) and Cluster 2 (blue; n=34 AA, 
21 European). Middle bar: self-reported AA (red) or European (blue) ancestry. 
Bottom bar: Estimated proportion of African (red) and European (blue) ancestry 
from supervised ADMIXTURE analysis. (c) Gene set enrichment analysis ranking 
plots. Each line represents a gene, while position from left to right represents 
ranking calculated by multiplying sign of fold change by inverse of FDR value. Top 
row shows bias towards downregulated genes in AA; bottom row shows bias 




Following differential expression analyses, we sought to validate that the population-
based variation in gene expression we observed is heritable and not solely attributable to 
environmental differences. By studying an admixed population, we can contrast the 
influences of European and African ancestry among individuals of mixed ancestry to the 
difference between the two predominant ancestry groups. Proportions of admixture in AA 
were estimated from common genotypes called from the RNA-Seq reads, using 
ADMIXTURE software (163) with 1000 Genomes CEU and YRI individuals as reference 
European and African populations (Figure 14a). AA who group with European ancestry 
individuals in Cluster 2 exhibit a highly significant (p = 6×10-5) trend of increased 
proportions of European admixture compared with AA grouping in Cluster 1 (Figure 14b). 
We then applied methods introduced by Price et al. (164) to estimate the percentage of 
gene expression variation between populations that can be attributed to genetic effects. 
They argued that the slope of the regression of gene expression against ancestry proportion 
should be the same as the regression of the difference between the two predominant 
ancestry groups if the effect of ancestry is purely genetic, whereas if the two measures are 
uncorrelated it is purely environmental.  The slope c of the two regressions assessed across 
all genes thus provides an estimate of the total sample heritability. By applying this method, 
we obtained c=0.43, which we validated as statistically significant (p = 0.05) relative to 
1000-permutations (Figure 14c, Appendix A: Supplementary Table 7). This value implies 
a substantial heritable component to differences in gene expression observed between AA 







Figure 14 – Influence of ancestry proportions on gene expression. (a) Proportions of 
ancestry assigned to AA individuals. CEU population consists of 1000 Genomes 
Utah Northern and Western European ancestry individuals (n=85) and European 
ancestry individuals from this study; YRI population consists of 1000 Genomes 
Yoruban individuals (n=88). (b) Representative boxplot for ANOVA between self-
identified AA in Cluster 1 (n=70) and Cluster 2 (n=34) from Figure 1b. Y-axis 
represents proportion of YRI ancestry. P = 6×10-5. Horizontal line is grand mean.  
(c) Plot of regressed estimates of the effect of ancestry proportion on gene 
expression for the top 5,000 most highly expressed genes, calculated in CEU vs YRI 





In summary, our study shows strong differential gene expression in key pathways 
based on African versus European ancestry. We further demonstrate that this variation in 
gene expression amongst populations can be partially attributed to heritable, genetic 
effects, rather than solely to differences in environmental factors. The pathways 
highlighted here are known to be critical in IBD pathogenesis, and elevation of 
inflammatory and TNFα signaling appears to be consistent with evidence of worse 
prognosis in AA. Further investigation into ancestry-specific variation in disease is 




CHAPTER 4. GENE EXPRESSION BASED STRATIFICATION 
OF RISK OF PROGRESSION TO COLECTOMY IN 
ULCERATIVE COLITIS 
An important goal of clinical genomics is to be able to stratify risk of disease 
progression. Between 5% and 10% of ulcerative colitis (UC) patients require colectomy 
within five years of diagnosis (165), but polygenic risk scores (PRS) utilizing findings from 
GWAS are unable to provide meaningful prediction of this adverse status (166). By 
contrast, in Crohn’s disease, gene expression profiling of GWAS-significant genes does 
provide some stratification of risk of progression to complicated disease in the form of a 
Transcriptional Risk Score (TRS) (8). Here we demonstrate that measured gene expression 
identifies UC patients at 5-fold elevated risk of colectomy with data from the PROTECT 
clinical trial (167). This chapter represents a collaborative effort of all of the members of 
the PROTECT consortium. I especially wish to recognize Drs. Jeffrey Hyams, Ted Denson, 
and Subra Kugathasan for their leadership efforts, and Kyle Gettler and Mamta Giri from 




PROTECT is a multicenter pediatric inception cohort study of response to 




mucosal gene expression at diagnosis, prior to therapeutic intervention, associates with 
corticosteroid-free remission with mesalamine alone observed in 38% of 400 patients by 
week 52 of follow-up (167). A signature of rectal mucosal gene expression associated with 
week 4 corticosteroid response in PROTECT is related to one indicative of response to 
anti-TNFα and anti-α4β7 integrin therapy in adults (168), and reciprocally, active pediatric 
UC was associated with suppression of mitochondrial gene expression, and increasing 
disease severity with elevated innate immune function. In order to more explicitly model 
progression to colectomy observed in 6% (25 of 400) of the patients within one year of 
diagnosis, we performed differential expression analysis between baseline rectal RNA-Seq 
biopsies of 21 patients who progressed to colectomy, and 310 who did not. 
 
4.2 Methods 
4.2.1 The PROTECT cohort 
428 participants aged 4 to 17 years were enrolled from 29 centers across North 
America into the PROTECT study upon clinical, histological, and endoscopic diagnosis of 
ulcerative colitis. Patients with disease extent beyond the rectum, a Pediatric Ulcerative 
Colitis Activity Index (PUCAI) score of ≥ 10, no prior therapy for colitis, and negative 
enteric bacterial stool culture were eligible to participate. All baseline assessments and 
sample collections were performed prior to the initiation of therapy. Initial treatment with 
mesalamine, oral corticosteroids, or intravenous corticosteroids was decided based on 




assessments were performed at 4, 12, and 52 weeks, with other therapeutic interventions 
administered based on guidelines for need for additional medical therapy. The study 
parameters are described in further detail in Hyams et al (169). 
4.2.2 RNAseq data processing and differential expression analyses 
RNA was isolated from 340 rectal biopsies taken at baseline and 92 rectal biopsies 
taken at week 52 follow-up. RNAseq was performed with the Lexogen QuantSeq 3’ 
platform. Using FastQC, the single end 150 bp reads were trimmed and adapters were 
removed (156). Reads were mapped to human genome hg19 using hisat2, and the aligned 
reads were converted into read counts per gene with SAMtools and HTSeq in the default 
union mode (121, 122, 157, 170). The raw read counts were normalized via trimmed mean 
of M-values normalization with the edgeR R package (123). 
Expression of the sex-specific genes RPS4Y1, EIF1AY, DDX3Y, KDM5D, and XIST 
was used to validate the gender of each individual, resulting in the removal of two 
mismatches. Further adjustment and removal of batch effects was performed with surrogate 
variable analysis (SVA) combined with supervised normalization (SNM) (124, 125). Race, 
gender, initial treatment group, time of sampling, and week 52 colectomy status were 
modeled with the SVA R package, where initial treatment group, time of sampling, and 
week 52 colectomy status were protected variables, which resulted in the identification of 
28 confounding factors. Of these, five variables significantly correlated with protected 




Two individuals that were outliers in a principal component analysis of total gene 
expression were removed. 
Differential gene expression testing was performed based on colectomy status with 
the voom R package. Log fold change and Benjamini-Hochberg adjusted p-values were 
obtained for all genes. The first principal component of the top 150 genes differentially 
expressed at baseline between patients who required colectomy by week 52 follow-up (n= 
21) and patients who did not (n= 310) formed the gene expression-based risk score for 
colectomy (PC1col).  This score is moderately correlated (r=0.46) with PC1 of overall 
expression of genes differentiating UC cases and controls, reported by Haberman et al 
(168). 
Cross validation for PC1col was performed by randomizing colectomy status 
amongst individuals prior to differential gene expression testing and calculation of 
PC1colRand, as in the calculation for PC1col. ANOVA was performed between randomized 
colectomy and non-colectomy individuals, with results from 1000 such tests reported in 
Appendix B: Supplementary Figure 7. 
We compared expression of the genes comprising PC1col at baseline and week 52 
with Mayo score as a marker for mucosal healing (Appendix B: Supplementary Figure 8). 
PC1col was calculated as previously described in the subset of individuals with baseline 
gene expression. Additionally, a restricted PC1col-wk52 was calculated by finding PC1 of the 
150 genes used in the calculation of PC1col, within the subset of individuals with week 52 




PC1col and PC1col-wk52. All p-values were generated with analysis of variance (ANOVA) 
tests. 
Transcriptional Risk Scores (TRS), first introduced by Marigorta et al. (8) for 
discriminating IBD cases versus controls, capture the summation of polarized expression 
of genes incorporated based on both proximity to IBD GWAS hits and presence of eQTL 
in peripheral blood. We generated the TRS with four different strategies, all of which gave 
similar highly significant differentiation between colectomy and no colectomy samples 
(Fig. S1).  Model 1 was a GLM using the top 9 genes RGS14, APEH, MRPL20, POP7, 
CDC42SE2, RORC, EDN3, PTK2B, and STAT3 that differentiate patients by colectomy 
status (p < 0.1), essentially the sum of the z-scores weighted by their magnitude of 
differential expression. Model 2 was a GLM using the 10 genes discussed in the text due 
to strong co-regulation and association with colectomy.  Models 3 and 4 were based on all 
26 genes, generated with a weighted GLM or simple PC1 score, respectively.  All four 
scores are highly correlated, r>0.8, indicating that they are capturing similar aspects of 
differential expression (Appendix B: Supplementary Figure 12).  We report Model 4 in the 
text. This TRS is highly correlated with PC1col (r=0.64). 
Relative proportions of epithelial and immune contributions to total rectal gene 
expression reported in Appendix B: Supplementary Figure 9 were evaluated by computing 
PC1 of the expression of 200 genes upregulated specifically in the total epithelial or 
immune components of the single cell gene expression dataset reported by Smillie et al 
(50). We checked each PC to ensure that positive values associate with elevated expression 




4.2.3 Replication of colectomy risk score and cell-type enrichment 
Surgical specimens from 210 ulcerative colitis patients undergoing bowel resection 
for IBD at Mount Sinai Health System and affiliated clinicians were recruited to be part of 
the Mount Sinai Crohn’s and Colitis Registry (MSCCR) between December, 2013 and 
September, 2016 as described (171-173).  The protocol required written informed consent 
that was approved by the Icahn School of Medicine at Mount Sinai Institutional Review 
Board (HSM#14-00210). Patients who were enrolled in the study were asked to provide 
blood and/or biopsies, which were collected during a colonoscopy planned for regular care. 
Clinical and demographic information was obtained through a questionnaire.  Patients were 
treated with a range or medications, including corticosteroids, infliximab, azathioprine, and 
mesalamine. All macroscopically moderate-to-severely inflamed tissues were confirmed 
as active colitis by pathology examination provided by the Mount Sinai Hospital (MSH) 
Pathology Department. Freshly collected representative 0.5-cm-wide tissue fragments 
were isolated from surgical specimen samples, flash frozen, and stored at −80 °C.  
RNA was isolated from frozen tissue using Qiagen QIAsymphony RNA Kit (cat.# 
931636) and samples with RIN scores >7 were retained. One microgram of total RNA 
depleted of ribosomal RNA using the Ribozero kit (Illumina Cat # MRZG12324) was used 
for the preparation of sequencing libraries using RNA Tru Seq Kits (Illumina (Cat # RS-
122-2001-48). These were sequenced on the Illumina HiSeq 2500 platform using 100 bp 
paired end protocol. Base calling from Images and fluorescence intensities of the reads was 
done in situ on the HiSeq 2500 computer using Illumina software, aiming for 70,000 paired 




Genome Browser) with 2-pass STAR, and processed using RAPiD, which is a RNA-seq 
analysis framework developed and maintained by the Technology Development group at 
the Icahn Institute for Genomics and Multi-scale Biology. Detailed quality control metrics 
were generated using the RNASeQC package. Raw count data was pre-filtered to keep 
genes with CPM>0.5 for at least 3% of the samples. After filtering, count data was 
normalized via the weighted trimmed mean of M-values and further variance stabilized 
using a logarithmic transformation. Normalized counts were further transformed into 
normally distributed expression values via the voom-transformation using a model that 
included technical covariates (processing batch, RIN, exonic rate and ribosomal RNA rate), 
while accounting for the intra-patient correlation across regions.   
We repeated the transcriptional risk assessment analysis in this external dataset 
after normalization for gender, age, exonic RNA ratio, and rRNA level expression levels, 
using the prcomp function in R with the 150 genes from the PROTECT PC1col, or the 26 
gene TRS. The R package ggplot2 was then used to plot the distribution of PC1 for patients 
who did (10 patients) or did not (201 patients) have follow-up colectomies (Appendix B: 
Supplementary Figure 10). Additionally, we performed hierarchical clustering of single-
cell gene expression data to identify cell types implicated by both the PC1 and TRS gene 
sets. Cell types enriched for PC1 genes included plasmacytoid dendritic cells, endothelial 






4.2.4 SNP data processing and eQTL studies 
The Affymetrix UK BioBank Axiom Array was used to perform genotyping of 424 
individuals across 800,000 SNPs. Imputation was performed using IMPUTE2 software 
(132), after which quality control performed using PLINK was used to remove SNPs not 
in Hardy-Weinberg equilibrium at p < 10-3, SNPs with a minor allele frequency < 1%, or a 
rate of missing data across individuals > 5% (130). Approximately 7 million imputed SNPs 
passed these thresholds and were tested in the eQTL analysis. SNPs within 250 kb of the 
start and stop sites of a gene were considered to be cis to the gene and tested for a potential 
eQTL association. Mapping was performed with the mixed linear modelling method in 
GEMMA, which tested a set of approximately 12 million SNP-gene pairs for associations 
at a common p-value threshold of 1×10-5 (133). Two separate comparative analyses were 
performed, where the initial set of eQTL mapping was performed on all 330 baseline 
samples and 87 week 52 follow-up samples, and the secondary analysis was performed on 
78 matched samples only, where the same individual was profiled at both time points. The 
initial full analysis yielded 91,774 significant SNP-gene associations at baseline and 19,371 
associations at week 52 follow-up, and the secondary matched analysis yielded 14,272 
significant unique SNP-gene associations at baseline and 12,617 significant associations at 
week 52 follow-up. These were further refined to 1,317, 218, 186, and 166 peak SNP to 






4.2.5 Single cell sequence analysis of the lamina propria 
The following single cell analyses were performed primarily by Kyle Gettler and 
Mamta Giri of the Cho lab at Mt. Sinai, and reviewed by myself for inclusion in this study. 
For the analyses reported in Appendix B: Supplementary Figure 11, we analyzed a total of 
34,157 cells from paired inflamed rectum (n = 4) and uninflamed sigmoid colon (n = 5) 
from 4 UC patients undergoing treatment at Mount Sinai Hospital. Resected tissue biopsies 
were collected in ice cold RPMI 1640 (Corning Inc.) and processed within one hour after 
termination of the surgery. To limit biased enrichment of specific cell populations related 
to local variations in the intestinal micro-organization, we pooled twenty mucosal biopsies 
sampled all along the resected specimens using a biopsy forceps (EndoChoice). Epithelial 
cells were dissociated by incubating the biopsies in a dissociation medium (HBSS w/o 
Ca2+ or Mg2+ (Life Technologies) with HEPES 10mM (Life Technologies) and enriched 
with 5mM EDTA (Life Technologies)) at 37°C with 100 rpm agitation for two cycles of 
15 min. After each cycle, the biopsies were vortexed vigorously for 30 seconds, and washed 
in complete RPMI media equilibrated at RT.  They were transferred to digestion medium 
(HBSS with Ca2+ Mg2+, FCS 2%, DNase I 0.5mg/mL (Sigma-Aldrich) and collagenase 
IV 0.5mg/mL (Sigma-Aldrich)) for 40 min at 37°C with 100 rpm agitation. After digestion, 
the cell suspension was filtered through a 70mm cell strainer, washed in DBPS / 2% FCS 
/ 1mM EDTA and spun down at 400 g for 10 min. After red blood cell lysis (BioLegend), 
dead cells were depleted using the dead cell depletion kit (Miltenyi Biotec, Germany), 




calculated using a Cellometer Auto 2000 (Nexcelom Biosciences) with AO/PI dye. The 
exclusion was routinely 70% or higher live cell rate. 
Single cells were processed through the 10X Chromium platform using the 
Chromium Single Cell 3′ Library and Gel Bead Kit v2 (10X Genomics, PN-120237) and 
the Chromium Single Cell A Chip Kit (10X Genomics, PN-120236) as per the 
manufacturer’s protocol. In brief, 10,000 cells from single cell suspension were added to 
each lane of the 10X chip. The cells were partitioned into gel beads in emulsion in the 
Chromium instrument, in which cell lysis and bar-coded reverse transcription of RNA 
occurred, followed by amplification, fragmentation and 5′ adaptor and sample index 
attachment. Libraries were sequenced on an Illumina NextSeq 500. 
We aligned reads to the GRCh38 reference using the Cell Ranger v.2.1.0 Single-Cell 
Software Suite from 10X Genomics. The unfiltered raw matrices were imported into R 
Studio as a Seurat object (Seurat v3.0.1 (174)). Genes expressed in fewer than three cells 
in a sample were excluded, as were cells that expressed fewer than 500 genes and with 
UMI count less than 500 or greater than 60,000. We normalized by dividing the UMI count 
per gene by the total UMI count in the corresponding cell and log-transforming. The Seurat 
integrated model (174) was used to generate a combined ulcerative colitis model with cells 
from both inflamed and uninflamed samples retaining their group identity. We performed 
unsupervised clustering with shared nearest-neighbor graph-based clustering, using from 1 
to 15 principal components of the highly variable genes; the resolution parameter to 
determine the resulting number of clusters was also tuned accordingly. Cell types were 




Visualization of relative abundance of specific genes in each cell type was performed using 
Seurat functions in conjunction with the ggplot2 (176). 
 
4.3 Results 
The volcano plot in Fig. 15a shows down-regulation of 783 transcripts in the 
colectomy cases (red), and up-regulation of 1,405 transcripts (blue) at the experiment-wide 
threshold of p < 4×10-6. Gene set enrichment analysis (160) summarized in Fig. 15b 
highlights engagement of multiple pathways previously implicated in adverse outcomes in 
inflammatory bowel disease, including TNF and interferon signaling, and various 
signatures of inflammation and immune response (7, 177). 
The first principal component (PC1col) of the top 150 of these differentially expressed 
genes has a weak negative correlation with our previously reported signature of remission 
detected in a subset of 206 patients using a different RNA-seq protocol (168). With very 
high significance, it distinguishes the colectomy cases from non-progressors, as all but one 
case have PC1 scores greater than 10, a value exceeded by only 20 of the 317 non-
colectomy cases (Fig. 15c). A 1000-fold cross validation test confirmed the significance of 
the PC1col predictor is several orders of magnitude greater than would be expected by 
chance (Appendix B: Supplementary Figure 7). All of the high PC1col individuals were 
placed initially on corticosteroids, the majority intravenously (Fig. 15d); the score also 
correlates with a gradient of disease severity indicated by baseline PUCAI (pediatric 




RNA-seq data for 92 patients at week 52 and observed significant depression of the score 
(Fig. 15e), indicative of mucosal healing even in the cases with elevated initial gene activity 
(none of the follow-up cases were colectomy, since the surgical procedure had been 
performed earlier). Appendix B: Supplementary Figure 8 shows that PC1 remains 
associated with Mayo score even at week 52, and that the change in PC1 molecular score 





Given the marked shift in gene expression at follow-up, we next asked whether local 
regulation of the gene expression might contribute, by performing comparative eQTL 
analysis. Figure 16a indicates generally high concordance in the effect sizes (betas) at both 
time-points, with slight inflation of the estimates at baseline (1,416 blue effects) or week 
Figure 15 – Differential Expression Associated with Colectomy in the PROTECT 
study. (a) Volcano plot of significance (negative log10 of the p-value) against 
difference in expression on log2 scale, with genes up- regulated in colectomy in blue. 
(b) Six pathways highlighted by gene set enrichment analysis as up- regulated in 
colectomy.  Each bar represents a gene in the indicated pathway, and position along 
the axis is representative of rank order of differential expression. From left to right, 
FDR = 0, 0, 0, 0, 2.43×10-4, and 2.02×10-4. PC1 of the differentially expressed genes 
as a function of (c) colectomy status at week 52; p = 2×10-45, (d) initial treatment; p 
= 5×10-20, and (e) baseline or week 52 follow-up biopsy profile; p = 2×10-7. All 
boxplots indicate 1st and 3rd quartile as box ends, with center median line and 




52 (421 magenta effects), likely due to winner’s curse. There were 72 eSNPs significantly 
regulating 308 genes at both time points, with the smaller number of eQTL at week 52 
attributable to the smaller sample size. One quarter of the baseline eQTL are at least 2-fold 
greater than at week 52, and one third of the follow-up eQTL are at least 2-fold greater 
than at baseline. Clearly visible in Fig 16a are 33 apparently week 52-specific effects that 
are more than 20-fold greater than at baseline, the majority with reduced expression of the 
minor allele. Examples of baseline and follow-up specific eQTL affecting a variety of gene 
functions in immunity and epithelial cell biology are shown in Fig. 16b. Some of the change 
in eQTL profiles is likely attributable to an increase in the proportion of epithelial relative 









Next, we asked whether the intersection of GWAS, eQTL and differential 
expression could be used to generate a transcriptional risk score (TRS) for colectomy, 
analogous to the one we recently developed for prediction of risk of progression to 
complicated Crohn’s disease (8). The heatmap in Fig. 17a showing the abundance of 26 
transcripts included in the TRSIBD derived with coloc overlap (137) of IBD GWAS and 
Figure 16 – eQTL contrast between baseline and week 52 follow-up in the 
PROTECT study. (a) Comparison of effect sizes (betas) for the effect of the minor 
allele on gene expression. Blue eQTL were discovered at baseline, and magenta only 
at week 52. (b) Examples of nine genes with differential eQTL effects at the two 
timepoints showing observed transcript abundance as a function of genotype at 
baseline or week 52 follow-up. The bottom row are genes with eQTL only at follow-
up. All boxplots indicate 1st and 3rd quartile as box ends, with center median line 
and whiskers extending to farthest point within 1.5 times the interquartile range. 
Note that many of the genes with large negative follow-up betas in panel (a) have 
relatively small minor allele frequencies, hence insufficient homozygous minor allele 




peripheral blood eQTL signals, indicates striking enrichment for elevated or reduced 
expression of a dozen transcripts in the baseline rectal biopsies of PROTECT patients 
destined for colectomy. The strongest clusters include RGS14, MRPL20, PTK2B, 
TNFRSF4, TNFRSF18 and CDC42SE2 up-regulation, and CISD1, EDN3, RORC, and 
PLA2R1 down-regulation. PC1 of the entire set of 26 genes results in a TRSUC that 
discriminates colectomy from non-progressors at p=1×10-28 (Fig. 17b). A score above 3.24 
has a sensitivity of 90% and specificity of 95% (Fig. 17c), generating a positive predictive 
value of 55%, which is nine times the prevalence of the rate of progression in the study. 
Corresponding likelihood ratios for positive and negative prediction are 18 and 10 





Figure 17 – Development of a Transcriptional Risk Score for Colectomy. (a) 
Heatmap of baseline rectal expression of 26 genes with evidence that the GWAS 
peak is the same as a blood eQTL (coloc H4 > 0.8), red high expression and blue 
low. The gray bar at the top indicates colectomy status, highlighting a cluster of 
patients for whom most of the genes are differentially expressed in the cases (red 
bars). (b) PC1 of the genes generates a TRS that is highly discriminatory between 
colectomy and non-colectomy at baseline; p=1×10-28. Boxplots indicate 1st and 3rd 
quartile as box ends, with center median line and whiskers extending to farthest 
point within 1.5 times the interquartile range. (c) Receiver operating characteristic 
curve contrasting sensitivity and specificity for colectomy showing that both the 
TRS (green) and PC1 of all differentially expressed genes (red) have high accuracy 





We replicated these findings in an independent adult ulcerative colitis cohort from 
Mt. Sinai Medical School in New York (172, 179). PC1 of the rectal expression of 146 
genes strongly correlated with the PROTECT PC1col signature highly significantly 
(p=0.0015) distinguished 10 patients who have had colectomy from the remaining 201 
(Appendix B: Supplementary Figure 10a), with the majority of genes differentially 
expressed in the same direction. Similarly, a TRS derived from the 26 GWAS-associated 
transcripts showed a strong trend toward differentiation of colectomy cases in the adult 
cohort (Appendix B: Supplementary Figure 10b), which was also highly significant 
(p=0.010) after removal of two outliers characterized by aberrant expression of 
CDC42SE2, the only transcript of the 26 tested which disagreed in direction of effect 
between the two studies. 
Examination of the expression of colectomy-associated genes in a single cell RNA-
seq dataset obtained from rectal biopsies provides strong evidence that both epithelial and 
immune cells contribute to the risk of disease progression (Appendix B: Supplementary 
Figure 11). Most of the genes are strongly expressed in just one or two of the 22 identified 
cell types, seven of which are notable for an excess of colectomy associated genes: 
plasmocytoid dendritic cells, immunoregulatory T-cells, ILC3 innate immune cells, and 
inflammatory macrophages from the immune compartment, and fibroblasts, secretory 
epithelial, and endothelial cells from the gut itself. The correlated expression of these gene 
sets suggests that risk of colectomy may in part reflect abnormal relative abundance of 
these cell types. On the other hand, each of these cell types is also represented in the single 




associations and hence are likely to be related to pathology through cis- regulatory effects. 
Prospective scRNAseq studies will likely reveal more insight into the cellular and genetic 
basis of the transcriptional risk of adverse disease progression. 
 
4.4 Conclusions 
Our results highlight the potential of transcriptional profiling for prediction of 
colectomy in ulcerative colitis. Direct measurement of rectal biopsy RNA provides a highly 
discriminatory signature observed in almost all children who will need surgery, and which 
predicts the adverse outcome in up to half of all cases. This expression profile reverts to a 
healthier state regardless of immunological therapy within one year. Our results are limited 
by the relatively small sample size of colectomies in the PROTECT study, which is 
nevertheless the largest treatment-naïve inception cohort to date. It is likely that more 
widespread sampling of this and other forms of inflammatory bowel disease will yield even 









CHAPTER 5. SINGLE-CELL CHARACTERIZATION OF ILEAL 
EPITHELIAL CELLS IN CROHN’S DISEASE 
 
5.1 Introduction 
The gastrointestinal tract is a unique system of organs responsible not only for 
essential digestive and metabolic functions, but also for maintaining a highly delicate state 
of immune homeostasis (180). A perturbation of the balance between immune tolerance 
and response can result in the development of intestinal inflammation that is characteristic 
of inflammatory bowel disease.  
The unique features of the intestinal epithelial cells that are primarily involved in 
this inflammation remain poorly characterized. Traditional bulk RNA-Seq experiments 
assume that tissues being sampled are comprised of homogeneous populations of cells. 
However, the intestinal epithelium is composed of highly heterogeneous cell types, 
including rare cell types and cells in varying states of development. Hence, bulk studies 
offer only a broadly averaged snapshot of gene expression across many different cells. In 
contrast, newer single cell sequencing technologies enable the dissection of cell-type 
specific contributions to gene expression in disease (181). 
 Several notable studies have sought to characterize gut mucosa at the single cell 
level (182). One of the earliest studies by Haber et al. in 2017 profiled intestinal epithelial 




subtypes of cells as well as gene markers of those populations (183). Numerous human-
based studies soon followed, characterizing mucosal biopsies of the colon, ileum, and 
immune cells in the context of Crohn’s disease and ulcerative colitis as well as in healthy 
individuals (49, 50, 175, 184-188). 
 
Table 2 – Current single cell RNA-Seq studies of the human intestine in IBD 
Year Author Biopsy Type Focal Cells Disease Sample Size 





17 individuals - 
62,854 cells 




Epithelial Healthy 6 individuals - 14,537 cells 
2019 Huang et al. (178) Colon 
Epithelial, 
stromal, immune CD, UC 
17 individuals - 
73,165 cells 
2019 Martin et al. (169) Ileum 
Stromal, 
immune CD 
11 individuals - 
82,417 cells 
2019 Parikh et al. (46) Colon Epithelial 
Healthy, 
UC 
6 individuals - 
11,175 cells 





30 individuals - 
360,650 cells 
2019 Uniken Venema et al. (179) Ileum Immune CD 
3 individuals - 
5,292 cells 
2018 Kinchen et al. (180) Colon Stromal 
Healthy, 
UC 
10 individuals - 
9,591 cells 
 
 The gut mucosa can be subdivided into three major cellular compartments—
epithelial, stromal, and immune. In this chapter, I focus on the epithelial compartment of 
ileal biopsies obtained from healthy, treatment-naïve, and treated Crohn’s disease patients. 




within the body, and act to modulate immune responses (189). Stem cells located at the 
base of the intestinal crypt work in conjunction with transit-amplifying (TA) cells to give 
rise to numerous differentiated cell lineages, including enterocytes, enteroendocrine cells, 
goblet cells, Paneth cells, tuft cells, and M cells. Of particular interest to us in this study 
are goblet cells, which secrete protective mucins. Prior non-single-cell studies have noted 
that degradation of goblet cell function contributes to the breakdown of the intestinal 
barrier in ulcerative colitis (190). A more recent scRNA-seq study by Parikh et al. 
uncovered diverse subpopulations of goblet cells within the colon and highlighted the 
existence of inflammation-associated subsets of goblet cells in ulcerative colitis (49). 
 Following up on these findings, in this chapter I examine ileal cell type proportions, 
gene expression, and associations with disease status in a cohort of 20 healthy, anti-TNFα 
naïve Crohn’s disease, and treated Crohn’s disease individuals. In particular, I examine the 
distinct subsets of goblet cells appearing in these ileal samples, which to my knowledge is 
the first such characterization specifically in Crohn’s ileum. This study was performed in 
collaboration with the Qiu Lab at Georgia Tech and Kugathasan lab at Emory University 










 A total of 6 healthy controls, 7 treatment-naïve Crohn’s disease, and 7 Crohn’s 
disease patients were profiled in this study. Of the 20 total participants in the study, 11 
were of self-identified African American ethnicity, 7 were of Caucasian ethnicity, and 2 
were of South Asian ethnicity. The majority of the cohort was considered to be pediatric, 
ranging in age from 9 years to 20 years old, with the exception of one adult patient aged 
47 years. The group was split approximately evenly by gender, with 8 female participants 
and 12 male participants. Biopsies of the ileum were cryopreserved for single cell RNA 
sequencing, which was performed in three batches of 4, 8, and 8 samples with the 10x 
Genomics Chromium platform. 
5.2.2 Single cell RNA-Seq processing 
FASTQ files and alignment to GRCh38 was performed with Cell Ranger’s mkfastq 
and count functions (191). Samples were then read into R using the Seurat package (174). 
A total of approximately 90,000 cells was analyzed across 20 samples. For the initial step 
of identifying epithelial cells, within the Seurat v3 framework, each of the samples was 
individually log2 normalized with a scale factor of 10,000 and scaled with the ScaleData 
function. The RunPCA function was used to identify PCs based on the top 2000 variable 
features. Finally, FindNeighbors, FindClusters, and RunUMAP were run to generate 




Within individually normalized samples, clusters were assigned to one of three 
major cell type groupings—epithelial, stromal, and immune—based on highest average 
gene expression of the marker genes reported in Smillie et al. for epithelial cells (EPCAM, 
KRT8, KRT18), stromal cells (COL1A1, COL1A2, COL6A1, COL6A2, VWF, PLVAP, 
CDH5, S100B), and immune cells (CD52, CD2, CD3D, CD3G, CD3E, CD79A, CD79B, 
CD14, CD16, CD68, CD83, CSF1R, FCER1G) (50). A total of 68,241 cells grouping in 
clusters assigned as epithelial subsets were extracted from the raw counts data for the 
following joined sample set normalization steps. 
5.2.3 Cell type annotation 
Each of the raw epithelial-subset samples was then normalized with SCTransform 
individually. The standard recommended 2000 integration features were selected for 
running anchor integration with the IntegrateData function. Following integration, samples 
were again clustered as previously described. Assignment of cell types was based on gene 
markers reported in the healthy ileum by Wang et al. for enterocytes (ALPI, SLC26A3, 
TMEM37, FABP2), goblet cells (ZG16, CLCA1, FFAR4, TFF3, SPINK4), Paneth cells 
(LYZ, CA7, SPIB, CA4, FKBP1A), enteroendocrine cells (CHGA, CHGB, CPE, 
NEUROD1, PYY), progenitor cells (SOX9, CDK6, MUC4, FABP6, PLA2G2A, LCN2), 
transit-amplifying cells (KI67, PCNA, TOP2A, CCNA2, MCM5), stem cells (LGR5, 






5.2.4 Gene expression analyses 
Following assignment of cell types to clusters, differential expression analysis was 
performed between cluster 16 against all other clusters, and each individual sub-cluster of 
goblet cells against all other goblet cell clusters, using the FindMarkers function’s 
implementation of the Wilcoxon rank sum test. Pathway annotation was performed with 
ToppFun, using genes upregulated and downregulated with an adjusted p-value of 0.05 or 
greater (192). All visualizations were generated with the ggplot2 package in conjunction 
with Seurat (176). 
 
5.3 Results 
5.3.1 Annotation of key epithelial cell subtypes 
Increasingly precise classifications of cell types have become possible with the 
advent of single cell sequencing technologies. Despite the recent publication of several 
single cell transcriptomic surveys, many hurdles remain for the establishment of robust, 
inter-experimentally replicable cell type assignments. The fine resolution of single cell data 
demands equally precise reference datasets to enable accurate classification of cell types 
underpinning differential gene expression and other downstream analyses. At this nascent 
stage of development of the field, ideal reference datasets may only exist for some of the 




In this chapter, I profiled human ileal epithelial cells biopsied from Crohn’s disease 
patients, a very specific subset of cells which to date has been rarely profiled. Hence, I 
prioritized the matching of both organism and tissue type over disease status and selected 
the single-cell transcriptomic survey of the healthy human ileum performed by Wang et al. 
to serve as the reference gene expression set for our study. Wang et al. reported their 
comprehensive survey of about 15,000 epithelial cells from the ileum, rectum, and colon, 
building upon prior knowledge established in the mouse model organism (187). Here, 
following the extraction of epithelial cells and SCTransform-based normalization and 
integration described in the Methods, I utilized the gene markers they reported to annotate 
28 Seurat-identified clusters to eight major cell types—enterocyte, enteroendocrine, goblet, 




Figure 18 – Clustering of 68,241 epithelial cells. (a) Unsupervised Seurat-based 
clustering of 68,241 epithelial cells results in the identification of 28 clusters. (b) 
Cells were classified into 8 broad categories of cell types—enterocyte (n=31,329), 
progenitor (n=10,587), goblet (n=15,347), stem (n=3,619), TA (n=4,159), Paneth 
(n=485), enteroendocrine (n=444), tuft (n=435), and unknown immune (n=1,836). (c) 
Gene expression of Wang et al. markers across clusters utilized to assign cell types. 
(d) Representative gene markers of enterocytes. The left 3 genes serve to distinguish 




In their own analysis, Wang et al. based cell assignments upon previously published 
cell markers (183, 193). They reported that certain markers, for example, the previously 
reported tuft cell marker DCLK1, was not detected in their dataset. Similarly, in my 
analysis I found the expression of certain marker genes did not distinguish clusters well, 
either due to low expression or overly broad expression. Panel (d) of Figure 18 illustrates 
examples of 3 gene markers that performed well to distinguish a subset of cells, and 1 
which performed poorly within our dataset. Additionally, one cluster, cluster 16, was 
ambiguously characterized based on the Wang et al. gene markers and may potentially 
contain a novel subset of cells unrepresented in the panel. Pathway analysis of genes 
differentiating cluster 16 against all other clusters within the dataset revealed upregulation 
of genes in pathways related to antigen binding and immune response, and downregulation 
of genes in oxidoreductase and mitochondrial activity. However, because these cells were 
filtered from the whole sample for stronger expression of epithelial genes over immune 
cell markers, it is unlikely that this cluster simply represents a cluster of typical immune 
cells. Hence, here I have labelled the ambiguously defined cluster as “Unknown Immune”. 
Appendix A: Supplementary Table 8 lists top relevant pathways implicated by the 
differential expression analysis. 
5.3.2 Disease status associations with differences in cell type proportions and extreme 
gene expression 
Following the establishment of cell type annotations to clusters, I examined 
proportions of each of the sub-populations within each of the disease categories (healthy, 




type clusters based on disease status emerge. Figure 19 visualizes these proportions across 
disease groups and cell types, while Table 3 lists these proportions. 
 
Table 3 – Cell type proportions by disease status 
Disease Cell Type Proportion of Disease Group in Cell Group 
Proportion of Cell Group 
in Disease Group 
Wang et al. 
Proportion 
CD Enterocyte 0.346 0.493  
Control Enterocyte 0.261 0.479 ~0.72 
TN-CD Enterocyte 0.393 0.422  
CD Enteroendocrine 0.369 0.007  
Control Enteroendocrine 0.306 0.008 ~0.005 
TN-CD Enteroendocrine 0.324 0.005  
CD Goblet 0.272 0.189  
Control Goblet 0.229 0.206 ~0.06 
TN-CD Goblet 0.500 0.263  
CD Paneth 0.254 0.006  
Control Paneth 0.384 0.011 ~0.01 
TN-CD Paneth 0.363 0.006  
CD Progenitor 0.342 0.164  
Control Progenitor 0.224 0.139 ~0.10 
TN-CD Progenitor 0.434 0.158  
CD Stem 0.300 0.049  
Control Stem 0.314 0.067 ~0.05 
TN-CD Stem 0.386 0.048  
CD TA 0.289 0.055  
Control TA 0.284 0.069 ~0.05 
TN-CD TA 0.426 0.061  
CD Tuft 0.294 0.006  
Control Tuft 0.389 0.010 Not reported 
TN-CD Tuft 0.317 0.005  
CD Unknown Immune 0.364 0.030 
 
Control Unknown Immune 0.107 0.011 Not reported 












The proportions of most cell types identified in this study show reasonable 
concordance with previously reported data from the healthy ileum by Wang et al., with the 
exception of an increased proportion of goblet cells irrespective of disease status 
conversely also resulting in a reduced proportion of enterocytes. Notably, the Unknown 
Immune cluster appears to be largely composed of cells from the two Crohn’s disease 
groups, with cells from the control samples constituting only about 10% of the cells. This, 
in conjunction with the immune-related pathways implicated by differential gene 
expression, suggest that this subset of cells may be related to response to disease. 
Additionally, there is some evidence of differences in proportions of goblet cells between 
the three disease states. The control and Crohn’s disease samples contain fewer goblet cells 
than the treatment-naïve Crohn’s samples, although the difference does not reach the 
threshold of significance with ANOVA testing (p = 0.13). Prior surveys of goblet cell 
proportions tended to focus on the colon rather than the ileum, although one review did 
Figure 19 – Cell type proportions associated with disease status. (a) Proportions of 
cell types constituting samples grouped by control (n=17,080), Crohn’s disease 
(n=22,002), and treatment-naïve Crohn’s disease (n=29,159). (b) Proportions of each 
of the major groups of cell types originating from each of the disease status 
categories. (c) Dot plot visualizing expression of TRS genes (x-axis) in each of the 
major cell type groups subdivided by case (Crohn’s disease and treatment-naïve 
Crohn’s disease) and control. (d) Select expanded subset of dot plot visualizing 
expression of TRS genes (x-axis) in each of the major cell type groups subdivided by 
individual. An example of extreme expression in an individual’s cell type is 




report that goblet cell proportions generally increase from the duodenum to distal colon, in 
association with increasing proportions of bacteria (194). 
As an initial examination of the potential utility of Transcriptional Risk Scores in 
single cell data, I compared the expression of 28 TRS genes as described by Marigorta et 
al. within case-control and cell type groupings (8). Differences in gene expression by 
disease status are apparent, for example in IRF1 (p < 2.2×10-308), STAT3 (p < 2.2×10-308), 
and NDFIP1 (p = 2.3×10-103). By further breaking down gene expression by cell type to 
sample, we observe instances of outlier individual-driven gene expression, for example in 
the high expression of EDN3 in stem cells of Crohn’s disease patient GCA3 (Figure 19d 
and Appendix B: Supplementary Figure 13). These suggest an alternate perspective of 
disease gene expression associations, in contrast to the broadly averaged case-control 
approach, where risk for disease may be mediated by different genes amongst individuals 
and thus may be more appropriately targeted with personalized therapeutics. Following on 
the example given here, we can imagine that amongst clinically similar Crohn’s disease 
patients, the aberrant expression of EDN3 in patient GCA3’s stem cells might suggest a 
more successful drug target unique to their transcriptomic profile.  
  
5.3.3 Distinct subtypes of goblet cells associated with disease status 
Goblet cells are critical for proper functioning of the mucosal barrier, and 
abnormalities in mucus secretion are well known to be associated with the onset of 




the ileum, especially in the context of Crohn’s disease, remain poorly characterized. A 
prior, non-single-cell-based survey of goblet cells in the colon found that proportions were 
moderately reduced in Crohn’s disease and the presence of goblet cell differentiation 
factors was increased in inflamed Crohn’s disease samples (190). In this study, following 
annotation of the nine broad categories of cell types, I further examined the subclusters of 
cells constituting the broad goblet cell cluster. I observed eight subclusters of goblet cells 
in our dataset, each differentiated by varying pathways implicated by gene expression. 
Table 4 summarizes these pathways. Defects in ribosomal synthesis have previously been 
linked with increased goblet cell differentiation, and upregulation of oxidoreductase 
activity may be indicative of stress responses to inflammation. 
 
Table 4 – Differentially regulated pathways amongst goblet subclusters 
Cluster Upregulated Downregulated 
5 Adhesion & Defense Response Ribosomal Activity 
8 Intestinal Epithelium Ribosomal Activity 
11 Ribosomal Activity Peptide Antigen Binding 
12 Oxidoreductase Activity Protein & TF Binding 
20 Oxidoreductase Activity Ribosomal Activity 
21 Ribosomal Activity Peptide Antigen Binding 
26 Ribosomal Activity Peptide Antigen Binding 






Figure 20 – Breakdown of differential proportions of goblet subclusters by 
individual and disease status. (a) The y-axis depicts proportion of cells 
constituting each sample (x-axis) subdivided by non-goblet and the eight clusters 
of goblet cells. (b) Expression of reported subcluster and spatial marker genes 




Parikh et al. previously reported in their single-cell study of the UC colon evidence 
of five subclusters of goblet cells with differential gene expression associations with 
disease (49). A number of gene markers of note that they report in their goblet cell analysis 
include BCAS1 (cluster 5), CLCA1 (crypt bottom, cluster 1), SPINK1 and SPINK4 
(expressed in healthy crypt bottoms and inflamed crypt tops), WFDC2 (crypt bottom, 
reduced expression in inflammation, cluster 2), MUC2 (general marker of goblet health), 
LCN2 and REG1A (expressed throughout crypt), CD74 (crypt bottom), and LAMB3 (crypt 
top). Figure 20b shows the expression of these genes in our dataset. Understandably, as 
their study was performed in UC colon as opposed to the CD ileum profiled in this chapter, 
several of the markers are too lowly or broadly expressed to be utilized for inferring 
mapping between clusters. A few interesting patterns can be observed here, such as 
expression of the crypt bottom marker CD74 in cluster 20 (p = 3.11×10-200 for 20 vs. all 
other clusters) and non-disease-specific absence of the focal UC inflammation-associated 
gene WFDC2 (expressed in approximately 2% of cells, p = 1 for case vs. control). Taken 
as a whole, it appears that goblet subclusters are not directly transferrable between studies 
and mechanisms for goblet cell associations with disease differ between UC and CD, a 









In this study, I reported ileal cell type proportions, gene expression, and associations 
with disease status in a cohort of 20 healthy individuals and Crohn’s disease patients. 
Additionally, I highlighted subclusters of goblet cells and potential associations with 
disease. One of the primary goals of this study was to establish a robust, standardized 
workflow for analysis of this unique single cell ileal epithelial dataset. To that end, several 
challenges and avenues of exploration remain to be addressed. Foremost, as was touched 
upon earlier, the inter-experimental replicability of certain gene markers, particularly for 
less commonly profiled cell types such as the ones we have analyzed, must be improved to 
enable appropriate cell type classification and accurate downstream gene expression 
analyses which are dependent on these assignments. As more and more single cell surveys 
are published, the increasing numbers of cells being profiled should ameliorate this issue 
in time. Another challenge to be addressed is the development of consistent bioinformatics 
algorithms for clustering that are just as important for accurate cell type assignment. Our 
group is now working on such strategies to improve the consistency of findings. One 
approach I am in the early stages of developing is a technique tentatively named “iterative 
clustering”, which is based upon repeated clustering attempts to identify a core set of highly 
confidently grouped cells. As the field of single cell is still very much growing and 
developing, I expect that numerous other strategies for improving the replicability of 





CHAPTER 6. CONCLUSIONS AND FUTURE DIRECTIONS 
Extensive genome-wide association studies of inflammatory bowel disease have left us 
with a wealth of loci to investigate. Uncovering the links between these genetic risk loci 
and the underlying mechanisms of disease is the fundamental aim of this thesis. The 
potential benefits of genomic and transcriptomic directed personalized medicine 
approaches to IBD are especially great, as early therapeutic interventions have been shown 
to slow the progression of disease in patients who would have otherwise experienced severe 
complications. 
The foundation upon which each of the analyses I have shared here is built is 
transcriptomic data. In chapter 2, I discuss a comparative analysis of juvenile idiopathic 
arthritis and inflammatory bowel disease which serves to highlight transcriptomic 
similarities and differences between two clinically heterogeneous and immune-mediated 
disorders. RNA-Seq data was also key to calculations performed in chapter 3 
demonstrating the heritable differences in gene expression between individuals of varying 
proportions of African ancestry. Across chapters 2 and 4, I describe mapping of eQTL in 
several states—across diseases, and timepoints. The utility of gene expression data for 
investigating potential causal mechanisms underlying genetic variants is underscored here, 
as despite the relatively small sample size in comparison with typical GWAS studies, the 
greater impact of individual regulatory variants on gene expression enables the mapping of 
eQTL and comparison of effect sizes across conditions. Furthermore, I sought to expand 




data, and demonstrated its ability to discriminate not just case-control status, but risk of 
progression to colectomy in ulcerative colitis. Finally, the advance to single cell RNA 
sequencing has enabled my most recent examinations of cell-type specific differences in 
gene expression associated with inflammatory bowel disease. 
Several barriers remain to the implementation of genomics-based precision medicine 
in IBD, and beyond. A few such challenges of particular interest to me that fall within the 
scope of this thesis are the following—accounting for population and ancestry-specific 
differences, developing techniques for replicable analysis of single cell data, and building 
upon the transcriptional risk score and other potential gene expression based predictive 
measures. 
It is well known that allele frequencies, linkage disequilibrium structure, and 
environmental exposures differ between populations(161, 196-198). With that in mind, it 
is rather unsurprising that studies have repeatedly demonstrated that genetic and polygenic 
risk scores based on European GWAS often perform poorly and do not reflect true risk of 
disease in populations not of European ancestry (199). From the perspective of 
evolutionary genomics as well, it makes sense that population-specific differences in 
immune response exist (63, 64). In order for genetics-based risk scores to be successfully 
and equitably applied, it is important for individual researchers to be cognizant of the 
potential for European-centered datasets to bias findings in other populations, and for the 





 With the development of the field of single cell transcriptomics, increasingly large 
datasets are being published and disseminated amongst researchers. Several micro-
challenges fall under the umbrella of improving the inter-experimental replicability of 
single cell analyses. Starting with the data-driven, the establishment of consistent gene 
markers for assignment of cell types is critical for downstream analyses such as differential 
gene expression. I am optimistic that with time, the costs of single cell RNA-seq will 
decline as with older sequencing technologies, resulting in the establishment of cell atlases 
encompassing a wide spectrum of tissues and cell states. From the bioinformatics angle, 
algorithms which can reproducibly perform unsupervised clustering of cells are just as 
important for accurate identification of cell types. In addition, other challenges unique to 
single cell data, such as handling large amounts of dropouts, must be resolved. To begin to 
address this issue of replicability, I have begun to develop my own approach to identifying 
highly confidently clustered cells via iterative clustering attempts. 
 Finally, the transcriptional risk score represents a linkage between GWAS loci, 
eQTL, gene expression, and disease. In this thesis, I have reported my varied applications 
of TRS and its principles, as well as my own version of a predictive score for risk of disease 
complication in chapter 4. The transcriptional risk score could be further expanded on in 
any number of ways, but a future direction I would especially like to highlight is single cell 
TRS. I believe that the finer resolution of single cell gene expression data will further reveal 
potential mechanisms of association with disease, and possibly explain some of the 




 In summary, this thesis has demonstrated the applicability of genomic and 
transcriptomic profiling for characterization and prediction of risk of disease in 
inflammatory bowel disease. Many of the principles and strategies described here are also 
broadly applicable across diseases. Several hurdles remain to be overcome before such 
precision medicine approaches can be successfully applied, but they will offer incredible 
advantages in guiding therapeutic decision-making and ensuring that patients receive the 
most optimal treatment tailored to their individual needs, reducing the burden of healthcare 








APPENDIX A. SUPPLEMENTARY TABLES 
Supplementary Table 1 – List of genes included in Transcriptional Risk Score. 
A.   RA-TRS (transcriptional risk score based on rheumatoid arthritis GWAS)          
GWAS information (Okada et al. Nat Gen, 2014) Target Gene 
eQTL activity at GWAS SNP 
(eQTLbloodbrowser) 
















































































































































































































rs28411352 1 38278579 T C 0.27 0.24 1.12 4E-12 INPP5B - - - - - rs2306627 T/C T 9.8 7E-23 High Expr 
rs2476601 1 114377568 A G 0.16 0.10 1.81 ##### PTPN22 rs2476601 G/A A 6.3 3E-10 - - - - - High Expr 
rs2228145 1 154426970 A C 0.62 0.60 1.08 4E-09 IL6R - - - - - rs4537545 T/C T -11.3 2E-29 High Expr 
rs2317230 1 157674997 T G 0.44 0.42 1.08 2E-08 FCRL3 - - - - - rs2210913 C/T T 35.6 ##### High Expr 
rs72717009 1 161405053 T C 0.11 0.10 1.13 2E-07 FCGR2B - - - - - rs7529225 G/A A 21.8 ##### High Expr 
rs34695944 2 61124850 T C 0.69 0.73 0.89 3E-13 REL - - - - - rs13017599 G/A A 3.8 1E-04 High Expr 





rs73081554 3 58302935 T C 0.08 0.07 1.18 5E-08 PDHB - - - - - rs6772228 T/A A -11.6 4E-31 Low Expr 
rs2561477 5 102608924 A G 0.29 0.31 0.92 2E-09 PAM rs2561477 G/A A 22.6 ##### - - - - - Low Expr 
rs657075 5 131430118 A G 0.17 0.17 1.09 1E-06 ACSL6 rs657075 G/A A 6.9 4E-12 - - - - - High Expr 
rs2451258 6 159506600 T C 0.75 0.74 1.11 2E-10 RSPH3 rs2451258 T/C C -4.0 7E-05 - - - - - High Expr 
rs1571878 6 167540842 T C 0.51 0.55 0.86 6E-30 RNASET2 rs1571878 C/T C -37.2 ##### - - - - - Low Expr 
rs2736337 8 11341880 T C 0.62 0.63 0.90 5E-12 BLK - - - - - rs998683 G/A A -23.3 ##### Low Expr 
rs10985070 9 123636121 A C 0.52 0.54 0.92 2E-09 TRAF1 rs10985070 C/A C -18.0 4E-72 - - - - - Low Expr 
rs2671692 10 50097819 A G 0.57 0.53 1.08 9E-08 WDFY4 rs2671692 G/A G 5.9 3E-09 - - - - - Low Expr 
rs968567 11 61595564 T C 0.16 0.18 0.90 7E-07 FADS1 rs968567 T/C T 16.6 8E-62 - - - - - Low Expr 
rs10774624 12 111833788 A G 0.49 0.51 0.92 2E-07 SH2B3 - - - - - rs4766578 T/A T 9.2 6E-20 High Expr 
rs4780401 16 11839326 T G 0.57 0.56 1.07 6E-07 TXNDC11 - - - - - rs8058003 T/C C 6.0 2E-09 Low Expr 
rs1877030 17 37740161 T C 0.15 0.16 0.90 3E-08 IKZF3 rs1877030 C/T T -8.6 8E-18 - - - - - High Expr 
rs2469434 18 67544046 T C 0.59 0.60 0.94 6E-06 CD226 - - - - - rs763362 G/A G -12.2 4E-34 Low Expr 
rs4239702 20 44749251 T C 0.28 0.31 0.89 9E-15 CD40 rs4239702 T/C T -12.3 1E-34 - - - - - High Expr 
rs1893592 21 43855067 A C 0.74 0.73 1.11 4E-12 UBASH3A rs1893592 C/A C 20.3 6E-92 - - - - - Low Expr 









B.   IBD-TRS (transcriptional risk score based on IBD GWAS, adapted from Supp. Table 4 in Marigorta et al. Nat Gen, 2017)  
GWAS information Liu et al. Nat Gen, 2015) Target Gene 
eQTL activity at GWAS SNP 
(eQTLbloodbrowser) 
















































































































































































































rs12103 1 1247494 A G - - 1.09 1E-05 TNFRSF18 - - - - - rs12142199 G/A G -9.4 3E-21 Low Expr 
rs12103 1 1247494 A G - - 1.09 1E-05 B3GALT6 - - - - - rs12142199 G/A G -13.2 9E-40 Low Expr 
rs12103 1 1247494 A G - - 1.09 1E-05 SSU72 - - - - - rs12142199 G/A G 8.6 1E-17 High Expr 
rs4845604 1 151801680 A G - - 0.88 2E-05 THEM4 rs4845604 G/A A 6.7 3E-11 - - - - - Low Expr 
rs4656958 1 160856964 A G - - 0.93 4E-06 LY9 - - - - - rs2184069 G/C G 10.3 9E-25 Low Expr 
rs4656958 1 160856964 A G - - 0.93 4E-06 CD244 - - - - - rs4656945 T/C C 9.0 3E-19 Low Expr 
rs1801274 1 161479745 G A - - 0.88 3E-13 FCGR2B rs1801274 A/G G -11.1 1E-28 - - - - - High Expr 
rs10185424 2 102662888 A C - - 1.09 6E-09 IL1R2 rs10185424 T/G T -8.3 1E-16 - - - - - Low Expr 
rs2382817 2 219151218 A C - - 1.08 4E-07 SLC11A1 rs2382817 C/A A 14.7 8E-49 - - - - - High Expr 
rs9868809 3 48681053 A G - - 1.15 6E-11 NCKIPSD rs9868809 C/T T -7.1 1E-12 - - - - - Low Expr 
rs3197999 3 49721532 A G - - 1.18 2E-21 USP4 - - - - - rs1800668 G/A A 12.8 1E-37 High Expr 
rs2930047 5 10695526 G A - - 1.08 1E-04 DAP rs2930047 T/C C -16.5 5E-61 - - - - - Low Expr 





rs11743851 5 130613600 G A - - 1.11 4E-07 CDC42SE2 rs11743851 T/C C 9.7 2E-22 - - - - - High Expr 
rs17622378 5 131778452 G A - - 1.15 1E-15 SLC22A4 rs17622378 A/G G -23.9 ##### - - - - - Low Expr 
rs17622378 5 131778452 G A - - 1.15 1E-15 SLC22A5 rs17622378 A/G G -27.0 ##### - - - - - Low Expr 
rs17622378 5 131778452 G A - - 1.15 1E-15 IRF1 rs17622378 A/G G 5.6 3E-08 - - - - - High Expr 
rs9313808 5 158820844 A G - - 0.87 1E-12 RNF145 rs9313808 G/A A -6.7 2E-11 - - - - - High Expr 
rs4976646 5 176788570 G A - - 1.08 4E-04 RGS14 rs4976646 T/C C 5.2 2E-07 - - - - - High Expr 
rs17057051 8 27227554 G A - - 0.94 9E-04 PTK2B rs17057051 A/G G 12.6 3E-36 - - - - - Low Expr 
rs4246905 9 117553249 A G - - 0.88 1E-16 TNFSF8 rs4246905 C/T T 12.6 2E-36 - - - - - Low Expr 
rs10781499 9 139266405 A G - - 1.17 4E-25 CARD9 rs10781499 G/A A 38.8 ##### - - - - - High Expr 
rs10781499 9 139266405 A G - - 1.17 4E-25 SNAPC4 - - - - - rs10781518 G/A G -4.2 3E-05 Low Expr 
rs10781499 9 139266405 A G - - 1.17 4E-25 SDCCAG3 rs10781499 G/A A -14.0 2E-44 - - - - - Low Expr 
rs10781499 9 139266405 A G - - 1.17 4E-25 INPP5E rs10781499 G/A A -34.4 ##### - - - - - Low Expr 
rs11230563 11 60776209 A G - - 0.92 3E-06 SLC15A3 rs11230563 T/C T 5.0 5E-07 - - - - - Low Expr 
rs559928 11 64150370 A G - - 0.91 3E-05 RPS6KA4 rs559928 C/T T 9.1 1E-19 - - - - - Low Expr 
rs8005161 14 88472595 A G - - 1.15 4E-07 GALC rs8005161 C/T T -8.9 6E-19 - - - - - Low Expr 
rs26528 16 28517709 G A - - 1.1 2E-09 SBK1 - - - - - rs4788084 T/C T -8.3 9E-17 Low Expr 
rs26528 16 28517709 G A - - 1.1 2E-09 CCDC101 - - - - - rs4788084 T/C T -16.1 3E-58 Low Expr 
rs727088 18 67530439 G A - - 1.06 9E-03 CD226 rs727088 G/A G -14.4 1E-46 - - - - - Low Expr 
rs12720356 19 10469975 C A - - 1.16 7E-11 ICAM4 rs12720356 A/C C 7.4 1E-13 - - - - - High Expr 
rs12720356 19 10469975 C A - - 1.16 7E-11 TYK2 rs12720356 A/C C 4.7 2E-06 - - - - - High Expr 
rs11879191 19 10512911 A G - - 0.89 5E-07 ICAM3 rs11879191 G/A A -6.7 2E-11 - - - - - High Expr 
rs913678 20 48955424 G A - - 0.93 8E-06 CEBPB rs913678 T/C C -8.6 9E-18 - - - - - High Expr 
rs6062504 20 62348907 A G - - 0.9 3E-15 ZGPAT - - - - - rs6062509 T/G G -15.0 7E-51 High Expr 
rs6062504 20 62348907 A G - - 0.9 3E-15 LIME1 - - - - - rs6011066 A/G G 23.1 ##### Low Expr 
rs2413583 22 39659773 A G - - 0.84 2E-12 PDGFB rs2413583 C/T T -4.8 2E-06 - - - - - High Expr 





Supplementary Table 2 – List of top 10 differentially expressed genes for various comparisons 
Control v. Oligoarticular JIA 
    
Upregulated in Control 
 
Upregulated in Oligoarticular JIA 
  
Gene logFC P-value Gene logFC P-value 
VPS26B 0.21 2.62E-04 CHRM3AS2 -1.00 1.05E-05 
COPS7A 0.22 2.69E-04 IL6ST -0.59 1.61E-04 
HENMT1 0.27 3.54E-04 LINC01003 -0.55 3.07E-04 
SIRT2 0.28 2.92E-05 SVIP -0.51 1.33E-04 
PIAS3 0.28 4.37E-05 PDK1 -0.46 3.05E-06 
FAM50A 0.28 2.34E-04 ZNF518B -0.31 1.58E-04 
ITGAL 0.30 2.31E-04 CYLD -0.29 3.14E-04 
MRPL10 0.31 2.79E-04 
   
GALE 0.35 1.86E-04 
   
TBCB 0.36 1.29E-04 
   
      
Control v. Polyarticular JIA 
    
Upregulated in Control 
 
Upregulated in Oligoarticular JIA 
  
Gene logFC P-value Gene logFC P-value 
BZRAP1 1.03 1.99E-08 SLC25A16 -0.37862 1.38E-05 
ERBB2 1.01 1.56E-07 ELOVL7 -1.14234 1.56E-05 
PLEKHF1 1.05 2.01E-07 PCYT1B -0.97186 4.47E-05 
NKG7 1.10 2.37E-07 PLA2G12A -0.52328 6.70E-05 
ARVCF 1.17 2.67E-07 PRRG4 -1.0844 6.76E-05 





PCDHGB1 1.07 3.68E-07 PRKAR2B -0.97044 0.00011 
NMUR1 1.20 3.89E-07 PDK1 -0.3763 0.00012 
DLG5 1.04 6.10E-07 USP15MIR6125 -0.67584 0.00012 
SCART1 1.36 6.79E-07 SCRN3 -0.38791 0.00013 
      
Control v. Systemic JIA 
    
Upregulated in Control 
 
Upregulated in Systemic JIA 
  
Gene logFC P-value Gene logFC P-value 
SCART1 2.00 6.16E-11 NFKBIZNXPE3 -0.83 2.22E-09 
LTK 1.59 4.28E-10 NBN -1.09 1.46E-08 
DLG5 1.41 7.33E-10 MIR6502IRAK3 -1.95 4.76E-08 
BZRAP1 1.24 8.33E-10 TNIP1 -0.91 2.94E-07 
PCDHGB1 1.39 2.21E-09 GK -1.59 3.12E-07 
COLQ 1.16 5.25E-09 CD274 -2.37 6.51E-07 
LGR6 1.88 5.27E-09 ST6GALNAC3 -1.62 6.55E-07 
ADRB2 0.77 5.85E-09 ACSL4 -1.09 7.30E-07 
NMUR1 1.50 1.34E-08 NAB1 -0.67 8.63E-07 
NCR3 1.09 4.75E-08 SOD2 -1.32 8.89E-07 
      
IBD v. Oligoarticular JIA 
    
Upregulated in IBD 
 
Upregulated in Oligoarticular JIA 
  
Gene logFC P-value Gene logFC P-value 
GYG1 1.46 8.28E-17 QSOX2 -0.56 1.11E-17 
PSENEN 0.61 5.56E-16 TTC39B -0.68 2.92E-16 





MMP8 3.94 1.19E-15 CTC1 -0.44 7.66E-16 
TIMP1 0.87 1.82E-15 DNHD1 -0.73 1.91E-15 
TXN 1.00 2.92E-15 CFAP44 -0.69 5.61E-15 
HP 2.82 3.14E-15 ZNF550 -0.59 9.02E-15 
S100A12 2.01 3.87E-15 ZBTB40 -0.48 1.01E-14 
GLIPR2 0.71 4.05E-15 KLHL3 -0.76 1.30E-14 
CLIC1 0.68 5.47E-15 CUBN -0.86 1.55E-14 
      
IBD v. Polyarticular JIA 
    
Upregulated in IBD 
 
Upregulated in Polyarticular JIA 
  
Gene logFC P-value Gene logFC P-value 
CD177 4.56 1.73E-15 PRPF3 -0.32 3.14E-14 
GYG1 1.29 2.55E-14 ZMAT1 -0.62 3.00E-13 
MCEMP1 2.01 1.93E-13 NPIPB3 -0.66 5.23E-13 
MMP8 3.40 2.39E-13 DDX26B -0.42 5.61E-13 
LRPAP1 0.57 5.00E-13 PROX2 -0.57 1.43E-12 
SEPHS2 0.34 2.60E-12 CFAP44 -0.61 1.80E-12 
PFKFB3 1.21 2.76E-12 NKTR -0.54 2.00E-12 
FCGR1A 1.61 4.06E-12 C3 -1.31 2.31E-12 
CST7 1.28 5.48E-12 MASP2 -0.67 2.98E-12 
ATP9A 1.31 1.53E-11 CTC1 -0.37 9.59E-12 
      
IBD v. Systemic JIA 
    
Upregulated in IBD 
 
Upregulated in Systemic JIA 
  





ALDH1A1 0.90 1.07E-09 ZC3H12A -0.93 2.63E-18 
C9orf47S1PR3 0.68 1.69E-07 TNFAIP3 -0.82 1.71E-14 
CEBPA 0.60 4.19E-07 GHRL -1.06 1.76E-10 
CRTAP 0.40 5.51E-07 NFKB2 -0.56 3.67E-10 
CPVL 0.65 5.83E-07 TTC21A -0.98 1.30E-09 
IL17RC 0.64 6.21E-07 PPM1N -0.97 2.72E-09 
PID1 0.82 6.34E-07 C3 -1.29 2.95E-09 
MIR4709NPC2 0.46 1.68E-06 NFKBIZNXPE3 -0.49 6.00E-09 
FOLR2 0.69 3.01E-06 USP18 -1.77 1.50E-08 










Supplementary Table 3 – Mean Blood Transcript Modules and BIT Axis Scores across Disease Subtypes 
 
BTM CTRL IBD_CD IBD_UC JIA_Olig JIA_Poly JIA_Syst 
integrin cell surface interactions (I) 0.992 -0.326 -0.492 0.479 -0.041 -0.130 
integrin cell surface interactions (II) 0.288 0.389 -0.015 -0.072 -0.175 -0.459 
extracellular matrix (I) 1.048 -0.341 -0.714 0.667 -0.066 -0.243 
extracellular matrix (II) -0.545 0.384 0.750 -0.583 -0.158 0.236 
extracellular matrix (III) 0.723 -0.516 -0.699 0.692 0.075 -0.069 
regulation of signal transduction 0.650 -0.359 -0.650 0.557 0.078 -0.189 
cell cycle and transcription 0.205 0.189 -0.100 -0.086 0.129 -0.531 
cell cycle (I) -0.389 -0.012 0.368 -0.139 -0.210 0.604 
PLK1 signaling events -0.465 0.046 0.401 -0.191 -0.233 0.621 
myeloid cell enriched receptors and transporters -0.434 0.461 0.596 -0.583 -0.093 -0.011 
mitotic cell cycle - DNA replication -0.211 -0.087 0.098 -0.036 -0.162 0.574 
mitotic cell cycle in stimulated CD4 T cells -0.479 0.011 0.351 -0.151 -0.191 0.583 
cell division in stimulated CD4 T cells -0.587 0.022 0.353 -0.164 -0.185 0.612 
mitotic cell cycle -0.379 0.013 0.419 -0.164 -0.214 0.569 
cell division - E2F transcription network 0.304 -0.015 0.095 0.144 -0.337 0.285 
cell cycle (II) -0.434 0.076 0.489 -0.210 -0.227 0.521 
C-MYC transcriptional network -0.433 0.043 0.413 -0.117 -0.263 0.556 
cell junction (GO) -0.528 0.529 0.893 -0.623 -0.165 -0.063 
Rho GTPase cycle -0.601 0.053 0.479 -0.171 -0.239 0.603 
enriched in monocytes (I) -0.120 0.531 0.736 -0.591 -0.126 -0.274 
regulation of antigen presentation and immune response -0.672 0.359 0.679 -0.568 -0.080 0.203 





mitotic cell division -0.487 -0.029 0.365 -0.115 -0.207 0.638 
enriched in T cells (I) 0.714 -0.230 -0.813 0.402 0.065 -0.137 
T cell activation (I) 0.470 -0.308 -0.756 0.510 0.069 -0.078 
enriched in NK cells (I) 1.345 0.028 -0.922 0.011 0.007 -0.162 
T cell activation (II) 0.893 -0.166 -0.849 0.323 0.051 -0.176 
T cell activation (III) 0.210 -0.385 -0.701 0.508 0.143 0.016 
E2F transcription factor network -0.517 0.049 0.547 -0.255 -0.183 0.562 
B cell development -0.586 0.405 0.556 -0.448 -0.130 0.052 
E2F1 targets (Q3) -0.342 -0.076 0.101 -0.026 -0.131 0.529 
E2F1 targets (Q4) -0.330 -0.086 0.070 -0.081 -0.105 0.592 
enriched in monocytes (II) -0.606 0.456 0.705 -0.580 -0.117 0.056 
blood coagulation -0.553 0.431 0.673 -0.600 -0.112 0.120 
formyl peptide receptor mediated neutrophil response -0.553 0.413 0.457 -0.496 -0.118 0.122 
CD28 costimulation -0.496 0.267 0.561 -0.510 -0.013 0.165 
innate activation by cytosolic DNA sensing -0.451 0.309 0.028 -0.450 0.002 0.210 
T cell differentiation 0.084 -0.380 -0.653 0.603 0.119 -0.066 
Ran mediated mitosis -0.203 0.133 0.405 -0.174 -0.311 0.458 
TLR and inflammatory signaling -0.658 0.371 0.623 -0.515 -0.104 0.168 
Hox cluster I -0.454 0.099 0.637 -0.485 0.171 0.065 
T cell differentiation via ITK and PKC 0.272 -0.312 -0.696 0.461 0.097 -0.002 
T cell differentiation (Th2) 0.355 -0.243 -0.600 0.449 0.057 -0.130 
AP-1 transcription factor network -0.480 0.359 0.669 -0.230 -0.287 0.017 
cell adhesion (lymphocyte homing) 0.633 -0.342 -0.747 0.468 0.126 -0.126 
mismatch repair (I) -0.346 -0.192 -0.006 0.119 -0.001 0.354 
mismatch repair (II) -0.200 -0.220 -0.216 0.219 0.010 0.287 
RA, WNT, CSF receptors network (monocyte) -0.329 0.342 0.511 -0.371 -0.139 0.002 
cell activation (IL15, IL23, TNF) -0.465 0.294 0.167 -0.367 -0.137 0.315 





TBA -0.663 -0.259 -0.104 0.111 0.238 0.225 
chemokine cluster (I) 1.206 -0.066 -0.692 -0.036 0.008 0.036 
chemokine cluster (II) 0.989 0.247 -0.655 -0.426 0.080 -0.082 
antigen presentation (lipids and proteins) 0.863 -0.220 -0.788 0.386 -0.024 -0.037 
proinflammatory cytokines and chemokines 0.258 0.074 -0.028 -0.472 0.114 0.251 
cell movement, Adhesion & Platelet activation -0.888 0.297 0.406 -0.344 -0.013 0.088 
cell cycle and growth arrest -0.348 0.374 0.398 -0.397 -0.206 0.167 
platelet activation (I) 0.317 0.456 0.476 -0.275 -0.378 -0.161 
platelet activation (II) 0.256 0.413 0.409 -0.259 -0.313 -0.162 
CORO1A-DEF6 network (I) 0.555 0.216 0.031 0.084 -0.311 -0.213 
KLF12 targets network 0.268 0.353 0.368 -0.195 -0.328 -0.095 
CORO1A-DEF6 network (II) 0.472 0.251 0.075 0.019 -0.294 -0.206 
cytoskeletal remodeling 0.120 0.416 0.324 -0.297 -0.218 -0.195 
inflammatory response -0.174 0.486 0.703 -0.591 -0.193 -0.018 
cytoskeletal remodeling (enriched for SRF targets) -0.883 0.365 0.464 -0.422 -0.076 0.157 
signaling in T cells (I) 1.166 0.084 -0.798 -0.127 0.050 -0.143 
signaling in T cells (II) 1.318 0.096 -0.805 -0.024 -0.061 -0.168 
T cell surface, activation 0.256 -0.220 -0.635 0.493 0.027 -0.127 
immune activation - generic cluster -0.678 0.388 0.710 -0.543 -0.113 0.158 
enriched in neutrophils (I) -0.653 0.331 0.577 -0.414 -0.119 0.148 
endoplasmic reticulum 0.891 -0.338 -0.647 0.522 0.050 -0.223 
cell division -0.025 -0.140 -0.121 0.229 -0.095 0.191 
chemokines and receptors 1.158 -0.216 -0.744 0.214 0.149 -0.255 
integrin mediated leukocyte migration -0.255 0.467 0.803 -0.556 -0.247 0.056 
complement and other receptors in DCs -0.383 0.526 0.697 -0.702 -0.173 0.116 
platelet activation (III) -0.519 0.364 0.613 -0.486 -0.150 0.175 
myeloid, dendritic cell activation via NFkB (I) -0.252 0.317 0.304 -0.392 -0.209 0.291 





T cell signaling and costimulation -0.641 0.487 0.782 -0.635 -0.172 0.154 
leukocyte activation and migration -0.191 0.319 0.649 -0.515 -0.143 0.147 
cell division stimulated CD4+ T cells -0.526 0.082 0.512 -0.195 -0.256 0.566 
enriched in B cells (I) 0.093 -0.315 -0.436 0.417 0.012 0.174 
enriched in B cells (II) 0.103 -0.317 -0.338 0.420 -0.018 0.176 
enriched in B cells (III) -0.293 0.356 0.438 -0.472 -0.021 -0.079 
enriched in B cells (IV) 0.059 -0.359 -0.384 0.481 0.009 0.161 
enriched in B cells (V) 0.492 -0.456 -0.766 0.491 0.175 0.044 
transcription regulation in cell development -0.622 0.418 0.694 -0.561 -0.153 0.183 
CD1 and other DC receptors -0.866 0.154 0.635 -0.270 -0.091 0.293 
cell adhesion -0.708 0.287 0.292 -0.309 -0.011 0.037 
T cell activation (IV) 0.769 -0.241 -0.606 0.375 0.064 -0.198 
inflammasome receptors and signaling -0.618 0.387 0.383 -0.538 -0.085 0.237 
BCR signaling 0.256 -0.333 -0.534 0.393 0.206 -0.139 
suppression of MAPK signaling -0.495 0.377 0.526 -0.464 -0.147 0.142 
immuregulation - monocytes, T and B cells 0.146 -0.286 -0.556 0.441 0.004 0.132 
B cell development/activation 0.438 -0.385 -0.502 0.507 0.055 -0.006 
CCR1, 7 and cell signaling -0.618 0.366 0.656 -0.539 -0.081 0.137 
lymphocyte generic cluster 0.406 -0.326 -0.704 0.482 0.090 -0.041 
enriched in NK cells (II) 1.430 0.033 -0.877 0.007 -0.040 -0.136 
enriched in NK cells (KIR cluster) 0.905 0.042 -0.491 -0.163 -0.076 0.185 
enriched in NK cells (receptor activation) 1.284 -0.135 -0.973 0.226 -0.004 -0.084 
T & B cell development, activation 0.249 -0.287 -0.615 0.544 0.038 -0.097 
enriched for unknown TF motif CTCNANGTGNY 0.871 0.014 -0.276 0.312 -0.114 -0.491 
regulation of localization (GO) 0.397 0.403 0.251 -0.195 -0.324 -0.195 
enriched in activated dendritic cells/monocytes -0.668 0.327 0.488 -0.448 -0.109 0.237 
IL2, IL7, TCR network 0.260 -0.266 -0.582 0.524 0.027 -0.110 





RIG-1 like receptor signaling -0.189 0.098 -0.565 -0.218 0.230 0.051 
enriched in B cells (VI) 0.034 -0.332 -0.476 0.407 0.068 0.160 
enriched in antigen presentation (I) -0.972 0.232 0.648 -0.547 0.052 0.315 
enriched in monocytes (III) -0.737 0.371 0.561 -0.524 -0.051 0.142 
transcriptional targets of glucocorticoid receptor 0.165 -0.368 -0.625 0.416 0.188 0.015 
antiviral IFN signature -0.383 0.134 -0.525 -0.321 0.266 0.119 
DNA repair -0.346 -0.237 -0.246 0.021 0.118 0.488 
collagen, TGFB family et al 0.508 -0.464 -0.740 0.488 0.224 -0.047 
myeloid cell cytokines, metallopeptidases and laminins 0.616 -0.404 -0.746 0.592 0.155 -0.234 
enriched in myeloid cells and monocytes -0.867 0.378 0.647 -0.539 -0.030 0.120 
signal transduction, plasma membrane 0.895 -0.229 -0.381 0.340 -0.017 -0.180 
enriched in naive and memory B cells -0.009 -0.335 -0.447 0.380 0.097 0.154 
integrins and cell adhesion -0.490 0.348 0.635 -0.502 -0.125 0.160 
platelet activation and degranulation -0.551 0.436 0.471 -0.561 -0.046 0.027 
chemokines and inflammatory molecules in myeloid cells -0.622 0.262 0.284 -0.424 -0.105 0.411 
proinflammatory dendritic cell, myeloid cell response 0.765 -0.241 -0.395 0.441 0.002 -0.285 
transmembrane transport (I) -0.585 0.394 0.679 -0.595 -0.113 0.201 
leukocyte migration 0.885 -0.331 -0.809 0.559 0.082 -0.270 
putative targets of PAX3 0.818 -0.055 -0.548 0.117 0.044 -0.202 
adhesion and migration, chemotaxis 1.174 0.306 -0.334 -0.465 0.015 -0.255 
lipid metabolism, endoplasmic reticulum -0.941 0.326 0.710 -0.502 0.009 0.094 
growth factor induced, enriched in nuclear receptor subfamily 4 0.632 -0.260 -0.356 0.483 0.050 -0.365 
enriched in antigen presentation (II) 0.644 -0.400 -0.603 0.602 0.073 -0.187 
enriched in antigen presentation (III) -0.626 0.419 0.512 -0.598 -0.098 0.226 
enriched for SMAD2/3 signaling 0.553 -0.219 -0.208 0.251 -0.054 0.053 
MAPK, RAS signaling 0.044 0.392 0.361 -0.272 -0.252 -0.110 
phosphatidylinositol signaling system -1.061 0.002 0.223 -0.159 0.136 0.288 





nuclear pore complex -0.050 -0.338 -0.433 0.365 0.156 0.080 
nuclear pore complex (mitosis) -0.244 -0.290 -0.405 0.362 0.109 0.140 
receptors, cell migration 0.598 -0.343 -0.765 0.512 0.112 -0.142 
axon guidance 0.895 0.366 0.152 -0.372 -0.113 -0.405 
viral sensing & immunity; IRF2 targets network (I) -0.371 0.541 0.305 -0.610 -0.098 -0.003 
viral sensing & immunity; IRF2 targets network (II) -0.403 0.372 -0.129 -0.461 0.069 0.030 
complement activation (I) -0.356 0.590 0.616 -0.720 -0.158 0.015 
complement activation (II) -0.790 0.372 0.478 -0.514 0.003 0.087 
golgi membrane (I) -0.998 0.329 0.740 -0.503 -0.054 0.217 
glycerophospholipid metabolism 0.935 -0.399 -0.771 0.537 0.060 -0.094 
cytokines - recepters cluster -0.335 0.476 0.744 -0.573 -0.179 -0.007 
cell adhesion (GO) 0.430 -0.373 -0.612 0.536 0.122 -0.142 
enriched in monocytes (IV) -0.774 0.369 0.672 -0.540 -0.070 0.167 
enriched in monocytes (surface) 0.647 -0.409 -0.792 0.564 0.152 -0.166 
enriched in activated dendritic cells (I) -0.469 0.378 0.622 -0.691 0.069 0.013 
enriched for cell migration 0.818 0.020 -0.842 -0.013 0.155 -0.221 
enriched in B cell differentiation 0.584 -0.256 -0.501 0.547 -0.113 -0.068 
enriched in membrane proteins -0.586 0.363 0.782 -0.525 -0.222 0.315 
double positive thymocytes 0.546 -0.321 -0.731 0.556 0.082 -0.190 
type I interferon response -0.515 0.158 -0.447 -0.329 0.222 0.179 
inositol phosphate metabolism -1.017 -0.078 0.163 -0.026 0.072 0.386 
enriched in G-protein coupled receptors 1.252 0.109 -0.669 -0.205 0.070 -0.213 
recruitment of neutrophils -0.623 0.354 0.510 -0.416 -0.119 0.125 
cell adhesion, membrane 1.372 -0.237 -0.788 0.381 0.087 -0.409 
Membrane, ER proteins -0.287 0.167 0.563 -0.416 -0.018 0.152 
enriched for ubiquitination -0.717 -0.139 -0.009 0.132 0.104 0.179 
lysosomal/endosomal proteins -0.267 0.535 0.834 -0.640 -0.182 -0.094 





nuclear pore, transport; mRNA splicing, processing -0.112 -0.329 -0.490 0.396 0.179 0.025 
cell cycle, ATP binding -1.163 0.062 0.530 -0.264 0.105 0.269 
cytoskeleton/actin (SRF transcription targets) -0.906 0.283 0.389 -0.431 0.062 0.122 
intracellular transport -0.989 -0.043 0.167 -0.036 0.106 0.252 
innate antiviral response -0.490 0.128 -0.363 -0.395 0.270 0.196 
amino acid metabolism and transport -0.317 0.413 0.572 -0.441 -0.103 -0.141 
G protein coupled receptors cluster 0.724 -0.302 -0.685 0.420 0.158 -0.263 
plasma cells & B cells, immunoglobulins 0.171 -0.330 -0.361 0.446 -0.026 0.164 
plasma cells, immunoglobulins 0.324 -0.052 0.257 0.268 -0.288 -0.008 
enriched in NK cells (III) 1.101 -0.137 -0.983 0.240 0.011 -0.052 
G protein mediated calcium signaling 0.840 -0.379 -0.616 0.457 0.008 0.043 
leukocyte differentiation -0.147 0.246 0.298 -0.230 -0.195 0.123 
plasma membrane, cell junction 1.147 -0.281 -1.047 0.494 0.152 -0.394 
cell junction 1.104 -0.021 -0.488 0.343 -0.127 -0.429 
enriched in neutrophils (II) -0.480 0.340 0.475 -0.429 -0.070 0.038 
enriched in activated dendritic cells (II) -0.789 0.242 -0.059 -0.486 0.209 0.185 
enriched in cell cycle -0.967 -0.093 0.126 -0.154 0.214 0.338 
enriched in dendritic cells 0.801 -0.423 -0.970 0.616 0.138 -0.160 
mitosis (TF motif CCAATNNSNNNGCG) -0.430 -0.308 -0.200 0.212 0.242 0.121 
heme biosynthesis (I) -0.367 0.197 0.340 -0.270 -0.164 0.295 
enriched for TF motif TTCNRGNNNNTTC -0.470 0.542 0.974 -0.415 -0.202 -0.394 
erythrocyte differentiation -0.378 0.244 0.435 -0.293 -0.183 0.223 
cell development -0.115 0.342 0.369 -0.641 0.029 0.073 
enriched for promoter motif NATCACGTGAY (putative SREBF1 targets) 0.176 -0.199 -0.414 0.389 -0.103 0.152 
enriched for TF motif PAX3 -0.520 -0.320 -0.291 0.342 0.257 0.003 
nucleotide metabolism 0.116 -0.236 -0.289 0.365 -0.040 0.105 
enriched in DNA interacting proteins 0.155 -0.206 -0.362 0.227 0.015 0.168 





transmembrane transport (II) -0.479 -0.294 -0.274 0.242 0.221 0.144 
muscle contraction, SRF targets -0.517 0.058 -0.077 -0.309 0.185 0.238 
platelet activation - actin binding -0.885 0.331 0.367 -0.395 0.054 -0.012 
platelet activation & blood coagulation -0.808 0.305 0.382 -0.339 0.031 -0.039 
chaperonin mediated protein folding (I) 0.152 -0.018 0.092 0.139 -0.082 -0.122 
chaperonin mediated protein folding (II) -0.013 -0.003 0.158 0.141 -0.102 -0.086 
Wnt signaling pathway 0.016 0.254 -0.279 0.025 -0.036 -0.353 
lysosome -0.324 0.549 0.842 -0.702 -0.148 -0.073 
extracellular matrix, collagen -0.257 0.448 0.685 -0.619 -0.133 0.031 
purine nucleotide biosynthesis 0.353 -0.066 -0.103 0.232 -0.130 -0.058 
regulation of transcription, transcription factors -0.858 -0.322 -0.212 0.055 0.348 0.359 
small GTPase mediated signal transduction -0.138 0.363 0.453 -0.385 -0.192 0.033 
respiratory electron transport chain (mitochondrion) 0.289 0.463 0.640 -0.242 -0.400 -0.254 
heme biosynthesis (II) -0.245 0.185 0.514 -0.276 -0.157 0.179 
enriched in T cells (II) 0.351 -0.390 -0.902 0.537 0.173 -0.032 
proteasome -0.324 0.368 0.613 -0.385 -0.188 0.010 
translation initiation -0.135 0.226 0.636 -0.259 -0.162 -0.028 
olfactory receptors 0.503 -0.418 -0.646 0.201 0.374 -0.040 
cell cycle, mitotic phase -0.109 -0.376 -0.563 0.405 0.246 0.014 
enriched for TF motif TNCATNTCCYR -0.035 0.018 -0.257 0.044 -0.043 0.122 
transcription elongation, RNA polymerase II 0.512 0.441 0.493 -0.143 -0.449 -0.280 
mitochondrial cluster 0.228 -0.145 -0.050 0.253 -0.033 -0.088 
golgi membrane (II) -1.115 0.045 0.334 -0.200 0.104 0.290 
chromosome Y linked -0.076 -0.002 0.388 -0.085 -0.204 0.356 
translation initiation factor 3 complex 0.390 0.136 0.064 0.163 -0.228 -0.274 
spliceosome -0.101 0.148 0.252 -0.167 -0.061 -0.020 
T cell surface signature 0.340 -0.267 -0.629 0.486 0.048 -0.099 





B cell surface signature 0.236 -0.417 -0.535 0.477 0.083 0.147 
Plasma cell surface signature 0.288 0.261 0.747 -0.092 -0.359 -0.200 
Monocyte surface signature -0.658 0.385 0.692 -0.539 -0.106 0.144 
DC surface signature 0.931 -0.305 -0.688 0.463 0.108 -0.306 
CD4 T cell surface signature Th1-stimulated 0.990 -0.095 -0.556 0.237 -0.007 -0.265 
CD4 T cell surface signature Th2-stimulated 0.030 -0.333 -0.478 0.458 0.110 0.008 
Naive B cell surface signature -0.066 -0.308 -0.488 0.336 0.165 0.078 
Memory B cell surface signature -0.442 0.114 -0.334 -0.372 0.289 0.123 
Resting dendritic cell surface signature 1.053 -0.235 -0.701 0.467 0.033 -0.356 
Activated (LPS) dendritic cell surface signature -0.823 0.302 0.322 -0.451 0.007 0.217 
Platelets -0.769 0.305 0.392 -0.335 0.044 -0.091 
Interferon -0.466 0.277 -0.240 -0.420 0.122 0.141 
Cell Cycle 0.151 -0.312 -0.399 0.351 0.122 0.014 
Erythrocytes -0.367 0.250 0.402 -0.316 -0.165 0.226 
Inflammation -0.704 0.400 0.684 -0.522 -0.134 0.164 
Cytotoxic/NK Cell 1.352 0.054 -0.904 0.012 -0.015 -0.188 
T cell 0.063 -0.441 -0.649 0.649 0.153 -0.068 
Protein Synthesis 0.323 0.079 -0.004 0.257 -0.170 -0.350 
B cell 0.181 -0.314 -0.422 0.424 -0.001 0.142 
Monocytes 0.141 0.362 0.427 -0.393 -0.016 -0.387 
T cells 0.512 -0.339 -0.779 0.547 0.085 -0.107 
Mitochondrial Stress / Proteasome -0.163 -0.010 0.126 -0.029 0.048 -0.025 
Mitochondrial Respiration -0.845 -0.322 -0.350 0.072 0.374 0.347 
Neutrophils -0.095 0.305 0.490 -0.378 -0.260 0.234 
Apoptosis / Survival -0.267 0.503 0.831 -0.477 -0.298 -0.051 
Mitochondrial Stress 0.528 -0.236 -0.334 0.515 -0.077 -0.189 
Cell Death -0.661 0.414 0.699 -0.554 -0.151 0.190 





Immune Responses -0.601 0.313 0.800 -0.644 0.012 0.146 
Axis T (1) 0.655 0.010 -0.325 0.425 -0.257 -0.269 
Axis R (2) -0.447 0.207 0.311 -0.295 -0.130 0.291 
Axis B (3) 0.265 -0.296 -0.364 0.398 -0.055 0.186 
Axis G (4) -0.991 0.129 0.364 -0.380 0.121 0.295 
Axis N (5) -0.462 0.393 0.609 -0.437 -0.182 0.083 
Axis I (7) -0.542 0.108 -0.616 -0.287 0.323 0.124 












Supplementary Table 4 – List of disease-by-eQTL interactions 
Gene rsID IBD β IBD p-val JIA β JIA p-val Interact p 
SKI rs3001167 -1.7 6.76E-06 0.163519 0.241677 1.64E-06 
FASTKD2 rs74345488 0.407 0.207 -1.3235 2.17E-05 7.08E-05 
FAM20C rs80086012 -0.507 0.105 0.747802 2.75E-05 0.000165 
CAMKK1 rs903506 -0.961 2.00E-05 0.01009 0.939037 0.000175 
RAC2 rs6000618 0.457 0.0349 -0.63489 7.42E-05 0.000232 
SIRT3 rs2043055 -0.694 9.68E-05 0.128827 0.333153 0.000268 
SDHC rs16832809 -2.15 3.87E-05 -0.1589 0.501788 0.000414 
NDUFA3 rs7254645 -0.192 0.215 0.562053 8.35E-05 0.000602 
USP14 rs8085585 -0.562 7.01E-05 -0.29858 0.151345 0.000649 
ACP1 rs34894023 0.449 0.227 -1.0482 6.42E-05 0.000688 
DCTN5 rs703767 0.227 0.195 1.020839 4.18E-09 0.00074 
ATAD3B rs4077630 0.0314 0.844 -0.57241 2.04E-05 0.000882 
PRDX6 rs4279882 1.84 3.83E-05 0.363601 0.054769 0.000985 
FN3K rs12940475 -0.0784 0.687 0.734389 1.44E-05 0.001501 
GRAP2 rs137981 -1.14 4.46E-05 -0.09066 0.666071 0.002091 
SNRNP25 rs8061370 0.605 2.99E-05 -0.06293 0.696224 0.002163 
BCKDK rs2855475 -0.153 0.38 0.561202 9.02E-05 0.002216 
THBS3 rs4971079 0.0511 0.768 -0.54813 5.18E-05 0.003202 
KIAA1683 rs10854163 0.0462 0.805 -0.65634 6.97E-08 0.004201 
PPOX rs12745476 0.206 0.35 -0.4601 5.42E-05 0.005352 
VPS28 rs1871538 -0.136 0.628 -1.19038 6.37E-05 0.008327 
ORMDL3 rs1565923 1.11 8.79E-07 0.468678 0.000618 0.008641 
CEACAM21 rs4802122 -1.33 2.06E-08 -0.64651 2.21E-05 0.009499 
ARPC2 rs13429408 -0.816 6.55E-05 0.175865 0.217886 0.009998 
ATAD3A rs973608 -0.726 1.14E-06 0.212146 0.288602 0.01189 
TBKBP1 rs4289035 1.06 4.90E-06 -0.39551 0.001875 0.013043 
SMG7 rs7550777 0.748 3.21E-05 0.231347 0.069313 0.016011 
MGAT3 rs5757680 0.397 0.0206 0.988105 1.40E-08 0.016343 
GEN1 rs10497450 1.58 3.92E-05 0.270692 0.253225 0.016633 





LOC728613 rs4958354 -0.774 4.79E-05 -0.12044 0.437221 0.01976 
ATP11B rs2314737 0.0528 0.786 0.654773 8.57E-06 0.026845 
PNRC2 rs1938341 0.0319 0.861 -0.56093 8.06E-05 0.027235 
TMEM180 rs2274351 -0.0751 0.687 -0.54095 3.44E-05 0.027943 
RPL12 rs2254437 -0.069 0.751 -0.53718 3.12E-05 0.028571 
DFNB31 rs2296262 0.319 0.0537 0.74847 1.56E-08 0.030896 
DNMBP rs7893702 0.0467 0.895 -0.71325 2.40E-05 0.039025 
CPTP rs11809901 -1.08 9.81E-05 -0.11297 0.696146 0.040807 
DCUN1D1 rs2314737 0.221 0.195 0.630321 2.14E-07 0.048337 
FAM195A rs16954348 0.357 0.51 -1.05988 1.14E-06 0.050343 
MILR1 rs17401012 1.81 3.40E-06 0.95454 0.000311 0.051946 
FAM118A rs136611 1.03 4.21E-05 1.545911 1.31E-20 0.054032 
METTL18 rs12130372 -0.565 0.063 -1.38499 1.93E-05 0.054107 
PPFIA4 rs6683283 0.165 0.394 0.803547 1.69E-05 0.05706 
JMJD8 rs16954348 0.624 0.327 -0.83088 6.34E-05 0.06035 
LOC100996324 rs12959287 0.16 0.41 0.595204 2.61E-05 0.060527 
LGALS9 rs11080242 -0.927 1.01E-05 -0.48729 0.000518 0.06209 
LGALS9 rs1984547 -0.884 2.36E-05 -0.55024 4.14E-05 0.157601 
ADAM1A rs16941831 1.23 1.92E-05 0.561453 0.014438 0.062618 
GPN3 rs4766500 -0.806 5.22E-05 -0.51343 0.000135 0.062985 
HEATR3 rs7186889 -0.51 0.00239 -0.89151 7.11E-13 0.072233 
RNASET2 rs398278 -0.443 0.0108 -1.06841 3.30E-15 0.073802 
SLC22A5 rs11950562 -0.534 8.00E-04 -0.86308 6.07E-14 0.074362 
SERAC1 rs11756587 0.239 0.423 0.9104 1.95E-05 0.091806 
C16orf13 rs16954348 0.312 0.591 -0.92939 9.97E-06 0.094278 
AHI1 rs12206850 -0.567 0.00285 -0.9239 2.93E-11 0.100782 
RBCK1 rs6081158 0.76 2.44E-05 -0.27994 0.076173 0.106272 
CD226 rs12969613 0.633 2.16E-07 0.179081 0.145273 0.109736 
LGALS9C rs11869582 -0.331 0.189 -0.66791 3.05E-05 0.109737 
PIGQ rs16954348 0.253 0.639 -0.91244 5.22E-05 0.111246 
C1QTNF6 rs73161818 0.901 1.97E-06 0.499751 0.002773 0.118617 
C1QTNF6 rs5756558 0.413 0.0106 0.519604 7.28E-05 0.587274 





B3GNT5 rs2314737 0.255 0.163 0.80748 3.54E-06 0.127941 
FGFR1OP rs56019630 1.33 6.73E-06 0.856966 1.67E-06 0.128701 
WDR27 rs4498361 0.165 0.34 0.586065 3.36E-05 0.129419 
EXTL2 rs17123491 -0.391 0.119 -0.82527 8.52E-05 0.142375 
WDR24 rs16954348 0.236 0.702 -0.88567 4.66E-05 0.159592 
VNN1 rs3798792 0.77 1.30E-05 0.502361 9.31E-06 0.167815 
IL32 rs17790434 -0.0846 0.778 -0.5365 5.70E-05 0.174578 
KLC1 rs729438 0.485 0.014 0.699987 1.37E-06 0.183549 
LOC645513 rs13113112 -1.13 1.04E-07 -0.90461 2.59E-11 0.19021 
LOC645513 rs6849889 -1.09 3.33E-07 -0.90465 1.03E-12 0.314709 
MORN3 rs2720022 -0.279 0.157 0.478632 3.63E-05 0.19601 
NTSR1 rs2427381 -0.786 0.00534 -0.48058 5.17E-05 0.207063 
C4orf33 rs10518544 0.425 0.242 1.006358 8.73E-05 0.214409 
SLC11A1 rs78846874 -0.35 0.36 -0.82787 3.85E-06 0.218666 
CYP27A1 rs1516086 0.413 0.0236 -0.79083 7.84E-10 0.219749 
NOD2 rs1981760 1.28 2.74E-08 1.045318 2.27E-16 0.233908 
EIF2D rs61048992 -0.505 0.146 -0.9922 1.72E-05 0.234918 
RAB40C rs1077352 -0.62 3.49E-05 -0.14382 0.343496 0.261467 
ANAPC13 rs4368544 -0.345 0.0451 -0.65629 8.42E-06 0.262567 
LINC01001 rs1440284 -0.284 0.228 -0.55358 9.25E-05 0.275624 
ARPC5 rs10797891 -0.281 0.123 0.484582 9.73E-06 0.280105 
UBE2E3 rs10195880 0.267 0.161 0.689888 8.70E-05 0.28372 
NBR2 rs4534897 -0.817 0.000121 -0.99417 2.31E-15 0.300471 
NADK rs1475766 -0.664 5.90E-06 -0.21048 0.125321 0.302007 
TMTC4 rs9585476 0.67 9.12E-05 0.864413 1.35E-10 0.31538 
GPR35 rs2975788 0.373 0.0424 0.553759 3.18E-05 0.32937 
DSE rs9400918 -0.423 0.0282 -0.59882 2.79E-05 0.330555 
GPD2 rs297581 0.593 8.98E-05 0.586601 0.000209 0.3329 
C5 rs10818500 -0.39 0.0168 0.737297 3.08E-07 0.339861 
C1orf85 rs2274226 1.15 1.89E-09 -1.01613 2.60E-21 0.344095 
MIB2 rs12075213 -0.26 0.526 -0.83477 5.90E-05 0.358394 
ZNF880 rs2059818 0.993 2.03E-08 0.960926 1.03E-10 0.371433 





MTRF1L rs6557250 -0.708 5.19E-05 -0.91534 6.32E-06 0.40392 
PNKD rs13430006 0.344 0.137 0.565642 6.76E-07 0.40517 
RPL3 rs137627 -0.272 0.1 0.504916 7.31E-05 0.409477 
TDRD9 rs1187448 0.424 0.112 0.650718 1.17E-05 0.41899 
NLRP2 rs12975582 0.562 0.0129 0.796243 1.19E-06 0.432793 
SPPL3 rs12427353 0.861 1.62E-05 -0.20224 0.313791 0.44264 
RAB11FIP3 rs16954348 -0.257 0.702 -0.84156 2.03E-05 0.446235 
CFAP126 rs35006684 -0.412 0.2 -0.6577 2.11E-05 0.454833 
PAM rs2431321 1.04 3.77E-09 1.151941 2.10E-23 0.476862 
LINC01061 rs13113112 0.98 3.46E-07 1.08365 4.07E-14 0.493742 
LINC01061 rs7661020 1.05 1.48E-08 1.030043 2.36E-13 0.937769 
CCDC127 rs422115 -0.873 5.14E-06 0.097156 0.583444 0.499223 
ST7L rs2999155 0.695 1.80E-05 0.833434 1.40E-07 0.508311 
THBD rs844885 -0.823 0.0258 -1.10479 3.29E-06 0.513719 
KSR1 rs2945378 -0.476 0.00619 -0.59863 4.37E-07 0.522783 
ST7L rs6682737 0.695 1.80E-05 0.831406 1.07E-07 0.530326 
YBEY rs2839235 0.765 0.000646 0.697255 9.23E-08 0.540517 
RMI2 rs11644184 0.581 0.000756 -0.69866 2.99E-07 0.540646 
LOC613037 rs13331817 0.409 0.00789 0.62636 2.26E-05 0.547664 
PLTP rs7275164 -0.555 0.000206 -0.71355 6.95E-07 0.583535 
CDK2AP1 rs11057223 1.29 8.09E-05 1.080669 1.73E-06 0.588468 
CDK2AP1 rs12317452 1.29 8.94E-05 1.102224 6.43E-07 0.637829 
PROCA1 rs8074623 -0.797 0.00504 -1.01211 3.52E-05 0.606873 
PPIL3 rs12620435 -0.592 0.0171 -0.73336 4.99E-05 0.612963 
GSN rs7028970 0.437 0.0169 0.539064 8.45E-05 0.613692 
ZNF467 rs855676 -0.532 0.027 -0.61017 4.81E-05 0.61607 
GBAP1 rs914615 0.604 0.000316 0.803634 7.82E-10 0.617967 
GBAP1 rs4971079 0.674 1.04E-05 0.661385 3.82E-07 0.98461 
ICAM4 rs3093029 1.22 0.000483 1.300892 2.89E-08 0.693603 
C17orf97 rs2857657 -0.747 1.63E-06 0.290567 0.142846 0.729101 
EPHB4 rs7784933 -0.412 0.0477 -0.64414 4.86E-05 0.733902 
MCCC1 rs2314737 -0.416 0.0414 -0.7201 2.08E-05 0.758154 





VIL1 rs56191141 -0.49 0.012 -0.66284 6.74E-06 0.77063 
SMDT1 rs133341 -0.735 0.00251 -0.7165 4.30E-07 0.773525 
LINC01260 rs2299686 -0.553 0.00686 -0.57997 3.18E-05 0.781926 
FLJ42351 rs4848286 0.798 0.000204 0.898136 3.36E-08 0.810656 
WARS rs11160582 0.644 0.00914 0.589059 2.43E-06 0.819379 
NUF2 rs10799928 1.42 1.61E-11 0.168798 0.335059 0.825918 
NT5C3B rs2304494 1.06 0.00123 1.09787 4.35E-06 0.859337 
LINC01089 rs7974348 -0.645 0.00126 -0.59437 3.27E-06 0.862302 
FAM206A rs2304779 -0.718 5.01E-05 -0.60913 0.000188 0.864452 
GSDMB rs11078926 -0.507 0.00589 -0.56385 9.90E-07 0.866853 
PAQR6 rs2274226 0.901 3.61E-06 -0.91761 1.02E-13 0.882854 
SMG5 rs2274226 1 1.46E-07 -1.13558 2.83E-22 0.884265 
IL12RB1 rs8109496 -0.823 0.00731 -0.78696 2.68E-06 0.912236 
SULT1A1 rs7191548 -0.487 0.00645 -0.61054 5.31E-07 0.930373 
ITLN1 rs2039415 -0.397 0.0806 -0.52389 6.34E-05 0.931464 










Supplementary Table 5 – Colocalization analyses: Posterior Probabilities for each Hypothesis 
A.   IBD 
GWAS (trait 
2); IBD eQTL 
(trait 1) 
        
D.   IBD 
GWAS (trait 
2); JIA eQTL 
(trait 1) 
 
Gene rsID H0 H1 H2 H3 H4 
  
Gene rsID H0 H1 H2 H3 H4 
ABHD16B rs6062504 0.00 0.00 0.92 0.01 0.08 
  
ABHD16B rs6062504 0.00 0.00 0.92 0.01 0.07 
ACO2 rs727563 0.79 0.00 0.19 0.00 0.02 
  
ACO2 rs727563 0.79 0.00 0.19 0.00 0.02 
ACTR1A rs3740415 0.01 0.00 0.91 0.00 0.07 
  
ACTR1A rs3740415 0.01 0.00 0.92 0.00 0.06 
AGPAT2 rs13300218 0.00 0.00 0.91 0.01 0.08 
  
AGPAT2 rs13300218 0.00 0.00 0.92 0.01 0.07 
APOBEC3G rs12627970 0.00 0.00 0.91 0.01 0.08 
  
APOBEC3G rs12627970 0.00 0.00 0.92 0.01 0.08 
APOBEC3H rs12627970 0.00 0.00 0.87 0.01 0.12 
  
APOBEC3H rs12627970 0.00 0.00 0.85 0.01 0.14 
ARFRP1 rs6062504 0.00 0.00 0.92 0.01 0.08 
  
ARFRP1 rs6062504 0.00 0.00 0.92 0.01 0.07 
ARL3 rs3740415 0.01 0.00 0.82 0.00 0.17 
  
ARL3 rs3740415 0.01 0.00 0.77 0.00 0.21 
ATF4 rs12627970 0.00 0.00 0.90 0.01 0.09 
  
ATF4 rs12627970 0.00 0.00 0.91 0.01 0.09 
ATP9B rs7236492 0.02 0.00 0.90 0.00 0.08 
  
ATP9B rs7236492 0.02 0.00 0.90 0.00 0.08 
B4GALT7 rs4976646 0.00 0.00 0.92 0.00 0.08 
  
B4GALT7 rs4976646 0.00 0.00 0.92 0.00 0.08 
BANK1 rs13126505 0.00 0.00 0.90 0.01 0.09 
  
BANK1 rs13126505 0.00 0.00 0.90 0.01 0.09 
BAZ2B rs4664304 0.04 0.00 0.88 0.00 0.08 
  
BAZ2B rs4664304 0.04 0.00 0.89 0.00 0.07 
C16orf74 rs2361755 0.00 0.00 0.90 0.00 0.10 
  
C16orf74 rs2361755 0.00 0.00 0.89 0.00 0.11 
C17orf67 rs3853824 0.00 0.00 0.90 0.00 0.10 
  
C17orf67 rs3853824 0.00 0.00 0.90 0.00 0.09 
C22orf46 rs727563 0.79 0.00 0.19 0.00 0.02 
  
C22orf46 rs727563 0.79 0.00 0.20 0.00 0.02 
C5orf56 rs17622378 0.00 0.00 0.91 0.01 0.08 
  
C5orf56 rs17622378 0.00 0.00 0.92 0.01 0.07 
CACNA1I rs12627970 0.00 0.00 0.90 0.00 0.10 
  
CACNA1I rs12627970 0.00 0.00 0.89 0.01 0.10 
CARD9 rs13300218 0.00 0.00 0.92 0.01 0.07 
  
CARD9 rs13300218 0.00 0.00 0.93 0.01 0.06 
CBX7 rs12627970 0.00 0.00 0.90 0.02 0.08 
  
CBX7 rs12627970 0.00 0.00 0.89 0.03 0.07 
CD226 rs727088 0.00 0.00 0.86 0.01 0.13 
  
CD226 rs727088 0.00 0.00 0.84 0.01 0.15 
CD28 rs3116494 0.19 0.00 0.60 0.01 0.20 
  
CD28 rs3116494 0.16 0.00 0.52 0.01 0.30 
CD40 rs6074022 0.00 0.00 0.91 0.01 0.08 
  
CD40 rs6074022 0.00 0.00 0.92 0.01 0.07 
CDK12 rs12946510 0.00 0.00 0.92 0.01 0.07 
  
CDK12 rs12946510 0.00 0.00 0.93 0.01 0.06 
CEBPA rs17694108 0.00 0.00 0.89 0.00 0.11 
  
CEBPA rs17694108 0.00 0.00 0.88 0.00 0.12 
CEBPG rs17694108 0.00 0.00 0.92 0.00 0.08 
  





COASY rs12942547 0.00 0.00 0.89 0.01 0.11 
  
COASY rs12942547 0.00 0.00 0.88 0.01 0.11 
COIL rs3853824 0.00 0.00 0.92 0.00 0.08 
  
COIL rs3853824 0.00 0.00 0.93 0.00 0.07 
COX4I1 rs2361755 0.00 0.00 0.91 0.00 0.09 
  
COX4I1 rs2361755 0.00 0.00 0.91 0.00 0.09 
CPEB4 rs72810983 0.00 0.00 0.90 0.02 0.08 
  
CPEB4 rs72810983 0.00 0.00 0.91 0.02 0.07 
CRYZL1 rs2284553 0.01 0.00 0.90 0.00 0.09 
  
CRYZL1 rs2284553 0.01 0.00 0.91 0.00 0.08 
CTDP1 rs7236492 0.02 0.00 0.89 0.00 0.08 
  
CTDP1 rs7236492 0.02 0.00 0.90 0.00 0.08 
CTLA4 rs3116494 0.21 0.00 0.68 0.01 0.10 
  
CTLA4 rs3116494 0.21 0.00 0.67 0.01 0.11 
CTSA rs6074022 0.00 0.00 0.91 0.01 0.08 
  
CTSA rs6074022 0.00 0.00 0.92 0.01 0.07 
CTSZ rs259964 0.00 0.00 0.89 0.00 0.11 
  
CTSZ rs259964 0.00 0.00 0.88 0.00 0.12 
CUEDC2 rs3740415 0.01 0.00 0.91 0.00 0.07 
  
CUEDC2 rs3740415 0.01 0.00 0.92 0.00 0.06 
CYTH1 rs17736589 0.91 0.00 0.08 0.00 0.01 
  
CYTH1 rs17736589 0.91 0.00 0.08 0.00 0.01 
DBN1 rs4976646 0.00 0.00 0.90 0.00 0.10 
  
DBN1 rs4976646 0.00 0.00 0.91 0.00 0.09 
DCTN5 rs7404095 0.06 0.00 0.87 0.00 0.07 
  
DCTN5 rs7404095 0.06 0.00 0.88 0.00 0.06 
DDX41 rs4976646 0.00 0.00 0.91 0.00 0.09 
  
DDX41 rs4976646 0.00 0.00 0.92 0.00 0.08 
DENND1B rs2488389 0.00 0.00 0.92 0.01 0.08 
  
DENND1B rs2488389 0.00 0.00 0.92 0.01 0.07 
DESI1 rs727563 0.77 0.00 0.19 0.00 0.05 
  
DESI1 rs727563 0.75 0.00 0.19 0.00 0.06 
DGKE rs3853824 0.00 0.00 0.92 0.00 0.08 
  
DGKE rs3853824 0.00 0.00 0.93 0.00 0.07 
DNAH17 rs17736589 0.91 0.00 0.08 0.00 0.01 
  
DNAH17 rs17736589 0.91 0.00 0.08 0.00 0.01 
DNAJC5 rs6062504 0.00 0.00 0.92 0.01 0.08 
  
DNAJC5 rs6062504 0.00 0.00 0.93 0.01 0.07 
DNLZ rs13300218 0.00 0.00 0.92 0.01 0.07 
  
DNLZ rs13300218 0.00 0.00 0.93 0.01 0.06 
DOK3 rs4976646 0.00 0.00 0.93 0.00 0.07 
  
DOK3 rs4976646 0.00 0.00 0.94 0.00 0.06 
DONSON rs2284553 0.01 0.00 0.91 0.00 0.08 
  
DONSON rs2284553 0.01 0.00 0.92 0.00 0.07 
DPH5 rs11583043 0.24 0.00 0.66 0.01 0.09 
  
DPH5 rs11583043 0.24 0.00 0.65 0.01 0.11 
ECHDC1 rs2503322 0.50 0.00 0.46 0.00 0.04 
  
ECHDC1 rs2503322 0.50 0.00 0.46 0.00 0.03 
EGFL7 rs13300218 0.00 0.00 0.77 0.01 0.22 
  
EGFL7 rs13300218 0.00 0.00 0.69 0.01 0.30 
ELOVL3 rs3740415 0.17 0.00 0.75 0.00 0.08 
  
ELOVL3 rs3740415 0.17 0.00 0.75 0.00 0.08 
EMC8 rs2361755 0.00 0.00 0.89 0.00 0.10 
  
EMC8 rs2361755 0.00 0.00 0.88 0.00 0.12 
ERBB2 rs12946510 0.00 0.00 0.92 0.01 0.07 
  
ERBB2 rs12946510 0.00 0.00 0.93 0.01 0.06 
EXTL2 rs11583043 0.23 0.00 0.63 0.01 0.13 
  
EXTL2 rs11583043 0.22 0.00 0.60 0.01 0.17 
F12 rs4976646 0.00 0.00 0.91 0.00 0.09 
  
F12 rs4976646 0.00 0.00 0.91 0.00 0.09 
FAM134C rs12942547 0.00 0.00 0.90 0.01 0.09 
  
FAM134C rs12942547 0.00 0.00 0.91 0.01 0.09 
FAM193B rs4976646 0.00 0.00 0.81 0.00 0.19 
  
FAM193B rs4976646 0.00 0.00 0.75 0.00 0.25 
FAM69B rs13300218 0.00 0.00 0.87 0.00 0.12 
  





FBXL15 rs3740415 0.01 0.00 0.91 0.00 0.07 
  
FBXL15 rs3740415 0.01 0.00 0.92 0.00 0.06 
FYN rs3851228 0.00 0.00 0.90 0.01 0.09 
  
FYN rs3851228 0.00 0.00 0.91 0.01 0.08 
GART rs2284553 0.01 0.00 0.91 0.00 0.07 
  
GART rs2284553 0.01 0.00 0.92 0.00 0.07 
GBF1 rs3740415 0.01 0.00 0.87 0.00 0.12 
  
GBF1 rs3740415 0.01 0.00 0.86 0.00 0.13 
GHDC rs12942547 0.00 0.00 0.87 0.01 0.13 
  
GHDC rs12942547 0.00 0.00 0.85 0.01 0.14 
GLS rs1517352 0.00 0.00 0.92 0.01 0.08 
  
GLS rs1517352 0.00 0.00 0.93 0.01 0.07 
GMEB2 rs6062504 0.00 0.00 0.92 0.01 0.08 
  
GMEB2 rs6062504 0.00 0.00 0.93 0.01 0.07 
GPATCH1 rs17694108 0.00 0.00 0.92 0.00 0.08 
  
GPATCH1 rs17694108 0.00 0.00 0.93 0.00 0.07 
GPSM1 rs13300218 0.00 0.00 0.88 0.01 0.11 
  
GPSM1 rs13300218 0.00 0.00 0.88 0.01 0.11 
GRK6 rs4976646 0.00 0.00 0.91 0.00 0.09 
  
GRK6 rs4976646 0.00 0.00 0.91 0.00 0.09 
GSDMB rs12946510 0.00 0.00 0.22 0.01 0.76 
  
GSDMB rs12946510 0.00 0.00 0.07 0.01 0.92 
HELZ2 rs6062504 0.00 0.00 0.91 0.01 0.08 
  
HELZ2 rs6062504 0.00 0.00 0.92 0.01 0.07 
HSD17B1 rs12942547 0.00 0.00 0.86 0.01 0.13 
  
HSD17B1 rs12942547 0.00 0.00 0.84 0.01 0.15 
ICOS rs3116494 0.20 0.00 0.63 0.01 0.16 
  
ICOS rs3116494 0.18 0.00 0.58 0.01 0.23 
IFNAR1 rs2284553 0.01 0.00 0.91 0.00 0.08 
  
IFNAR1 rs2284553 0.01 0.00 0.92 0.00 0.07 
IFNAR2 rs2284553 0.01 0.00 0.91 0.00 0.08 
  
IFNAR2 rs2284553 0.01 0.00 0.92 0.00 0.07 
IFNGR2 rs2284553 0.01 0.00 0.91 0.00 0.08 
  
IFNGR2 rs2284553 0.01 0.00 0.92 0.00 0.07 
IKZF3 rs12946510 0.00 0.00 0.91 0.01 0.08 
  
IKZF3 rs12946510 0.00 0.00 0.91 0.01 0.08 
IL10RB rs2284553 0.01 0.00 0.91 0.00 0.08 
  
IL10RB rs2284553 0.01 0.00 0.92 0.00 0.07 
INPP5E rs13300218 0.00 0.00 0.89 0.01 0.10 
  
INPP5E rs13300218 0.00 0.00 0.89 0.01 0.10 
IRF1 rs17622378 0.00 0.00 0.90 0.02 0.08 
  
IRF1 rs17622378 0.00 0.00 0.91 0.02 0.07 
IRF8 rs2361755 0.00 0.00 0.91 0.00 0.09 
  
IRF8 rs2361755 0.00 0.00 0.91 0.00 0.09 
ITSN1 rs2284553 0.01 0.00 0.91 0.00 0.08 
  
ITSN1 rs2284553 0.01 0.00 0.92 0.00 0.07 
KIF3A rs17622378 0.00 0.00 0.91 0.01 0.09 
  
KIF3A rs17622378 0.00 0.00 0.91 0.01 0.08 
L3MBTL2 rs727563 0.79 0.00 0.19 0.00 0.02 
  
L3MBTL2 rs727563 0.79 0.00 0.20 0.00 0.01 
LCN10 rs13300218 0.00 0.00 0.92 0.00 0.08 
  
LCN10 rs13300218 0.00 0.00 0.93 0.00 0.07 
LGALS3BP rs17736589 0.99 0.00 0.01 0.00 0.00 
  
LGALS3BP rs17736589 0.99 0.00 0.01 0.00 0.00 
LIME1 rs6062504 0.00 0.00 0.90 0.01 0.09 
  
LIME1 rs6062504 0.00 0.00 0.90 0.01 0.09 
LINC01573 rs13300218 0.00 0.00 0.86 0.01 0.13 
  
LINC01573 rs13300218 0.00 0.00 0.84 0.01 0.15 
LITAF rs11641184 0.00 0.00 0.89 0.00 0.11 
  
LITAF rs11641184 0.00 0.00 0.89 0.00 0.11 
LMAN2 rs4976646 0.00 0.00 0.91 0.00 0.09 
  
LMAN2 rs4976646 0.00 0.00 0.92 0.00 0.08 
LOC101927131 rs11641184 0.00 0.00 0.89 0.00 0.10 
  
LOC101927131 rs11641184 0.00 0.00 0.89 0.00 0.11 
LOC101928370 rs11583043 0.36 0.00 0.57 0.00 0.07 
  





LOC102606465 rs11583043 0.24 0.00 0.67 0.01 0.08 
  
LOC102606465 rs11583043 0.24 0.00 0.66 0.01 0.08 
LRP3 rs17694108 0.00 0.00 0.89 0.00 0.11 
  
LRP3 rs17694108 0.00 0.00 0.88 0.00 0.12 
MANBA rs3774937 0.94 0.00 0.06 0.00 0.01 
  
MANBA rs3774937 0.94 0.00 0.06 0.00 0.01 
MEI1 rs727563 0.79 0.00 0.19 0.00 0.02 
  
MEI1 rs727563 0.79 0.00 0.19 0.00 0.02 
MGAT3 rs12627970 0.00 0.00 0.90 0.02 0.08 
  
MGAT3 rs12627970 0.00 0.00 0.84 0.09 0.07 
MIEF1 rs12627970 0.00 0.00 0.90 0.01 0.08 
  
MIEF1 rs12627970 0.00 0.00 0.90 0.02 0.08 
MIEN1 rs12946510 0.00 0.00 0.92 0.01 0.08 
  
MIEN1 rs12946510 0.00 0.00 0.93 0.01 0.07 
MIR647 rs6062504 0.00 0.00 0.75 0.00 0.24 
  
MIR647 rs6062504 0.00 0.00 0.64 0.00 0.36 
MLX rs12942547 0.00 0.00 0.67 0.01 0.32 
  
MLX rs12942547 0.00 0.00 0.51 0.01 0.48 
MMP9 rs6074022 0.00 0.00 0.90 0.01 0.09 
  
MMP9 rs6074022 0.00 0.00 0.90 0.01 0.09 
MXD3 rs4976646 0.00 0.00 0.93 0.00 0.07 
  
MXD3 rs4976646 0.00 0.00 0.94 0.00 0.06 
NAGLU rs12942547 0.00 0.00 0.91 0.01 0.08 
  
NAGLU rs12942547 0.00 0.00 0.92 0.01 0.08 
NCOA5 rs6074022 0.00 0.00 0.89 0.01 0.10 
  
NCOA5 rs6074022 0.00 0.00 0.89 0.01 0.10 
NFATC1 rs7236492 0.02 0.00 0.89 0.00 0.09 
  
NFATC1 rs7236492 0.02 0.00 0.89 0.00 0.08 
NFKB1 rs3774937 0.94 0.00 0.06 0.00 0.01 
  
NFKB1 rs3774937 0.94 0.00 0.06 0.00 0.00 
NFKB2 rs3740415 0.01 0.00 0.91 0.00 0.08 
  
NFKB2 rs3740415 0.01 0.00 0.91 0.00 0.07 
NHP2L1 rs727563 0.79 0.00 0.19 0.00 0.02 
  
NHP2L1 rs727563 0.79 0.00 0.20 0.00 0.01 
NOG rs3853824 0.00 0.00 0.91 0.00 0.09 
  
NOG rs3853824 0.00 0.00 0.92 0.00 0.08 
NOTCH1 rs13300218 0.00 0.00 0.90 0.01 0.09 
  
NOTCH1 rs13300218 0.00 0.00 0.90 0.01 0.09 
NSD1 rs4976646 0.00 0.00 0.92 0.00 0.08 
  
NSD1 rs4976646 0.00 0.00 0.93 0.00 0.07 
ORMDL3 rs12946510 0.00 0.00 0.67 0.01 0.32 
  
ORMDL3 rs12946510 0.00 0.00 0.52 0.01 0.46 
PALB2 rs7404095 0.06 0.00 0.86 0.00 0.08 
  
PALB2 rs7404095 0.06 0.00 0.86 0.00 0.08 
PCIF1 rs6074022 0.00 0.00 0.90 0.01 0.09 
  
PCIF1 rs6074022 0.00 0.00 0.90 0.01 0.09 
PDGFB rs12627970 0.00 0.00 0.90 0.01 0.09 
  
PDGFB rs12627970 0.00 0.00 0.90 0.01 0.09 
PDLIM7 rs4976646 0.00 0.00 0.91 0.00 0.09 
  
PDLIM7 rs4976646 0.00 0.00 0.92 0.00 0.08 
PEPD rs17694108 0.00 0.00 0.86 0.00 0.14 
  
PEPD rs17694108 0.00 0.00 0.82 0.00 0.18 
PGAP3 rs12946510 0.00 0.00 0.92 0.01 0.08 
  
PGAP3 rs12946510 0.00 0.00 0.93 0.01 0.07 
PHF5A rs727563 0.78 0.00 0.19 0.00 0.02 
  
PHF5A rs727563 0.78 0.00 0.19 0.00 0.02 
PLCL1 rs1440088 1.00 0.00 0.00 0.00 0.00 
  
PLCL1 rs1440088 1.00 0.00 0.00 0.00 0.00 
PLK1 rs7404095 0.06 0.00 0.85 0.00 0.09 
  
PLK1 rs7404095 0.06 0.00 0.86 0.00 0.09 
PLTP rs6074022 0.00 0.00 0.82 0.01 0.17 
  
PLTP rs6074022 0.00 0.00 0.76 0.01 0.23 
PMM1 rs727563 0.79 0.00 0.19 0.00 0.02 
  
PMM1 rs727563 0.79 0.00 0.19 0.00 0.02 
PMPCA rs13300218 0.00 0.00 0.92 0.01 0.07 
  





POLR3H rs727563 0.79 0.00 0.19 0.00 0.02 
  
POLR3H rs727563 0.79 0.00 0.20 0.00 0.02 
PPA2 rs2189234 0.00 0.00 0.93 0.00 0.07 
  
PPA2 rs2189234 0.00 0.00 0.93 0.00 0.06 
PPDPF rs6062504 0.00 0.00 0.91 0.01 0.09 
  
PPDPF rs6062504 0.00 0.00 0.91 0.01 0.08 
PRELID1 rs4976646 0.00 0.00 0.91 0.00 0.09 
  
PRELID1 rs4976646 0.00 0.00 0.92 0.00 0.08 
PRKCB rs7404095 0.03 0.00 0.46 0.00 0.50 
  
PRKCB rs7404095 0.02 0.00 0.23 0.00 0.75 
PRR7 rs4976646 0.00 0.00 0.92 0.00 0.08 
  
PRR7 rs4976646 0.00 0.00 0.93 0.00 0.07 
PSD rs3740415 0.01 0.00 0.90 0.00 0.09 
  
PSD rs3740415 0.01 0.00 0.91 0.00 0.08 
PSMC3IP rs12942547 0.00 0.00 0.92 0.01 0.07 
  
PSMC3IP rs12942547 0.00 0.00 0.93 0.01 0.07 
PSMD3 rs12946510 0.00 0.00 0.91 0.00 0.08 
  
PSMD3 rs12946510 0.00 0.00 0.92 0.00 0.08 
PTK6 rs6062504 0.00 0.00 0.90 0.01 0.09 
  
PTK6 rs6062504 0.00 0.00 0.90 0.01 0.09 
PTPRK rs13204742 0.00 0.00 0.88 0.01 0.11 
  
PTPRK rs13204742 0.00 0.00 0.87 0.01 0.12 
RAB24 rs4976646 0.00 0.00 0.92 0.00 0.08 
  
RAB24 rs4976646 0.00 0.00 0.92 0.00 0.08 
RAB5C rs12942547 0.00 0.00 0.92 0.00 0.08 
  
RAB5C rs12942547 0.00 0.00 0.93 0.00 0.07 
RAD50 rs17622378 0.00 0.00 0.90 0.01 0.09 
  
RAD50 rs17622378 0.00 0.00 0.91 0.01 0.08 
RANGAP1 rs727563 0.79 0.00 0.19 0.00 0.02 
  
RANGAP1 rs727563 0.79 0.00 0.20 0.00 0.02 
REV3L rs3851228 0.00 0.00 0.90 0.01 0.09 
  
REV3L rs3851228 0.00 0.00 0.90 0.01 0.08 
RGS14 rs4976646 0.00 0.00 0.87 0.00 0.13 
  
RGS14 rs4976646 0.00 0.00 0.85 0.00 0.15 
RNF145 rs56167332 0.00 0.00 0.88 0.03 0.10 
  
RNF145 rs56167332 0.00 0.00 0.87 0.03 0.10 
RNF146 rs2503322 0.50 0.00 0.46 0.00 0.04 
  
RNF146 rs2503322 0.50 0.00 0.46 0.00 0.03 
RPL3 rs12627970 0.00 0.00 0.88 0.03 0.09 
  
RPL3 rs12627970 0.00 0.00 0.84 0.08 0.08 
RPS19BP1 rs12627970 0.00 0.00 0.90 0.01 0.09 
  
RPS19BP1 rs12627970 0.00 0.00 0.91 0.01 0.08 
RSL1D1 rs11641184 0.00 0.00 0.89 0.00 0.11 
  
RSL1D1 rs11641184 0.00 0.00 0.88 0.00 0.12 
RTTN rs727088 0.00 0.00 0.91 0.01 0.08 
  
RTTN rs727088 0.00 0.00 0.91 0.01 0.08 
S1PR1 rs11583043 0.35 0.00 0.56 0.00 0.08 
  
S1PR1 rs11583043 0.35 0.00 0.55 0.00 0.09 
SCPEP1 rs3853824 0.00 0.00 0.91 0.00 0.09 
  
SCPEP1 rs3853824 0.00 0.00 0.91 0.00 0.09 
SDCCAG3 rs13300218 0.00 0.00 0.88 0.01 0.10 
  
SDCCAG3 rs13300218 0.00 0.00 0.88 0.01 0.11 
SEC16A rs13300218 0.00 0.00 0.92 0.01 0.07 
  
SEC16A rs13300218 0.00 0.00 0.93 0.01 0.06 
SFXN2 rs3740415 0.01 0.00 0.88 0.00 0.11 
  
SFXN2 rs3740415 0.01 0.00 0.88 0.00 0.11 
SLC22A4 rs17622378 0.00 0.00 0.91 0.01 0.07 
  
SLC22A4 rs17622378 0.00 0.00 0.92 0.01 0.06 
SLC22A5 rs17622378 0.00 0.00 0.00 0.98 0.02 
  
SLC22A5 rs17622378 0.00 0.00 0.00 1.00 0.00 
SLC2A4RG rs6062504 0.00 0.00 0.90 0.01 0.09 
  
SLC2A4RG rs6062504 0.00 0.00 0.91 0.01 0.08 
SLC30A7 rs11583043 0.24 0.00 0.66 0.01 0.09 
  
SLC30A7 rs11583043 0.23 0.00 0.64 0.01 0.11 
SLC35C2 rs6074022 0.00 0.00 0.91 0.00 0.09 
  





SLC39A8 rs3774937 0.94 0.00 0.06 0.00 0.01 
  
SLC39A8 rs3774937 0.94 0.00 0.06 0.00 0.01 
SNAPC4 rs13300218 0.00 0.00 0.90 0.01 0.09 
  
SNAPC4 rs13300218 0.00 0.00 0.91 0.01 0.09 
SNN rs11641184 0.00 0.00 0.86 0.00 0.14 
  
SNN rs11641184 0.00 0.00 0.84 0.00 0.16 
STARD3 rs12946510 0.00 0.00 0.84 0.01 0.15 
  
STARD3 rs12946510 0.00 0.00 0.81 0.01 0.18 
STAT1 rs1517352 0.00 0.00 0.90 0.01 0.09 
  
STAT1 rs1517352 0.00 0.00 0.90 0.01 0.09 
STAT3 rs12942547 0.00 0.00 0.84 0.01 0.15 
  
STAT3 rs12942547 0.00 0.00 0.80 0.01 0.19 
STAT4 rs1517352 0.00 0.00 0.92 0.01 0.07 
  
STAT4 rs1517352 0.00 0.00 0.93 0.01 0.06 
STAT5A rs12942547 0.00 0.00 0.92 0.01 0.08 
  
STAT5A rs12942547 0.00 0.00 0.93 0.01 0.07 
STAT5B rs12942547 0.00 0.00 0.91 0.01 0.09 
  
STAT5B rs12942547 0.00 0.00 0.91 0.01 0.08 
STMN3 rs6062504 0.00 0.00 0.92 0.01 0.08 
  
STMN3 rs6062504 0.00 0.00 0.92 0.01 0.07 
SUFU rs3740415 0.01 0.00 0.91 0.00 0.08 
  
SUFU rs3740415 0.01 0.00 0.92 0.00 0.07 
SYNGR1 rs12627970 0.00 0.00 0.91 0.01 0.08 
  
SYNGR1 rs12627970 0.00 0.00 0.92 0.01 0.07 
TCAP rs12946510 0.00 0.00 0.92 0.01 0.07 
  
TCAP rs12946510 0.00 0.00 0.93 0.01 0.06 
TEF rs727563 0.79 0.00 0.19 0.00 0.02 
  
TEF rs727563 0.79 0.00 0.19 0.00 0.02 
TET2 rs2189234 0.00 0.00 0.92 0.00 0.08 
  
TET2 rs2189234 0.00 0.00 0.92 0.00 0.08 
THEMIS rs13204742 0.00 0.00 0.88 0.01 0.11 
  
THEMIS rs13204742 0.00 0.00 0.86 0.01 0.12 
TIMP2 rs17736589 0.91 0.00 0.08 0.00 0.01 
  
TIMP2 rs17736589 0.91 0.00 0.08 0.00 0.01 
TMED9 rs4976646 0.00 0.00 0.93 0.00 0.07 
  
TMED9 rs4976646 0.00 0.00 0.94 0.00 0.06 
TMEM180 rs3740415 0.00 0.00 0.26 0.00 0.74 
  
TMEM180 rs3740415 0.00 0.00 0.08 0.00 0.92 
TMEM50B rs2284553 0.01 0.00 0.91 0.00 0.08 
  
TMEM50B rs2284553 0.01 0.00 0.92 0.00 0.07 
TOB2 rs727563 0.79 0.00 0.19 0.00 0.02 
  
TOB2 rs727563 0.79 0.00 0.20 0.00 0.01 
TPD52L2 rs6062504 0.00 0.00 0.91 0.01 0.08 
  
TPD52L2 rs6062504 0.00 0.00 0.92 0.01 0.07 
TRAF3IP2 rs3851228 0.00 0.00 0.90 0.01 0.09 
  
TRAF3IP2 rs3851228 0.00 0.00 0.90 0.02 0.08 
TRIM8 rs3740415 0.01 0.00 0.90 0.00 0.09 
  
TRIM8 rs3740415 0.01 0.00 0.91 0.00 0.08 
TUBB1 rs259964 0.00 0.00 0.91 0.00 0.09 
  
TUBB1 rs259964 0.00 0.00 0.91 0.00 0.09 
TUBG1 rs12942547 0.00 0.00 0.91 0.00 0.08 
  
TUBG1 rs12942547 0.00 0.00 0.92 0.00 0.08 
TXNDC11 rs11641184 0.00 0.00 0.87 0.00 0.13 
  
TXNDC11 rs11641184 0.00 0.00 0.85 0.00 0.15 
UBLCP1 rs56167332 0.00 0.00 0.89 0.03 0.08 
  
UBLCP1 rs56167332 0.00 0.00 0.89 0.03 0.07 
UCKL1 rs6062504 0.00 0.00 0.91 0.00 0.09 
  
UCKL1 rs6062504 0.00 0.00 0.91 0.00 0.09 
USP36 rs17736589 0.91 0.00 0.08 0.00 0.01 
  
USP36 rs17736589 0.91 0.00 0.08 0.00 0.01 
XRCC6 rs727563 0.79 0.00 0.19 0.00 0.02 
  
XRCC6 rs727563 0.79 0.00 0.20 0.00 0.01 
ZBTB46 rs6062504 0.00 0.00 0.91 0.01 0.08 
  
ZBTB46 rs6062504 0.00 0.00 0.92 0.01 0.07 
ZC3H7A rs11641184 0.00 0.00 0.90 0.00 0.10 
  





ZC3H7B rs727563 0.79 0.00 0.19 0.00 0.02 
  
ZC3H7B rs727563 0.79 0.00 0.20 0.00 0.02 
ZGPAT rs6062504 0.00 0.00 0.92 0.01 0.08 
  
ZGPAT rs6062504 0.00 0.00 0.93 0.01 0.07 
ZNF335 rs6074022 0.00 0.00 0.91 0.01 0.08 
  
ZNF335 rs6074022 0.00 0.00 0.91 0.01 0.08 
ZNF512B rs6062504 0.00 0.00 0.92 0.00 0.08 
  
ZNF512B rs6062504 0.00 0.00 0.93 0.00 0.07 
ZNF831 rs259964 0.00 0.00 0.92 0.00 0.08 
  
ZNF831 rs259964 0.00 0.00 0.93 0.00 0.07 
ZSWIM1 rs6074022 0.00 0.00 0.91 0.01 0.08 
  
ZSWIM1 rs6074022 0.00 0.00 0.92 0.01 0.08 
ZSWIM3 rs6074022 0.00 0.00 0.91 0.01 0.09 
  
ZSWIM3 rs6074022 0.00 0.00 0.91 0.01 0.08                 
B.  JIA GWAS 
(trait 2); JIA 
eQTL (trait 1) 
      
  
 
E.   JIA 
GWAS (trait 
2); IBD eQTL 
(trait 1) 
 
Gene rsID H0 H1 H2 H3 H4 
  
Gene rsID H0 H1 H2 H3 H4 
ADPRH rs4688013 0.10 0.12 0.34 0.41 0.03 
  
ADPRH rs4688013 0.09 0.13 0.32 0.43 0.03 
ARHGAP31 rs4688013 0.11 0.12 0.35 0.39 0.03 
  
ARHGAP31 rs4688013 0.10 0.13 0.33 0.42 0.03 
CEP192 rs2847293 0.05 0.05 0.45 0.40 0.04 
  
CEP192 rs2847293 0.04 0.03 0.49 0.39 0.05 
CEP76 rs2847293 0.05 0.04 0.47 0.39 0.04 
  
CEP76 rs2847293 0.04 0.03 0.51 0.38 0.04 
CHST10 rs6740838 0.78 0.09 0.11 0.01 0.01 
  
CHST10 rs6740838 0.78 0.08 0.12 0.01 0.01 
CLEC16A rs66718203 0.00 0.00 0.24 0.73 0.02 
  
CLEC16A rs66718203 0.00 0.00 0.21 0.76 0.03 
COX17 rs4688013 0.11 0.12 0.36 0.38 0.03 
  
COX17 rs4688013 0.10 0.12 0.33 0.41 0.04 
KIAA1109 rs1479924 0.42 0.05 0.43 0.05 0.04 
         
LITAF rs66718203 0.00 0.01 0.30 0.66 0.03 
  
LITAF rs66718203 0.00 0.00 0.30 0.67 0.03 
LOC100996324 rs2847293 0.05 0.04 0.45 0.39 0.06 
  
LOC100996324 rs2847293 0.02 0.04 0.22 0.52 0.20 
LOC101927131 rs66718203 0.00 0.00 0.24 0.73 0.02 
  
LOC101927131 rs66718203 0.00 0.00 0.23 0.75 0.02 
POGLUT1 rs4688013 0.10 0.12 0.33 0.42 0.04 
  
POGLUT1 rs4688013 0.08 0.14 0.28 0.47 0.03 
POPDC2 rs4688013 0.10 0.13 0.33 0.42 0.03 
  
POPDC2 rs4688013 0.09 0.14 0.29 0.46 0.03 
PSMG2 rs2847293 0.06 0.04 0.48 0.38 0.04 
  
PSMG2 rs2847293 0.04 0.03 0.51 0.38 0.04 
PTPN2 rs2847293 0.06 0.04 0.49 0.37 0.04 
  
PTPN2 rs2847293 0.04 0.03 0.50 0.39 0.04 
RMI2 rs66718203 0.00 0.00 0.10 0.88 0.01 
  
RMI2 rs66718203 0.00 0.00 0.04 0.96 0.00 
SEH1L rs2847293 0.05 0.04 0.47 0.39 0.04 
  
SEH1L rs2847293 0.04 0.03 0.51 0.38 0.04 
SOCS1 rs66718203 0.00 0.00 0.23 0.74 0.02 
  
SOCS1 rs66718203 0.00 0.00 0.22 0.76 0.02 
SPIRE1 rs2847293 0.05 0.04 0.46 0.38 0.06 
  
SPIRE1 rs2847293 0.04 0.03 0.47 0.41 0.04 
TIMMDC1 rs4688013 0.11 0.12 0.35 0.39 0.03 
  
TIMMDC1 rs4688013 0.10 0.12 0.33 0.42 0.03 
TMEM39A rs4688013 0.11 0.12 0.35 0.39 0.03 
  





                
C.   RA GWAS 
(trait 2); JIA 
eQTL (trait 1) 
        
F.   RA GWAS 
(trait 2); IBD 
eQTL (trait 1) 
 
Gene rsID H0 H1 H2 H3 H4 
  
Gene rsID H0 H1 H2 H3 H4          
ALS2CR12 rs6715284 0.06 0.01 0.77 0.07 0.09 
ARHGAP30 rs4656942 0.99 0.01 0.00 0.00 0.00 
         
         
ATG5 rs9372120 0.43 0.01 0.50 0.01 0.05          
BUB1 rs6732565 0.87 0.01 0.11 0.00 0.01 
C16orf74 rs13330176 0.01 0.00 0.92 0.00 0.07 
  
C16orf74 rs13330176 0.01 0.00 0.91 0.01 0.07 
C5orf30 rs2561477 0.00 0.00 0.92 0.01 0.08 
  
C5orf30 rs2561477 0.00 0.00 0.92 0.01 0.07          
CASP10 rs6715284 0.07 0.00 0.83 0.02 0.07          
CASP8 rs6715284 0.06 0.00 0.81 0.02 0.10 
CCR6 rs1571878 0.00 0.00 0.92 0.01 0.08 
  
CCR6 rs1571878 0.00 0.00 0.53 0.03 0.44 
CD2 rs624988 0.01 0.00 0.90 0.01 0.08 
  
CD2 rs624988 0.01 0.00 0.91 0.01 0.07 
CD244 rs4656942 0.99 0.01 0.00 0.00 0.00 
         
CD40 rs4239702 0.00 0.00 0.91 0.01 0.08 
  
CD40 rs4239702 0.00 0.00 0.92 0.01 0.07 
CD48 rs4656942 0.99 0.01 0.00 0.00 0.00 
         
CD58 rs624988 0.01 0.00 0.91 0.01 0.07 
  
CD58 rs624988 0.01 0.00 0.91 0.01 0.07 
CDK12 rs1877030 0.01 0.00 0.86 0.01 0.12 
  
CDK12 rs1877030 0.01 0.00 0.90 0.02 0.07          
CEP192 rs8083786 0.00 0.00 0.86 0.07 0.06          
CEP76 rs8083786 0.00 0.00 0.92 0.02 0.07          
CFAP126 rs72717009 0.00 0.00 0.76 0.16 0.08          
CFLAR rs6715284 0.06 0.00 0.82 0.02 0.09 
COX4I1 rs13330176 0.01 0.00 0.91 0.00 0.08 
  
COX4I1 rs13330176 0.01 0.00 0.90 0.02 0.07 
CTSA rs4239702 0.00 0.00 0.92 0.01 0.07 
  
CTSA rs4239702 0.00 0.00 0.92 0.01 0.07 
ELMO2 rs4239702 0.00 0.00 0.92 0.00 0.08 
  
ELMO2 rs4239702 0.00 0.00 0.92 0.01 0.07 
EMC8 rs13330176 0.01 0.00 0.91 0.00 0.08 
  
EMC8 rs13330176 0.01 0.00 0.90 0.02 0.07 
ERBB2 rs1877030 0.01 0.00 0.90 0.01 0.08 
  
ERBB2 rs1877030 0.01 0.00 0.91 0.02 0.06 
F11R rs4656942 0.99 0.01 0.00 0.00 0.00 
         
         
FAM126B rs6715284 0.12 0.00 0.79 0.02 0.07 
FBXL20 rs1877030 0.05 0.00 0.86 0.01 0.08 
  
FBXL20 rs1877030 0.03 0.00 0.87 0.01 0.08          
FCER1G rs72717009 0.03 0.00 0.78 0.11 0.07          





         
FCGR2B rs72717009 0.00 0.00 0.60 0.02 0.38          
FCGR2C rs72717009 0.00 0.00 0.88 0.03 0.09          
FCGR3A rs72717009 0.00 0.00 0.85 0.08 0.08          
FCGR3B rs72717009 0.00 0.00 0.89 0.02 0.09 
FGFR1OP rs1571878 0.00 0.00 0.90 0.01 0.09 
  
FGFR1OP rs1571878 0.00 0.00 0.87 0.06 0.07 
GIN1 rs2561477 0.00 0.00 0.92 0.01 0.08 
  
GIN1 rs2561477 0.00 0.00 0.84 0.02 0.14 
GLS rs11889341 0.00 0.00 0.91 0.01 0.08 
  
GLS rs11889341 0.00 0.00 0.83 0.01 0.15 
HIC2 rs11089637 0.11 0.00 0.80 0.00 0.08 
  
HIC2 rs11089637 0.03 0.00 0.88 0.01 0.08          
HSPA6 rs72717009 0.00 0.00 0.86 0.05 0.10          
HSPA7 rs72717009 0.00 0.00 0.80 0.02 0.18 
IKZF3 rs1877030 0.01 0.00 0.86 0.01 0.11 
  
IKZF3 rs1877030 0.01 0.00 0.91 0.01 0.07 
IRF8 rs13330176 0.01 0.00 0.91 0.00 0.08 
  
IRF8 rs13330176 0.01 0.00 0.90 0.02 0.07 
ITLN1 rs4656942 0.99 0.01 0.00 0.00 0.00 
         
         
KIAA1109 rs45475795 0.00 0.00 0.89 0.02 0.10          
LOC100996324 rs8083786 0.00 0.00 0.77 0.15 0.08          
LOC101928673 rs2105325 0.00 0.00 0.90 0.02 0.08 
LY9 rs4656942 0.98 0.01 0.00 0.00 0.00 
         
MAPK1 rs11089637 0.11 0.00 0.81 0.00 0.07 
  
MAPK1 rs11089637 0.03 0.00 0.85 0.02 0.10 
MED1 rs1877030 0.01 0.00 0.77 0.02 0.20 
  
MED1 rs1877030 0.01 0.00 0.90 0.02 0.07 
MIEN1 rs1877030 0.01 0.00 0.87 0.01 0.11 
  
MIEN1 rs1877030 0.01 0.00 0.90 0.02 0.07 
MMP9 rs4239702 0.00 0.00 0.92 0.01 0.07 
  
MMP9 rs4239702 0.00 0.00 0.89 0.01 0.10          
MPZ rs72717009 0.00 0.00 0.86 0.03 0.11 
NCOA5 rs4239702 0.00 0.00 0.91 0.01 0.08 
  
NCOA5 rs4239702 0.00 0.00 0.88 0.01 0.10          
NDUFB3 rs6715284 0.09 0.00 0.80 0.02 0.09          
NDUFS2 rs72717009 0.03 0.00 0.83 0.02 0.12 
PAM rs2561477 0.00 0.00 0.91 0.01 0.08 
  
PAM rs2561477 0.00 0.00 0.03 0.80 0.18 
PCIF1 rs4239702 0.00 0.00 0.92 0.01 0.08 
  
PCIF1 rs4239702 0.00 0.00 0.90 0.01 0.09          
PCP4L1 rs72717009 0.00 0.00 0.68 0.06 0.25 
PFDN2 rs4656942 0.99 0.01 0.00 0.00 0.00 
         
PGAP3 rs1877030 0.01 0.00 0.86 0.01 0.12 
  
PGAP3 rs1877030 0.01 0.00 0.89 0.02 0.09 
PI4KAP2 rs11089637 0.11 0.00 0.80 0.00 0.09 
  
PI4KAP2 rs11089637 0.03 0.00 0.85 0.02 0.11 
PLTP rs4239702 0.00 0.00 0.73 0.01 0.26 
  
PLTP rs4239702 0.00 0.00 0.72 0.02 0.26 
PPIL2 rs11089637 0.11 0.00 0.81 0.00 0.08 
  





PPIP5K2 rs2561477 0.00 0.00 0.89 0.01 0.09 
  
PPIP5K2 rs2561477 0.00 0.00 0.92 0.01 0.07          
PRDM1 rs9372120 0.41 0.01 0.48 0.01 0.08          
PRDX6 rs2105325 0.00 0.00 0.89 0.03 0.08          
PSMG2 rs8083786 0.00 0.00 0.91 0.02 0.07 
PTGFRN rs624988 0.01 0.00 0.89 0.01 0.09 
  
PTGFRN rs624988 0.01 0.00 0.91 0.01 0.07          
PTPN2 rs8083786 0.00 0.00 0.91 0.02 0.07 
PTPRC rs17668708 0.38 0.00 0.54 0.00 0.08 
  
PTPRC rs17668708 0.15 0.00 0.77 0.01 0.06 
RNASET2 rs1571878 0.00 0.00 0.87 0.01 0.12 
  
RNASET2 rs1571878 0.00 0.00 0.00 0.99 0.01          
RSPH3 rs2451258 0.00 0.00 0.88 0.03 0.09 
SDF2L1 rs11089637 0.11 0.00 0.81 0.00 0.08 
  
SDF2L1 rs11089637 0.03 0.00 0.82 0.02 0.14          
SDHC rs72717009 0.00 0.00 0.89 0.03 0.08          
SEH1L rs8083786 0.00 0.00 0.91 0.02 0.07 
SLAMF1 rs4656942 0.99 0.01 0.00 0.00 0.00 
         
SLAMF7 rs4656942 0.98 0.01 0.00 0.00 0.00 
         
SLC35C2 rs4239702 0.00 0.00 0.92 0.01 0.07 
  
SLC35C2 rs4239702 0.00 0.00 0.91 0.01 0.08          
SPIRE1 rs8083786 0.00 0.00 0.91 0.02 0.07 
STARD3 rs1877030 0.01 0.00 0.87 0.01 0.10 
  
STARD3 rs1877030 0.01 0.00 0.89 0.02 0.08 
STAT1 rs11889341 0.00 0.00 0.91 0.01 0.08 
  
STAT1 rs11889341 0.00 0.00 0.73 0.01 0.25 
STAT4 rs11889341 0.00 0.00 0.91 0.01 0.08 
  
STAT4 rs11889341 0.00 0.00 0.90 0.01 0.09          
STRADB rs6715284 0.07 0.00 0.84 0.02 0.08          
TAGAP rs2451258 0.00 0.00 0.90 0.02 0.08 
TCAP rs1877030 0.01 0.00 0.89 0.01 0.08 
  
TCAP rs1877030 0.01 0.00 0.87 0.02 0.10          
TNFSF4 rs2105325 0.00 0.00 0.91 0.02 0.07          
TRAK2 rs6715284 0.07 0.00 0.84 0.02 0.07 
TSTD1 rs4656942 0.99 0.01 0.00 0.00 0.00 
         
UBE2L3 rs11089637 0.11 0.00 0.80 0.00 0.08 
  
UBE2L3 rs11089637 0.03 0.00 0.84 0.02 0.11 
USF1 rs4656942 0.99 0.01 0.00 0.00 0.00 
         
YDJC rs11089637 0.11 0.00 0.81 0.00 0.08 
  
YDJC rs11089637 0.03 0.00 0.85 0.01 0.10 
YPEL1 rs11089637 0.11 0.00 0.81 0.00 0.08 
  
YPEL1 rs11089637 0.03 0.00 0.88 0.02 0.07 
ZNF335 rs4239702 0.00 0.00 0.92 0.01 0.07 
  
ZNF335 rs4239702 0.00 0.00 0.91 0.01 0.08 
ZSWIM1 rs4239702 0.00 0.00 0.91 0.01 0.08 
  
ZSWIM1 rs4239702 0.00 0.00 0.91 0.01 0.08 
ZSWIM3 rs4239702 0.00 0.00 0.92 0.01 0.07 
  












Supplementary Table 6 – GSEA Enrichment Scores. 1Enrichment Score: Degree to which gene set is overrepresented at the 
top of bottom of the ranked list of genes. 2Normalized Enrichment Score: Enrichment score divided by the mean of 
enrichment scores against all permutations of the ranked list. 
NAME ES1 NES2 NOM p-val FDR q-val 
HALLMARK_MITOTIC_SPINDLE -0.96953654 -2.738665 0.036809817 0.24540035 
HALLMARK_TNFA_SIGNALING_VIA_NFKB -0.78459835 -2.131841 0.061099797 1 
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION -0.7627758 -2.1261334 0.064718165 0.6822187 
HALLMARK_INTERFERON_GAMMA_RESPONSE -0.75405574 -2.0704424 0.06290673 0.5373365 
HALLMARK_XENOBIOTIC_METABOLISM 0.7114698 1.7093651 0.14814815 0.8671167 
HALLMARK_ANGIOGENESIS -0.7054058 -1.7550359 0.047528517 0.33538553 
HALLMARK_ESTROGEN_RESPONSE_EARLY 0.70333433 1.7096115 0.14570858 1 
HALLMARK_COMPLEMENT -0.6963707 -1.8607478 0.08898305 0.5260123 
HALLMARK_ESTROGEN_RESPONSE_LATE 0.69636387 1.6763769 0.13644859 0.6136178 
HALLMARK_OXIDATIVE_PHOSPHORYLATION 0.68012977 1.6174641 0.17375231 0.51181173 
HALLMARK_KRAS_SIGNALING_UP -0.6740996 -1.8120219 0.09544469 0.46603143 
HALLMARK_INFLAMMATORY_RESPONSE -0.66156536 -1.8029977 0.10107527 0.4036422 





HALLMARK_INTERFERON_ALPHA_RESPONSE -0.6433157 -1.8028818 0.057539683 0.35318694 
HALLMARK_MYC_TARGETS_V1 -0.63430864 -1.6890604 0.12035011 0.30162588 
HALLMARK_IL6_JAK_STAT3_SIGNALING -0.6031751 -1.66111 0.06584362 0.28307122 
HALLMARK_SPERMATOGENESIS -0.5676277 -1.557379 0.061099797 0.28568843 
HALLMARK_HEDGEHOG_SIGNALING -0.5453301 -1.3602403 0.13793103 0.29140854 
HALLMARK_APOPTOSIS -0.5123841 -1.419991 0.111561865 0.30515093 
HALLMARK_PANCREAS_BETA_CELLS 0.50091386 1.2124683 0.23517382 0.6139624 
HALLMARK_GLYCOLYSIS 0.5003059 1.1435319 0.256654 0.48104674 
HALLMARK_MYOGENESIS -0.4992916 -1.3265461 0.14197531 0.27315947 
HALLMARK_ALLOGRAFT_REJECTION -0.49219608 -1.3456522 0.12778905 0.28104284 
HALLMARK_UV_RESPONSE_DN -0.4788568 -1.3921219 0.09381663 0.29563344 
HALLMARK_IL2_STAT5_SIGNALING -0.4648526 -1.2194562 0.1826087 0.32190385 
HALLMARK_PEROXISOME 0.45880708 1.1639911 0.21142857 0.5433961 
HALLMARK_ADIPOGENESIS 0.42392758 1.0107353 0.29338843 0.5345546 
HALLMARK_G2M_CHECKPOINT -0.42264763 -1.1181176 0.18828452 0.39563367 





HALLMARK_TGF_BETA_SIGNALING -0.38988957 -1.0531788 0.34435797 0.45401844 
HALLMARK_BILE_ACID_METABOLISM 0.37280008 0.92135537 0.38345864 0.5846342 
HALLMARK_COAGULATION -0.35666084 -0.96529174 0.36305732 0.55080724 
HALLMARK_P53_PATHWAY -0.35356408 -0.9617617 0.28817204 0.5333001 
HALLMARK_E2F_TARGETS -0.3495585 -0.89524615 0.31905782 0.5649946 
HALLMARK_FATTY_ACID_METABOLISM 0.3491053 0.86028254 0.4208494 0.6140024 
HALLMARK_PI3K_AKT_MTOR_SIGNALING -0.34672815 -0.9346718 0.4032258 0.5377159 
HALLMARK_APICAL_SURFACE -0.34615594 -0.9051891 0.53373015 0.5665438 
HALLMARK_CHOLESTEROL_HOMEOSTASIS -0.34555647 -0.9500684 0.43452382 0.5313629 
HALLMARK_ANDROGEN_RESPONSE 0.31548336 0.7782141 0.5708333 0.7003621 
HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY -0.3002477 -0.81362534 0.6687631 0.70644766 
HALLMARK_WNT_BETA_CATENIN_SIGNALING -0.29808396 -0.766772 0.7231076 0.73594713 
HALLMARK_PROTEIN_SECRETION 0.29019544 0.6923406 0.65957445 0.80639565 
HALLMARK_MYC_TARGETS_V2 -0.28258362 -0.77286494 0.69753087 0.74765736 
HALLMARK_DNA_REPAIR -0.27484703 -0.77776295 0.6492693 0.7620492 





HALLMARK_MTORC1_SIGNALING -0.25699028 -0.6710301 0.7731481 0.87532324 
HALLMARK_KRAS_SIGNALING_DN 0.25573143 0.64437884 0.83943087 0.83299124 
HALLMARK_APICAL_JUNCTION -0.23773567 -0.65685195 0.8586724 0.87192327 
HALLMARK_UNFOLDED_PROTEIN_RESPONSE 0.22921126 0.56387246 0.8996139 0.90224123 







Supplementary Table 7 – Ancestry Proportion Permutation Test Summary Statistics. 1Based on the ranking of true 
correlation (c =0.43) out of 1000 permutation tests. 
Statistic Value 
Minimum -0.619 
1st Quartile -0.227 
Median 0.013 
Mean -0.005 
3rd Quartile 0.210 
Maximum 0.567 








Supplementary Table 8 – Cluster 16 Differentially Expressed Pathways 
Upregulated     



































































GO:0046649 lymphocyte activation 4.06E-09 6.66E-07 
ToppCell 
Atlas 4d105437487bf04f8cd6129b822d5c060af0bee8 
ILEUM-inflamed-(5)_Plasma|inflamed / shred on tissue, 
inflammation_status, cell class(v3), cell subclass (v2) 1.95E-77 1.28E-73 
ToppCell 
Atlas f3c583f8521f63834d1afbf8b07940fee7712f9a 
Sigmoid-(2)_B_cell-(20)_B_cell_IgA_Plasma|Sigmoid / shred 
on region, Cell_type, and subtype 3.65E-76 4.80E-73 
ToppCell 
Atlas ea65cadaf464ff4c1040fceb5f3724706f8447c1 
Transverse-B_cell-B_cell_IgA_Plasma|Transverse / Region, 





Sigmoid-B_cell-B_cell_IgA_Plasma|Sigmoid / Region, Cell 








Location, Cell class and cell subclass 1.19E-75 1.31E-72 
ToppCell 
Atlas a113558ca4220bac31f9336033dff82a618d9258 
ILEUM-inflamed-(5)_IgA_plasma_cells|inflamed / shred on 








MALT_B_cells|tumor_Lymph_Node_/_Brain / Location, Cell 












ILEUM-non-inflamed-(5)_Plasma|non-inflamed / shred on 
tissue, inflammation_status, cell class(v3), cell subclass (v2) 1.23E-74 8.05E-72 
 
Downregulated     
Category ID Name p-value q-value FDR B&H 
GO: Molecular 
Function GO:0016491 oxidoreductase activity 3.46E-45 5.34E-42 
GO: Molecular 
Function GO:0003954 NADH dehydrogenase activity 3.81E-38 1.47E-35 
GO: Molecular 
Function GO:0050136 NADH dehydrogenase (quinone) activity 3.81E-38 1.47E-35 
GO: Molecular 
Function GO:0008137 NADH dehydrogenase (ubiquinone) activity 3.81E-38 1.47E-35 
GO: Molecular 
Function GO:0016655 
oxidoreductase activity, acting on NAD(P)H, quinone or 
similar compound as acceptor 8.23E-38 2.54E-35 
GO: Molecular 
Function GO:0009055 electron transfer activity 7.94E-29 2.04E-26 
GO: Molecular 
Function GO:0016651 oxidoreductase activity, acting on NAD(P)H 1.08E-25 2.39E-23 
GO: Molecular 
Function GO:0044877 protein-containing complex binding 6.59E-25 1.27E-22 
GO: Molecular 






Function GO:0015078 proton transmembrane transporter activity 1.54E-22 2.37E-20 
GO: Biological 
Process GO:0006119 oxidative phosphorylation 1.01E-73 7.26E-70 
GO: Biological 
Process GO:0015986 ATP synthesis coupled proton transport 1.01E-72 2.41E-69 
GO: Biological 
Process GO:0015985 
energy coupled proton transport, down electrochemical 
gradient 1.01E-72 2.41E-69 
GO: Biological 
Process GO:0006754 ATP biosynthetic process 4.24E-72 7.60E-69 
GO: Biological 
Process GO:0009206 purine ribonucleoside triphosphate biosynthetic process 7.36E-69 1.06E-65 
GO: Biological 
Process GO:0009145 purine nucleoside triphosphate biosynthetic process 1.33E-68 1.59E-65 
GO: Biological 
Process GO:0009201 ribonucleoside triphosphate biosynthetic process 2.38E-67 2.44E-64 
GO: Biological 
Process GO:0009142 nucleoside triphosphate biosynthetic process 3.06E-67 2.74E-64 
GO: Biological 
Process GO:0009144 purine nucleoside triphosphate metabolic process 4.25E-67 3.39E-64 
GO: Biological 
Process GO:0009205 purine ribonucleoside triphosphate metabolic process 6.28E-67 4.51E-64 
GO: Cellular 
Component GO:0098800 inner mitochondrial membrane protein complex 1.14E-68 1.13E-65 
GO: Cellular 
Component GO:0005743 mitochondrial inner membrane 1.95E-64 9.69E-62 
GO: Cellular 
Component GO:0005740 mitochondrial envelope 5.59E-64 1.85E-61 
GO: Cellular 
Component GO:0031966 mitochondrial membrane 3.18E-61 7.89E-59 
GO: Cellular 
Component GO:0070469 respirasome 1.37E-60 2.72E-58 
GO: Cellular 






Component GO:0031967 organelle envelope 3.6E-60 5.1E-58 
GO: Cellular 
Component GO:0031975 envelope 4.12E-60 5.12E-58 
GO: Cellular 
Component GO:0019866 organelle inner membrane 7.02E-60 7.74E-58 
GO: Cellular 






APPENDIX B. SUPPLEMENTARY FIGURES 
 
Supplementary Figure 1 – Effects of medication and sample time on gene 
expression. Changes in gene expression following adjustment for treatment with 
DMARDs, biologics, and steroids, as well as time from diagnosis to sample 
collection. From left to right in pairs, (a) depicts the principal component of 
unadjusted expression of Axis genes versus adjusted expression. (b) depicts the 







Supplementary Figure 2 – Correlation of betas in non-adjusted and medication-
adjusted SNPs. Effect sizes in DMARD, biologic, and steroid treatment-adjusted 
SNPs versus non-adjusted SNPs. SNPs highlighted in red are significant at p < 






Supplementary Figure 3 – Replication of gene expression trends in the Hinze et al. 
dataset. The principal component of Axis gene expression in the dataset presented in 







Supplementary Figure 4 – Examples of disease-specific eQTL. Selection of eQTL 
with JIA- or IBD-biased effects on transcript abundance. The p-values for presence 







Supplementary Figure 5 – Interaction effects with addition of ethnicity. The p-value 
for presence of interaction effects in a model including ancestry, versus p-value in a 
model without. The genotype-disease interaction effects remain significant even 















Supplementary Figure 6 – Case-control, disease subtype, and medication 
associations with DEGs. (a) First principal component (PC1) of genes differentially 
expressed between IBD cases and controls. P = 1.42×10-6 (b) PC1 of case-control 
DEGs in AA individuals and European individuals. P = 0.15 (c) PC1 of genes 
differentially expressed between AA IBD patients and European IBD patients in 
IBD cases and controls. P = 0.27 (d) First principal component of genes 
differentially expressed between AA IBD patients and European IBD patients. P = 
1.38×10-6 (e) PC1 of ancestry-related DEGs in controls and subtypes of IBD. P = 
0.54 (f) PC1 of ancestry-related DEGs in known patients treated with steroids. P = 
9.22×10-6; note that only AA patients received steroids (g) PC1 of ancestry-related 
DEGs in patients known to b treated with anti-TNF. P = 0.44 (h) PC1 of ancestry-






Supplementary Figure 7 – Cross-validation of PC1col. Colectomy status was 
randomized prior to differential expression testing and calculation of PC1colRand. 
Histogram shows frequency of log10 p-value for ANOVA test of PC1colRand between 








Supplementary Figure 8 – Associations between PC1col and Mayo score. All boxplots 
indicate 1st and 3rd quartile as box ends, with center median line and whiskers extending 
to farthest point within 1.5 times the interquartile range. (a) PC1col calculated on baseline 
gene expression with baseline Mayo score; p=0.004. (b) PC1col calculated on week 52 gene 
expression with week 52 Mayo score; p=8.73×10-8. (c) Change in PC1col and Mayo score 
from baseline to week 52; p=4×10-4. 
Supplementary Figure 9 – Switch in proportions of epithelial and immune components of 
rectal gene expression between baseline and week 52 follow-up. All boxplots indicate 1st 
and 3rd quartile as box ends, with center median line and whiskers extending to farthest 
point within 1.5 times the interquartile range. First principal components of 200 genes 
differentially expressed between the two tissue compartments in [Supplement ref. 27] 
were calculated and polarized such that PC1 reflects elevated expression of the genes. 







Supplementary Figure 10 – Replication of transcriptional risk prediction in the Mt 
Sinai cohort. All boxplots indicate 1st and 3rd quartile as box ends, with center 
median line and whiskers extending to farthest point within 1.5 times the 
interquartile range. (a) PC1 of colectomy-associated genes in Mt Sinai significantly 
differentiates colectomy (green) from non-colectomy (red). (b) TRSUC developed 
from IBD GWAS- associated genes also predicts progression to colectomy in the Mt 
























Supplementary Figure 11 – Cell-type specific expression of colectomy-associated 
genes. (a) Heat map showing up- regulation (red) of each gene contributing to 
PC1 in a rectal scRNAseq dataset. Dozens of genes are enriched in seven cell-
types. (b) Similar analysis but for the TRSUC genes. Note the similarity of the 







Supplementary Figure 12 – Comparison of TRS generated with different subsets of genes. 
Each plot shows the computed TRS for each individual who did or did not require 
colectomy during the study period. All boxplots indicate 1st and 3rd quartile as box ends, 
with center median line and whiskers extending to farthest point within 1.5 times the 
interquartile range. (a) 9 gene TRS for genes significantly differentiated by status at p<0.1; 
p=2×10-25. (b) 10 gene TRS for genes highlighted in the text as the major clusters of up- and 
down-regulated in colectomy; p=8×10-43. (c) 26 gene TRS as sum of z-scores weighted by 
the magnitude of differential expression; p=9×10-49. (d) TRS computed simply as PC1 of 










Supplementary Figure 13 – Dot plot visualizing individual-driven differences in 
gene expression. The x-axis consists of each of the 9 major cell type groups 
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